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ABSTRACT 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
after Alzheimer’s disease. The etiology of PD is currently not fully understood, but strong 
evidence has existed pointing to gene-environmental interactions that contribute to various 
pathogenic mechanisms of neurodegeneration: oxidative stress, neuroinflammation, 
mitochondrial dysfunction, and epigenetic modulation. While cell signaling mechanisms 
underlying neurotoxic injury have been actively studied in recent years, the signaling 
molecules contributing to compensatory survival signaling are largely unknown. Recently, 
we reported that the secreted neuropeptide prokineticin-2 (PK2) is upregulated during early 
stages of neurotoxic stress induced by MPP+, and plays a major compensatory protective 
function in nigral dopaminergic neurons in vitro and in vivo. Thus, the goal of my thesis 
work was to determine the transcriptional regulation and translational relevance of PK2 in 
cell culture and animal models of PD.  
In Chapter 2, we studied the transcriptional and molecular regulatory mechanisms 
of Parkinsonian toxicants MPP+ and manganese (Mn)-induced PK2 upregulation. In a set 
of experiments, we performed in silico analysis of the PK2 promoter and revealed the 
presence of early growth response-1 (EGR1), hypoxia inducible factor 1 (HIF1α), 
transcription factor E2F, and nuclear respiratory factor-1 (NRF1) putative binding sites. 
Importantly, we observed that MPP+ and Mn exposure increased HIF1α and EGR1 levels 
at early stages of neurotoxicity. Since overexpression of HIF1α or EGR1 upregulated PK2 
expression, these studies suggest that Mn regulates PK2 expression via EGR1 or HIF1α-
dependent pathway. A toxicologically relevant dose of Mn exposure by an oral route 
significantly upregulated global PK2 levels in the brain, especially in the substantia nigra 
vii 
with concomitant increases in HIF1α transcription factor. Taken together, the results in this 
chapter suggest that dopaminergic neurotoxicants upregulates PK2 levels to counter the 
early neurotoxic stress, and that Mn-induced upregulation of PK2 expression is 
transcriptionally regulated by EGR1, HIF1α and NRF1. 
 Building on the findings in chapter 2, the focus of Chapter 3 is the role of PK2 in 
Mn-induced Parkinsonism because the cellular mechanism by which Mn impairs the 
dopaminergic neurotransmitter system remains unclear. Here we found that the 
dopaminergic neurotoxicant Mn rapidly induce PK2 during the early stages of Mn 
neurotoxic stress in an N27 dopaminergic cell model. To better understand the functional 
role of PK2 upregulation, we created stable PK2-expressing dopaminergic cells by 
delivering PK2 myc-tagged cDNA into mouse dopaminergic MN9D cells. Interestingly, 
PK2-overexpressing cells exposed to Mn showed significant protection against 
neurotoxicity relative to vector control cells, suggesting a neuroprotective role for PK2 in 
dopaminergic neurons. The protective effect was both dose- and time-dependent. 
Furthermore, the PK2 receptor blocker PC7 attenuated the PK2-induced neuroprotective 
effects in PK2-overexpressing cells. Overexpressing PK2 protected against manganese-
induced apoptosis as measured by Annexin 5 and caspase-3 activation. We also found that 
mitochondrial integrity was well maintained in PK2-overexpressing cells relative to vector 
cells following exposure to Mn. Additional results also showed that key proteins involved 
in mitochondrial functions, including BCL2, PGC1-α and TFAM levels, were preserved in 
PK2-overexpressing cells during neurotoxic stress. Collectively, our results suggest that 
neurotoxic insults upregulate PK2 in dopaminergic neurons to protect against the early 
stages of neurotoxicity. Finally, observed the effect of Mn treatment on PK2 expression 
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using a GENSAT PK2 GFP transgenic mouse model. During early exposure to Mn, PK2 
levels were significantly upregulated in the SN while slightly decreasing in striatum. 
Prolonged exposure to Mn (30 mg/kg for 30 days) significantly upregulated PK2 levels in 
the brain, especially in the substantia nigra. Interestingly, in the striatum, where Mn-
induced cell death mainly occurs, decreased PK2 levels were noted. Significant amount of 
methylation of the PK2 promoter region is also observed in the striatum. Combined with 
cell culture studies, the differential regulation of PK2 in the striatum and substantia nigra 
might suggest a possible neuroprotective role of PK2 in the SN during early exposure to 
Mn. Taken together, the results in this chapter suggest that Mn upregulates PK2 levels to 
counter early neurotoxic stress in vitro and in vivo.  
Despite a wealth of preclinical studies establishing neuroprotective and 
neurorestorative properties of glial cell-line derived neurotrophic factor (GDNF) in animal 
models of PD, a number of phase II clinical trials utilizing direct intracranial injection of 
GDNF protein and AAV-mediated Gdnf gene transfer did not achieve efficacy that was 
hoped for. Setbacks from recent clinical trials might prompt a rethinking of the strategy 
which focused on ectopic expression of GDNF targeted towards neurons. Devising 
strategies to elevate GDNF expression by means other than genetic manipulation is the 
current challenge. The pharmacologically modulated signaling pathways that are in 
crosstalk with GDNF or could induce its endogenous upregulation represent opportunities 
to fully harness the clinical benefits of GDNF, without the side effects associated with 
current methods for GDNF delivery. In Chapter 4, we show that GDNF has significant 
crosstalk with prokineticin signaling in astrocytes. A small molecule, IS20, could activate 
prokineticin signaling to induce secretion and expression of GDNF from in cultured 
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astrocytes via activation of prokineticin receptor 1 (PKR1) preferentially expressed by 
astrocytes. Further, non-invasive administration of the blood-brain-barrier-permeable 
lipophilic IS20 through intranasal delivery could pharmacologically modulate GDNF 
levels in the nigrostriatal system of C57B/6 mice. Importantly, IS20 treatment yielded 
significant neuroprotective and neurorestorative effects in the MPTP and MitoPark mouse 
models of PD. Our results indicate that the full clinical benefits of GDNF could be 
leveraged by pharmacological modulation using IS20. 
In summary, we showed that PK2 could protect against classic Parkinsonian 
toxicants MPP+ and Mn induced neurotoxicity in MN9D mouse dopaminergic neuronal 
cells. We characterized the transcriptional regulation of PK2 by analyzing the PK2 
promoter, and the results revealed that transcriptional factors HIF1α, EGR1, and NRF1 
contribute to basal and neurotoxicity-induced PK2 expression. While studying the PK2 
neuroprotective mechanisms, we found a fundamental relationship between PK2 and 
GDNF signaling pathways in astrocytes. Activation of PK2 signaling upregulates GDNF 
levels in vitro and in vivo. The protective role and therapeutic potential of the PK2-PKR1-
GDNF signaling axis was further confirmed using a PKR1 agonist, IS20, in a MPTP mouse 
model of neurodegeneration as well as in the MitoPark genetic mouse model of PD. 
Collectively, we show that PK2 can be transcriptionally induced by multiple pro-survival 
factors and that PK2 signaling activation is a protective compensatory response to 
neurodegeneration. Pharmacological modulation of PK2 could induce GDNF upregulation 
and offer neuroprotective effects in multiple mouse models of PD. Thus, PK2 signaling 
represents a therapeutic target with great potential for PD treatment. 
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CHAPTER 1.    GENERAL INTRODUCTION 
 
Dissertation Layout and Organization 
This dissertation is written in the alternative format which consists of manuscripts that 
are in preparation for submission to peer reviewed journals. The dissertation contains the 
General Introduction, followed by three research manuscripts as individual chapters, and ends 
with the Conclusion and Future Directions chapter. The references are listed at the end of the 
dissertation, except for each of the three manuscript chapters, which are followed immediately 
by works that are cited within the manuscript chapter. The General Introduction (Chapter 1) 
provides a concise review of current knowledge and hypotheses for the etiology of Parkinson’s 
disease, and the role of genetics and environmental exposures, especially heavy metal 
exposures. Recent and current clinical trials for experimental PD therapies are discussed, as 
well as their shortcomings. The role of Prokineticin-2 (PK2) in PD is discussed, in relevance 
to studies presented here in the following three research manuscripts. The first research 
manuscript (Chapter 2) is titled: Transcriptional Regulation Of Prokineticin-2 Promoter By 
Egr1, Hif1α, And Nrf1 in Cell Cultures of Dopaminergic Neurodegeneration. The second 
research manuscript (Chapter 3) is titled: Prokineticin 2 Protects Against Manganese-Induced 
Neurotoxicity by Inducing Mitochondrial Biogenesis in Dopaminergic Cells. The third 
research manuscript (Chapter 4) is titled: Pharmacological Modulation of Astrocyte-Derived 
GDNF by Prokineticin 2 Receptor Agonist IS20: Preclinical Assessments Using MPTP And 
MitoPark Rodent Models of Parkinson’s Disease. All of the above manuscripts are in 
preparation for submission to peer-reviewed journals.  
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This dissertation contains the experimental results obtained by the author during his 
Ph.D. study, under the supervision of his major professor Dr. Anumantha G. Kanthasamy at 
Iowa State University, Department of Biomedical Sciences. 
 
Introduction  
Parkinson’s disease (PD) is a complex neurological disorder. It is the most common 
neurodegenerative disorder after Alzheimer’s disease, affecting about 1.5 million people in the 
United States and over 10 million worldwide. With an aging world population, it is projected 
to increase by more than 50% by 2030 (Dorsey et al., 2007). It will cost a national economic 
burden in the United States exceeding $13 billion in by 2030, and $18 billion by 2050 (Kowal, 
Dall, Chakrabarti, Storm, & Jain, 2013).  
In 1817, James Parkinson described a disease which is characterized today by akinesia, 
bradykinesia, rigidity, postural instability and fatigue (Barzilai & Melamed, 2003; Jarraya et 
al., 2009; Nassif & Pereira, 2018), a set of conditions with the earliest reference dating back to 
600 B.C. in the ancient Indian medical literature (Manyam, 1990; Ovallath & Deepa, 2013). 
Current understanding of PD indicates that the early death of dopaminergic neurons in the 
ventrolateral substantia nigra pars compacta (SNpc), and the resulting severe dopamine 
depletion in the dorsal caudate putamen sit at the core of the disease. Postmortem analysis of 
PD patient brains has found another hallmark of PD: the accumulation of Lewy bodies in the 
neuron bodies and Lewy neurites in neuron processes, which comprised of mainly alpha-
synuclein aggregates. The role of Lewy bodies and PD pathogenesis still stands unclear 
(Recasens et al., 2014; Wakabayashi et al., 2012).  
PD diagnosis by clinicians is aided by medical imagining using PET scans, which could 
assess the functional integrity of the nigrostriatal dopaminergic system (Niccolini, Su, & 
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Politis, 2014; Poewe, 1993). However, PD is diagnosed incorrectly in about 25% of patients, 
in part due to a lack of laboratory diagnostic tests for definitive diagnosis (Kalia & Lang, 2015; 
Tolosa, Wenning, & Poewe, 2006). The definitive diagnosis only comes after post-mortem 
histopathological examination of degenerated dopaminergic neurons in the brain of patients. 
Motor deficits occur when an estimated 60% of the dopaminergic neurons in the SNpc are lost 
with 80% reduction in striatal dopamine levels, attesting to the brain’s immense compensatory 
capacity for reduced dopamine production during early stage of the disease, while underscoring 
a need for early diagnosis independent of motor symptoms. Non-motor symptoms associated 
with PD have been increasing recognized and used in the differential diagnosis of PD from 
other similar conditions during the last decade (Richard L. Doty, 2012; Rodríguez-Violante, 
Zerón-Martínez, Cervantes-Arriaga, & Corona, 2017). Because of prevalence of non-motor 
symptoms (over 90%) in PD patients, non-motor symptoms can be taken into consideration 
during differential diagnosis, together with motor symptoms and medical imagine data, to 
lower the rate of misdiagnosis. Because non-motor dysfunctions appear before motor 
dysfunctions, the progressive loss of dopaminergic neurons has presumably already begun, 
during the manifestation of non-motor symptoms, with its effects unseen until various 
compensatory mechanisms are overwhelmed. Therefore, the prodromal period preceding 
massive dopaminergic cell death represents a critical window of opportunity for a potential 
therapeutic intervention to alter the course of disease progression (Siderowf & Lang, 2012).  
The first mutations in SNCA (PARK1) were found to be responsible for PD in 1997 
(M H Polymeropoulos et al., 1997; Mihael H. Polymeropoulos et al., 1996). Since then, with 
help from large scale genome-wide association studies (GWAS) enabled by advances in 
sequencing technology, a total of 28 mutations in various genomic loci have since been linked 
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to increased risks of PD (Klein et al., 2012; Simón-Sánchez et al., 2009). However, PD patients 
who have mutations in these genes comprise of only roughly 5% of clinical cases (Pankratz et 
al., 2012; Shulman, De Jager, & Feany, 2011), indicating that rather than being purely 
hereditary, the etiology of PD is multifactorial, involving an interplay of PD-susceptibility 
genes that are modified or influenced by environmental factors, leading to a cascade of events 
which result in PD pathology.  
A meta-analysis had found 11 environmental factors that have positive association with 
PD, and the top risk factors are pesticide exposure, well-water drinking, beta-blocker use, prior 
head injury, agricultural occupation, and rural living (Foubert-Samier et al., 2012). Exposure 
to pesticides such as rotenone, paraquat, dieldrin, organophosphates and Mn (in the form of 
pesticide Maneb) are implicated in development of PD (A. G. Kanthasamy, Kitazawa, Yang, 
Anantharam, & Kanthasamy, 2008; Roede & Miller, 2014; Semchuk, Love, & Lee, 1992; 
Singh et al., 2018; Tanner et al., 2011). In addition, aerosolized metals exposure has been 
reported as an environmental risk factor for PD  (Brown, Lockwood, & Sonawane, 2005). In 
particular, exposure to manganese in an occupational setting could increase risks for 
developing Parkinsonian symptoms by 3 - 10 fold (Gorell et al., 1999). Therefore, studying 
both the environmental and genetic factors of PD could provide insight into possible points of 
failure within the cell caused by mutations in the PARK genes, that can be exacerbated by 
environmental factors, leading to neurodegeneration.   
Collectively, the consensus might be that PD is a multifactorial disease with 
contributions from genetic and environmental sources, which converge on the vulnerabilities 
of the dopaminergic neurons in the SNpc. Looking beyond the risk factors of the disease, some 
of which are inherently unavoidable, several common themes appearing during the 
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neurodegenerative process have emerged. Oxidative stress, neuroinflammation, and 
mitochondrial dysfunction are seen from in vitro, in vivo studies, and post mortem analyses of 
PD patient brains. Until recently, these processes that accompany nigral dopaminergic 
degeneration was presumed to be consequences of cell death. However, over the past decades, 
evidence had pointed to their active participation in neurodegeneration and had implicated 
them in PD pathogenesis and disease progression. 
The mainstay of PD symptomatic management remains to be therapies that increase 
dopamine concentrations or receptor activity in the caudate putamen. L-DOPA, the precursor 
for dopamine, was discovered by Arvid Carlsson in the 1950s to have effects on Parkinsonian 
animals, experiments for which the Nobel Prize in Physiology or Medicine was awarded in 
2000. Decades later, L-DOPA remains today the strongest thearapy against disease symptoms. 
However, common therapies such as L-DOPA, dopamine agonists, monoamine type B 
inhibitors, induce side effects such as dyskinesia with long-term treatments. Without disease-
modifying treatments, current therapies could manage motor symptoms but do not treat non-
motor symptoms, and do little to slow disease progression.  
One of the most promising candidates for neuroprotection and neuro-restoration of 
SNpc dopaminergic neurons are members of the glial-cell line derived neurotrophic factor 
(GDNF) family, consisting of GDNF, artemin, persephin, and neurturin. Since the discovery 
of GDNF in 1992 (O’Malley, Sieber, Black, & Dreyfus, 1992), extensive evaluation in cell 
culture, rodent, and primate models of PD had demonstrated its exceptional neuroprotective 
effects on the dopaminergic system (Bilang-Bleuel et al., 1997; Björklund, Rosenblad, 
Winkler, & Kirik, 1997; J. H. Kordower et al., 2000; L. F. Lin, Doherty, Lile, Bektesh, & 
Collins, 1993; Tseng, Baetge, Zurn, & Aebischer, 1997). Nerve injury induces upregulation of 
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GDNF (Araujo & Hilt, 1997), and GDNF seem to be upregulated in post-mortem brains of PD 
patients in some studies (Backman et al., 2006). Therefore, GDNF could be a protective 
compensatory mechanism against neurodegeneration. Several landmark GDNF clinical trials 
had initially showed relative safety and efficacy in open-label studies, but ultimately, GDNF 
delivery using currently employed adeno-associated virus (AAV) showed no efficacy in phase 
II clinical trial (Blits & Petry, 2016; Remy, 2014; Tenenbaum & Humbert-Claude, 2017). 
Hence, the greatest challenge in meeting  unmet medical need for PD remains to be the 
development of disease course-modifying therapies that could slow or stop the progression of 
the disease (Kalia & Lang, 2015).  
We had recently discovered that a neuropeptide, prokineticin-2, is upregulated in 
response to neurotoxic stress. We found that its upregulation is a protective, compensatory 
response during neurodegeneration in animal models of PD. We had also found that it protects 
against neurodegeneration by activating pro-survival ERK1/2, AKT pathways, countering pro-
apoptotic signals, and bolstering mitochondrial biogenesis (Gordon et al., 2016). We recently 
have also found that PK2 reduces neuroinflammation by activating pro-survival astrocytic 
phenotype. Yet, little is known about the regulation of PK2 during neurotoxic stress in 
dopaminergic neurons, or the relationship of PK2 with other neurotrophic factors co-regulated 
with it during neurotoxic stress. The focus of the following chapters will center around PK2’s 
role during neurotoxic stress—PK2’s transcriptional regulation, PK2’s role in manganese 
model of Parkinsonism, and the role of PK2 in regulation of GDNF expression. 
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Background and Literature Review I 
The goal of this section is to summarize the pathophysiology of Parkinson’s disease 
and current understanding of its etiology through discussion of environmental risk factors as 
well as genetic risk factors for Parkinson’s disease. The proposed mechanisms and hypotheses 
for disease progression will be presented. Parkinson’s disease animal models relevant to the 
research presented in this work will also be discussed.  
 
Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative diseases 
behind Alzheimer’s disease. The mean onset for PD is 60 years of age, and it affects 10 million 
people worldwide, or 4-5% of people over 85, for whom mortality rate is 2-3 times that of the 
general population (de Lau et al., 2006; Lang & Espay, 2018). Its prevalence and incidence 
nearly exponentially increase by age, and peak after 80 years of age (Callesen, Scheel-Krüger, 
Kringelbach, & Møller, 2013; Driver, Logroscino, Gaziano, & Kurth, 2009). Each year, 50,000 
new cases of PD are diagnosed in the US alone, and the more than 1 million PD patients in the 
US exact a yearly national economic burden exceeding $14.4 billion in 2010 and is projected 
to exceed $ 18 billion by 2050 (Kowal et al., 2013). Due to relative complex etiologies of 
neurodegenerative diseases such as PD, they remain largely incurable, and are projected by the 
World Health Organization to overtake cancer as a leading cause of death by 2050 (Menken, 
Munsat, & Toole, 2000). Due to its progressively debilitating nature, PD is one of the most 
feared diseases of mankind (Fan et al., 2015).  
In his famous monograph "An Essay on the Shaking Palsy" in 1817, James Parkinson 
described a condition characterized by “Involuntary tremulous motion, with lessened muscular 
power, in parts not in action and even when supported; with a propensity to bend the trunk 
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forwards...” (Parkinson et al., 2002), a condition with the earliest reference dating back to 600 
B.C. in the ancient Indian medical literature by the name of Kampavata (Manyam, 1990; 
Ovallath & Deepa, 2013). Today, PD is characterized clinically by akinesia, bradykinesia, 
rigidity, postural instability and fatigue (Barzilai & Melamed, 2003; Jarraya et al., 2009; Nassif 
& Pereira, 2018). The degree and severity of the motor disability is measured clinically by the 
Unified Parkinson’s Disease Rating Scale (UPDRS) that measure motor functions of activities 
of daily living (Fahn & Elton, 1987). The pathophysiology of PD is characterized by the death 
of dopaminergic neurons in the SNpc resulting in dopamine deficiency in the caudate putamen 
and leading to motor symptoms. Post-mortem analysis of PD patient brains also revealed 
accumulation of Lewy bodies in dopaminergic neurons, consist largely of insoluble alpha 
synuclein, which seem to accompany dying neurons and is therefore the second hallmark of 
PD. Although is found to be protective during early stages of PD (Harischandra, Jin, 
Anantharam, Kanthasamy, & Kanthasamy, 2015), during later stage of PD, the misfolding of 
α-synuclein and accumulation of Lewy bodies are thought to be an essential mechanism 
causing the lesions seen in PD and dementia with Lewy body (Chartier & Duyckaerts, 2018). 
PD is also associated with numerous non-motor symptoms, include: hyposmia, taste perception 
deficit, psychosis, depression constipation, sleep disturbances, and sexual dysfunctions, all of 
which further reduce quality of life for PD patients (Cecchini et al., 2014; Richard L. Doty, 
2017; Friedman, 2013; Martinez-Martin, 2011; Masala et al., 2018; Pfeiffer, 2016; Rossi, 
Merello, & Perez-Lloret, 2015; Santos-García & De La Fuente-Fernández, 2013; Thobois, 
Prange, Sgambato-Faure, Tremblay, & Broussolle, 2017; Varanda et al., 2016; Videnovic & 
Golombek, 2013) Interestingly, these non-motor symptoms generally do not correlate with 
UPDRS scores or disease duration, and some symptoms, such as olfactory function, as 
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measured by University of Pennsylvania Smell Identification Test (UPSIT), is correlated with 
age (Haehner, Hummel, & Reichmann, 2009). Together with other symptoms such as sleep 
disturbances, these non-motor symptoms could precede the development of motor symptoms 
by a decade or more (Postuma et al., 2012). Although the etiology of the disease is still largely 
not understood, our understanding of the molecular mechanisms behind PD has greatly 
advanced in the last two decades. 
 
Genetic Risk Factors in PD Pathogenesis  
 
Until two decades ago, PD was not considered to have a genetic basis (Billingsley, 
Bandres-Ciga, Saez-Atienzar, & Singleton, 2018). Advances in molecular genetics and 
sequencing technology had enabled the discovery of underlying causes of PD for several 
families with increased PD occurrence. SNCA mutation discovered in 1997 was the first 
mutation found to cause monogenic PD (M H Polymeropoulos et al., 1997), where a single 
mutation is sufficient to cause the disease. LRRK2 mutation was discovered in 2004 (Zimprich 
et al., 2004), the most common cause of monogenic PD. To date, six genes, SNCA (PARK1), 
LRRK2 (PARK8), Parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7), and ATP13A2 
(PARK9) are found to cause monogenic PD. Mutations in these genes comprise of 30% of 
familial PD cases, and 3–5% of sporadic PD cases. Beyond mutations in genes that cause 
monogenic PD, mutations in other genes have been found to contribute as risk factor for PD. 
PRKN, PINK1, and DJ-1 mutations are associated with early-onset PD, and altogether, 28 
distinct chromosomal regions have been found to be associated with PD (Klein et al., 2012). 
Yet, mutations in these genes accounts for only 10% of all cases of PD, while most cases of 
PD remain idiopathic. It had therefore come to light that PD is most likely multifactorial, 
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resulting from gene-environment interactions that act on mutated susceptibility alleles present 
in the patient, to impact the aging brain.  
 
Environmental Risk Factors and Role of Mn Exposure in development of PD and PD-
Like Pathologies 
A large-scale meta-analysis analyzed 30 potential risk factors for developing PD 
(Noyce et al., 2012). Interestingly, tobacco smoking was negatively associated with PD, but 
the association is confounded by the fact that early-stage PD patients experienced decreased 
responsiveness to nicotine and therefore quit tobacco use more often (Shahi & Moochhala, 
1991). Although several other studies had found protective effects of nicotine in tobacco smoke 
and suggested its role in PD therapy (Barreto, Iarkov, & Moran, 2015; Ma, Liu, Neumann, & 
Gao, 2017), a history of smoking increased the risk of dementia in PD by almost two fold 
(Yaqian Xu, Yang, & Shang, 2016) and the nature of its effect on PD remain controversial 
(Ascherio & Schwarzschild, 2016; Shahi & Moochhala, 1991). The meta-analysis had found 
11 environmental factors considered as risk factors for PD. Among them, the top risk factors 
are pesticide exposure, well-water drinking, beta-blocker use, prior head injury, agricultural 
occupation, and rural living (Foubert-Samier et al., 2012). Exposure to pesticides such as 
rotenone, paraquat, dieldrin, organophosphates and Mn (in the form of pesticide Maneb) are 
implicated in development of PD (A. G. Kanthasamy et al., 2008; Roede & Miller, 2014; 
Semchuk et al., 1992; Singh et al., 2018; Tanner et al., 2011). Additionally, exposure to Mn in 
an occupational setting could increase risks for developing Parkinsonian symptoms by 3 - 10 
fold (Gorell et al., 1999). Longitudinal cohort study of 886 welding-exposed workers had 
found yearly changes in UPDRS scores dependent on dose of Mn exposed, which was 
especially severe in flux core arc welders who work in a confined space (Racette et al., 2017). 
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Farmers exposed to Mn-containing pesticides Maneb and Mancozeb also showed adverse 
neurological effects (Thrash, Uthayathas, Karuppagounder, Suppiramaniam, & Dhanasekaran, 
2007). 
 
Mn exposure, target organ, clinical features, pathophysiology 
 
Mn is a trace element found in all life on earth. It is an essential cofactor needed for 
such fundamental cellular processes as metabolism of fats and carbohydrates, regulation of 
blood sugar, and calcium absorption (Erikson, Syversen, Aschner, & Aschner, 2005). Mn is a 
cofactor in the reactive catalytic centers of essential enzymes manganese catalase and MnSOD, 
both of which convert and reduce oxidants (Species, Finkel, & Species, 2001). Mn exists in 
various chemical forms including several oxidation states (Mn2+, Mn3+, Mn4+) (Rask, Miner, 
& Buseck, 1987; Reaney & Smith, 2005), a property which enabled its wide industrial uses. 
Current safety measures may not adequately protect welders from aerosolized metals, and 
consequently, risks of overexposure to Mn for workers such as welders and miners in 
occupational settings are increased, usually via dermal absorption and inhalation routes. 
Excessive absorbed Mn can accumulate in the brain, a major organ of Mn toxicity during 
overexposure, where it preferentially concentrate in globus pallidus and striatum in monkeys 
(Dastur DK, Manghani DK, 1971; Fujii, 1975) and humans (Aschner, 2006; Aschner, Guilarte, 
Schneider, & Zheng, 2007; Sarkar et al., 2018; Wooten, Aweda, Lewis, Gross, & Lapi, 2017; 
Yokel, 2009), to cause cell death in the basal ganglia and disruption of the nigrostriatal 
pathway. Disruption of several neurotransmitter systems, particularly the dopaminergic 
system, results in pathology that manifests itself in a set of extrapyramidal symptoms similar 
to Parkinson’s disease, called manganism: postural instability, bradykinesia, micrographia, and 
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a characteristic cock-walk caused by dystonia of the legs (Cersosimo & Koller, 2006; C. W. 
Olanow, 2004; Perl & Olanow, 2007). Due to these similarities, Mn exposure has been used 
as a mouse model for PD since 1973 (Villalobos et al., 2009). Studies assessing Mn toxicity 
are listed in Table 1. Furthermore, mitochondrial dysfunction and oxidative stress processes 
occurring in PD are strikingly similar to the neurodegenerative processes occurring also in 
manganism, suggesting that these dysregulated processes could be common in both 
manganism and PD. 
 
Table 1. Studies showing a wide range of doses used for Mn treatment in rodents. 
Animal 
Model 
Dose, Route of Administration 
and Duration 
Effects Study 
White Rats Oral, 5.6mg/kg/day, 30 days Decreased 
performance in 
maze test 
Shukakidze et al., 
2003 
White Rats Oral, 6.5mg/kg/day, 30 days Decreased 
activity in open 
field test 
Vezer et al., 2005, 
2007 
Sprague-
Dawley Rats 
Oral, 328mg/kg/day, 21 days Increased 
acoustic startle 
response 
Golub et al., 2005 
C57B/6 mice Intranasal, 30mg/kg/day, 21 days Decreased 
activity in open 
field test 
Johnson et al., 2018 
C57B/6 mice Oral, 30mg/kg/day/21 days Decreased 
activity in open 
field 
D.-S. Kim et al., 
2017 
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Mn mechanisms of toxicity: transport, mitochondrial accumulation, induction of 
epigenetic changes 
In the body, Mn can be transported into the cell by a few metal transporters: divalent 
metal transporter 1 (DMT1), bicarbonate ion symporters ZIP8 and ZIP14, transferrin receptor 
(TFR), solute carrier-39 (SLC39) family of zinc transporters, ATP13A2, and magnesium 
transporter HIP14. Among these, DMT1 and TFR are most studied in their function to transport 
Mn. In the cell, Mn is sequestered to the mitochondria by Ca2+ uniporter (Gunter, Gavin, 
Aschner, & Gunter, 2006), and gradually increase in concentration due to extremely slow 
efflux (Gavin, Gunter, & Gunter, 1990; Martinez-Finley, Gavin, Aschner, & Gunter, 2013). 
Mn treatment in cells has been shown to increase oxidative stress, and some studies had shown 
that Mn could inhibit mitochondrial efflux of Ca2+, thus increasing Ca2+ concentration and 
leading to overproduction of ROS (Tjalkens, Zoran, Mohl, & Barhoumi, 2006).  
In dopaminergic neuronal cells, Mn could cause caspase-3-dependent PKCδ cleavage 
of an active PKCδ product (41 kDa) capable of translocating into the nucleus for expression of 
proapoptotic genes (Masashi Kitazawa et al., 2005; Latchoumycandane et al., 2005; D. Zhang, 
Kanthasamy, Anantharam, & Kanthasamy, 2011). Meanwhile, PKCδ also negatively regulates 
tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis, by enhancing 
protein phosphatase-2A activity in dopaminergic neurons (D. Zhang et al., 2011). Since Mn 
preferentially accumulates in the basal ganglia, it could profoundly affect dopamine release 
from dopaminergic neuronal terminals in the striatum (Guilarte, 2010). Furthermore, Mn 
exposure is capable of inhibiting the acetylation of core histones in SH-SY5Y cell models of 
PD (Guo et al., 2018) and inducing epigenetic changes in several PD-associated PARK genes 
(Tarale et al., 2017). Maternal developmental Mn exposure in mice could affect neurogenesis 
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of newborn mice and increased promoter hypermethylation and transcript down-regulation of 
large number of genes even through postnatal day 77 (L. Wang et al., 2013).  
Currently, Mn overexposure is treated with chelation therapy for immediate 
sequestration of remaining Mn in body fluids, most commonly with edetate calcium disodium 
(EDTA), and more recently, with para-aminosalicylic acid (PAS), for the primary goal of 
removing the patient from further exposure (J. Lee, 2000). The extrapyramidal symptoms of 
manganism patients initially respond to L-DOPA treatment after short-term observation 
(Mena, Court, Fuenzalida, Papavasiliou, & Cotzias, 1970), but failed to show significant 
benefit from L-DOPA treatment in patients with chronic manganese poisoning. Furthermore, 
no treatment is available for the neurorestoration of degenerated neurons affected by Mn 
overexposure. Since cellar mechanisms of toxicity overlaps with PD, the common pathways 
of neuronal degeneration are similar between manganism and PD, the differences of 
manganism vs PD arises out of preferential accumulation of Mn in basal ganglia. It is therefore 
speculated that protective strategies against neurodegeneration caused by Mn overexposure 
could also have similar protective effects against neurodegeneration in PD.  
 
Induction of Neuroinflammation from Exposure to Environmental Neurotoxicants 
 
Inflammation of the brain, or neuroinflammation, triggered by environmental toxicants, 
is recognized as a major contributor of PD progression during neurodegeneration. Although 
divergent molecular events characterize the progression of Parkinson’s disease (PD), 
Alzheimer’s disease, and amyotrophic lateral sclerosis, neuroinflammation emerges as one 
common theme among the cellular events underlying these neurodegenerative diseases (Block 
& Hong, 2005; Heneka et al., 2015; J. K. Lee, Tran, & Tansey, 2009; McGeer & McGeer, 
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2004; Mrak & Griffin, 2005). Recent work from animal studies and epidemical studies have 
provided evidence that neuroinflammation contributes to progressive cell death events (Y. S. 
Kim & Joh, 2006; McGeer & McGeer, 2008).  
Neuroinflammation is mediated primarily by two types of glial cells: microglia and 
astrocytes. normally quiescent in a healthy brain, glia are immune effector cells that provide 
critical support for the neurons which they surround. Resting microglia secrete low amounts 
of pro-inflammatory cytokines and exhibit a ramified morphology, a characteristic of 
“surveilling” microglia. Similarly, astrocytes normally participate in the glutamine-glutamate 
cycle, maintain glial-neuron contact, and secrete neurotrophic factors. However, upon toxicant 
insult, both can be activated. Microglia undergo morphological changes into an amoeba-like 
morphology, and dramatically increase the release of pro-inflammatory cytokines. Astrocytes 
upregulate surface expression of GFAP, and secrete pro-inflammatory cytokines. Activation 
of glia is one of the earliest response to injury that is intended to be a compensatory, 
neuroprotective response to neurodegeneration as evident by glial release of neurotrophic 
factors during early phase of injury, and is intended to facilitate phagocytic removal of dead 
cells or debris or preserve neuronal survival.  
However, chronic injury, as can be caused by repeated exposure to environmental 
toxicants, trigger glial activation that could establish a self-sustaining cycle of 
neuroinflammation (Orr, Rowe, & Halliday, 2002), which manifests itself as proliferation of 
activated microglia and astrocytes, activation and nuclear translocation of NF-κB and elevation 
of cytotoxic cytokines, including tumor necrosis factor-α (TNF-α), inducible nitric oxide 
synthase (iNOS), nitric oxide (NO), interleukin (IL)-1beta, IL-6, cyclooxygenase-2(COX-2), 
and prostaglandins E2 (PGE2). 
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Potent inducers of neuroinflammation, such as MPTP, could elevate brain 
inflammatory factors years after a single administration in nonhuman primates, long after 
initial injury and cell death (Orr et al., 2002; Tansey, McCoy, & Frank-Cannon, 2007), 
suggesting that a cascade of events involving neuronal cell death could aggravate glia 
activation and produce a vicious cycle of  a self-propelling and self-sustaining neurotoxicity. 
In the case of PD, sustained neuroinflammation in the substantia nigra and elsewhere 
contribute to disease progression, as it is detrimental to dopaminergic neuron survival. 
Postmortem brains of AD, PD, and HD patients have revealed extensive neuroinflammation 
with distinct elevation of pro-inflammatory cytokines TNF-α, IL-12, IL-6, and IL-1β. While 
each of the chemicals described below (manganese, MPTP, rotenone, and dieldrin) may impact 
cellular processes through unique mechanisms, a common pathway of toxic 
neuroinflammation emerges.  
 
Mn 
Manganese (Mn) is an essential trace element in all known living organisms for such 
fundamental cellular processes as fat and carbohydrate metabolism, regulation of blood sugar, 
and calcium absorption (Erikson et al., 2005). Mn has a wide range of industrial uses, and is 
present in welding fumes, mining dust, and fungicides. Risks of its occupational overexposure 
are therefore increased for welders (Ngwa, Kanthasamy, Jin, Anantharam, & Kanthasamy, 
2014), miners (Gendelman et al., 2015), or famers who are exposed to Mn-based pesticides 
Maneb (Mn ethylene-bis-dithiocarbamate) and Mancozeb. Mn is transported into neuronal 
cells by divalent metal transporter 1 (DMT1), and chronic overexposure to Mn could directly 
cause neuronal cell death (Roth, Horbinski, Higgins, Lein, & Garrick, 2002). Mn3+ participate 
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in the oxidation of dopamine to aminochrome (dopaminochrome), the precursor of 
neuromelanin. However, aminochrome accumulation in cell culture medium induces acute cell 
death (Paris & Segura-Aguilar, 2011). In neuronal cell cultures, Mn treatment induced 
cytochrome C release, caspase-3 activation, and DNA fragmentation. More recently, 
mechanistic studies had shown that caspase-3 activation following Mn treatment could 
proteolytically activate protein kinase Cdelta (PKCδ), a noncanonical member of protein 
kinase C family of kinases(Masashi Kitazawa et al., 2005). Cultured neurons expressing a 
dominant negative form of PKCδ protein were found to be resistant to Mn-induced apoptosis. 
Small interfering RNA suppression of PKCδ expression or cotreatment with the PKCδ 
inhibitor rottlerin significantly blocked Mn-induced DNA fragmentation, suggesting that 
activation of PKCδ signaling represents a major mechanism in Mn-induced apoptotic cell death 
(Latchoumycandane et al., 2005). Mn could directly cause neuronal cell death, while at the 
same time also induce neuroinflammation (Sarkar et al., 2018). In astrocyte cultures, Mn 
exposure increased expression of GFAP, a marker for activated astrocytes, and stimulated the 
release of proinflammatory cytokines. Mn also disrupts astrocytic regulation of glutamate by 
increasing the promoter activity of Ying Yang 1, (YY1), a negative regulator of glutamate 
transporter (GLT-1) (Karki et al., 2014). Microglial activation in response to Mn is even more 
pronounced. In primary and immortalized microglia cultures, manganese could induce much 
higher excessive expression of TNF-α, IL-12, IL-6, IL-10, and IL-1β and stimulate iNOS 
protein levels through the activation of the NF-κB and p50/p65 nuclear translocation to induce 
expression of inflammatory genes (Filipov, Seegal, & Lawrence, 2005; Verina, Kiihl, 
Schneider, & Guilarte, 2011). These toxic inflammatory factors are directly cytotoxic to 
neurons (Filipov et al., 2005) 
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MPTP/MPP(+) 
MPTP is a contaminant during the synthesis of meperidine (pethidine), an opioid drug 
used illicitly. Users who accidently injected MPTP developed irreversible PD-like symptoms 
of rigidity and bradykinesia (J. Langston, Ballard, Tetrud, & Irwin, 1983). Postmortem analysis 
of these patients showed selective dopaminergic cell death and marked increase in glial 
activation in the substantia nigra (J. W. Langston et al., 1999). As a lipophilic pro-toxicant, 
MPTP readily crosses the blood brain barrier, where it is metabolized by monoamine oxidase 
B (MAO-B) in astrocytes into active toxicant MPP(+) (Heikkila, Manzino, Cabbat, & 
Duvoisin, 1984, 1985). The exact mechanism of MPP(+) release from astrocytes is not clear, 
but nonetheless, it can be taken up by dopaminergic neurons via the dopamine transporter 
(DAT) (Gainetdinov, Fumagalli, Jones, & Caron, 2002). MPP(+) accumulates in the 
mitochondria to inhibit complex I of the electron transport chain, thereby causing a dissipation 
of mitochondrial potential, a collapse in ATP production, and neuronal cell death. Surface 
expression of signals by dying neurons to stimulate phagocytosis by microglia leads to greater 
infiltration of the region by activated microglia to remove dead neurons(Tansey et al., 2007).  
In microglia, MPP(+) can be taken up via organic cation transporter 3 (OCT3) and 
potentiates LPS-induced TNF-α expression(Qian He, Wang, Yuan, & Wang, 2017). MPP(+) 
downregulates miR-7116-5p in microglia, which normally suppresses overproduction of TNF-
α, suggesting that MPP(+)-induced dysregulation of this suppression sends TNF-α production 
in microglia into overdrive (Qian He et al., 2017).  
MPP(+) in astrocytes activates inflammasomes, further aggravates neuroinflammation 
(Qiao et al., 2016). Mechanistically, MPP(+) downregulates ATP13A2, thereby increasing 
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lysosomal membrane permeabilization and cathepsin B release. This induces activation of nod-
like receptor protein 3 (NLRP3) inflammasome, to produce excess IL-1β from astrocytes (Qiao 
et al., 2016). Furthermore, MPTP treatment reduced IGF-1 levels in the substantia nigra of 
aged rats (Labandeira-Garcia, Costa-Besada, Labandeira, Villar-Cheda, & Rodríguez-Perez, 
2017), which reduced the stimulation AKT phosphorylation and activation (Madathil et al., 
2013). When optimally activated, AKT signaling leads to a robust anti-inflammatory response 
by inducing DJ-1 and HIF1alpha levels (Jha, Jha, Kar, Ambasta, & Kumar, 2015). Disruption 
of this pro-survival, anti-inflammatory signaling pathway compounds the inflammatory effects 
produced by glial cells.   
 
Rotenone 
Rotenone is a broad-spectrum insecticide, piscicide, and pesticide, and exposure to it 
has been implicated in the development of neuroinflammation and the progression of PD 
(Betarbet & Greenamyre, 2008; Cannon et al., 2009; Dranka, Zielonka, Kanthasamy, & 
Kalyanaraman, 2012; Sherer, Betarbet, Kim, & Greenamyre, 2003; Tanner et al., 2011). 
Rotenone is a known inhibitor of mitochondrial complex I; its exposure in neuronal cells 
causes the collapse of mitochondrial potential and release of mitochondrial cytochrome C, 
initiating the intrinsic apoptotic pathway. In microglia, rotenone exposure directly induces the 
phosphorylation of p38 and activation of p38 MAPK pathway, a stress activated protein kinase 
pathway that leads to NF-κB activation and p50/p65 transcription factor nuclear translocation 
for expression of pro-inflammatory genes IL-1beta and TNF-α (Bachstetter et al., 2011). 
Although the role of NF-κB remains controversial, activation of NF-κB in microglia and 
astrocytes generally results in production of proinflammatory cytokines TNF-α and IL-6, 
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which are produced in particularly high amounts by glial cells (Mattson & Camandola, 2001). 
In addition, transcription factor p65 can bind to the NF-κB consensus sequence on the COX-2 
promoter, leading to expression of COX-2, a major pro-inflammatory mediator (Minghetti, 
2004).   
Rotenone exposure also induces the activity of GSK3β (Han, Casson, Chidlow, & 
Wood, 2014), a crucial regulator of the inflammatory response. GSK3β has an inhibitory effect 
on CREB nuclear translocation, thereby allowing for transcription of pro-inflammatory genes 
such as interleukin-1-Beta (IL-1β) and TNF-α(Maixner & Weng, 2013).  Inversely, inhibition 
of GSK3β increases CREB DNA binding activity and increases transcription of anti-
inflammatory IL-10 (Maixner & Weng, 2013). Rotenone-induced cytotoxicity in cultured 
dopaminergic neuronal cells could be attenuated by the GSK3β inhibitor SB216763 (Hongo et 
al., 2012), suggesting that GSK3β signaling could mediate rotenone-induced neuronal toxicity. 
In astrocytes, GSK3β induction generally increases iNOS, nitric oxide (NO), cyclooxygenase-
2(COX-2), prostaglandins E2 (PGE2), and TNF-α expression (H.-M. Wang et al., 2013). 
In microglia, GSK3β mediates the increased release of pro-inflammatory cytokines (Q. 
Cao, Karthikeyan, Dheen, Kaur, & Ling, 2017). A general mechanism could be mediated 
through activation of mixed lineage kinases (MLK). Both rotenone and MPP(+) can activate 
GSK3β, and decreasing GSK3β activity blocked MLK3 signaling cascades through disruption 
of MLK3 dimerization-induced autophosphorylation, inhibiting the downstream stress 
activated JNK pathway, ultimately leading to a decrease in TNF-α secretion(L. H. Wang, 
Besirli, & Johnson, 2004; M.-J. Wang, Huang, Chen, Chang, & Kuo, 2010). Furthermore, the 
pan-MLKs inhibitor, CEP-1347, was shown to prevent dopaminergic neuronal loss in pre-
clinical animal models of PD (A. Kanthasamy et al., 2012).  
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Dieldrin 
Dieldrin is an organochlorine pesticide that was used in the US in the late 1980s for 
control of insects. Despite its discontinuation of use in early 1990s, it persists heavily in the 
environment. Dieldrin could stimulate pro-inflammatory IL-8 and TNF-α responses in Jurkat 
cells(Saliha, Eric, Frederique, Etinne, & Christian, 2018), and can activate peripheral 
neutrophils to promote the production of IL-8 (Pelletier et al., 2001). The highly lipophilic 
dieldrin readily crosses the blood brain barrier (Moretto & Colosio, 2011) and its exposure has 
been implicated in PD disease progression (Cowie et al., 2017; A. G. Kanthasamy et al., 2008). 
Presence of dieldrin could be seen in postmortem analysis of brains in some PD patients but 
not in control brains (Corrigan, Murray, Wyatt, & Shore, 1998; Fleming, Mann, Bean, Briggle, 
& Sanchez-Ramos, 1994; A. G. Kanthasamy, Kitazawa, Kanthasamy, & Anantharam, 2005), 
together with high levels of glial activation, thus correlating dieldrin exposure with 
neuroinflammation. While less is known about dieldrin’s role in induction of 
neuroinflammation, evidence from in vitro studies so far has shown that dieldrin could activate 
microglia via NADPH oxidase 2 (NOX2) activation (Taetzsch & Block, 2013) to increase 
ROS, thereby causing a pro-inflammatory state in microglia. Additionally, dieldrin could 
activate the non-receptor tyrosine kinase, Fyn kinase (Saminathan, Asaithambi, Anantharam, 
Kanthasamy, & Kanthasamy, 2011), which, could phosphorylate PKCδ at the Y311 site, 
resulting in increased PKCδ kinase activity (Panicker et al., 2015). Similar to Mn, dieldrin 
could also induce neuronal cell death by activating caspase-3, then caspase-3-dependent 
proteolytic activation of PKCδ (M. Kitazawa, Anantharam, & Kanthasamy, 2003). 
Furthermore, dieldrin exposure has been found to induce aberrant acetylation of core histone 
H3 and H4 within minutes of exposure in dopaminergic neuronal cultures (C. Song, 
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Kanthasamy, Anantharam, Sun, & Kanthasamy, 2010). Alternatively, dieldrin treatment could 
also induce caspase-dependent proteolytic cleavage and inactivation of poly(ADP-ribose) 
polymerase (PARP), a cellular pathway for DNA damage repair that can be inactivated by 
extensive DNA damage and activated by pro-survival BCL-2 overexpression (Masashi 
Kitazawa, Anantharam, Kanthasamy, & Kanthasamy, 2004). Interestingly, dieldrin exposure-
induced epigenetic changes in Jurkat T cells could cause increased transcription of human 
endogenous retroviruses, vestiges of ancient retroviral infections of the germline normally kept 
in check by heterochromatin (Saliha et al., 2018). Expression of these degenerated copies of 
viral genes nonetheless could induce inflammation and is implicated in multiple sclerosis. 
 
Synergistic Effects  
The cause of neuroinflammation and the resulting neuronal cell death is generally 
multifactorial, involving exposure to chemicals that could initiate such toxic conditions, or 
several such initiators that could potentiate neuroinflammatory effects, as well as cellular 
responses to disturbances of signaling pathways. Bacterial inflammogen LPS has been shown 
to potentiate neurotoxic effects induced by environmental toxicant rotenone (Gao, Hong, 
Zhang, & Liu, 2002). Similarly, Mn-containing pesticide Maneb could act synergistically with 
paraquat, another pesticide with structural similarity with MPTP, to produce compounded 
toxicity on the dopaminergic system (Thiruchelvam, Brockel, Richfield, Baggs, & Cory-
Slechta, 2000). Such multifactorial mode of exposure more realistically reflects the condition 
experienced in patients during neuroinflammation induced by neurodegeneration.  
As mechanisms of action for environmental toxicants to cause neuroinflammation are 
elucidated, therapeutic strategies are devised against these target pathways. For example, the 
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Fyn inhibitor saracatinib is used to inhibit Fyn-PKCδ signaling in status epilepticus-induced 
neuroinflammation (Sharma et al., 2018), and rotenone-induced cytotoxicity in cultured 
dopaminergic neuronal cells could be attenuated by the GSK3β inhibitor SB216763 (Hongo et 
al., 2012). Epidemiology studies and animal studies had suggested that non-steroidal anti-
inflammatory drugs (NSAIDs) could lower risk of PD (McGeer & McGeer, 2004). Lastly, 
neuroinflammation could also aggravate tissue damage by inducing oxidative stress in glia, 
through production of high levels of ROS, and through arachidonic acid signaling by activating 
cyclooxygenase (COX) and lipoxygenase (LOX) pathways.  
 
Hypotheses Regarding PD Pathogenesis  
 
Several hypotheses have attempted to correlate environmental exposures with the 
development of PD motor and non-motor pathologies.  
Braak staging  
The Braak staging hypothesis attempts to explain PD pathology in terms of PD 
temporal and spatial progression; it correlates the exposure of environmental agents 
(chemicals, viruses, bacteria) in the peripheries (nose, gut) with initial appearance of Lewy 
bodies in the olfactory system and enteric nervous system (Braak et al., 2003; Jellinger, 2009), 
resulting in gut constipation and lessened sense of smell. Interestingly, a 1918 pandemic flu 
that became strongly associated with post-encephalitic parkinsonism also had lend strength to 
this hypothesis (Billingsley et al., 2018). During stage II-III of the Braak staging, Lewy body 
pathology subsequently enters the central nervous system, and by spreading in a caudal-to-
rostral direction, affects the brain stem, followed by substantia nigra, (Dickson, Uchikado, 
Fujishiro, & Tsuboi, 2010), damaging particularly the non-myelinated dopaminergic neurons. 
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In later stages of PD, Lewy pathology have been found in the cortex, corresponding to the later 
Braak stages (Del Tredici & Braak, 2016).  
 
Oxidative stress and mitochondrial dysfunction 
SNpc dopaminergic neurons are uniquely vulnerable to damage. These non-myelinated 
neurons, number approximately 300,000-600,000 in humans (Chinta & Andersen, 2005; 
Schultz, 2007), have extensive innervations extending into the striatum (each neuron has an 
upwards of 150,000 presynaptic terminals in the striatum (Roberts, Force, & Kung, 2002)), 
resulting in neuronal soma accounting for only 1% of cell volume (Sulzer, 2007). The 
extensive networks of innervations require relatively higher energy demands and are thus more 
susceptible to defects in organelle trafficking. Further, since neuromelanin is a major iron 
storage in the brain, the highest concentrations of iron are found in the SN and the striatum 
(Fernandez, Ferrer, Gil, & Hilfiker, 2017). The accumulation of excess iron is further 
substantially increased in brains of PD patients (Jiang, Luan, Wang, & Xie, 2006). Excessive 
iron can cause hydroxyl radical production via the Fenton reaction, leading to oxidative stress 
accompanied by the oxidation and modification of proteins, lipids, carbohydrates and DNA. 
The oxidative stress is compounded by the spontaneous auto-oxidation of dopamine to produce 
O2-, which is converted to H2O2 (Miyazaki & Asanuma, 2008) in mitochondria of 
dopaminergic neurons, inducing mitochondrial damage (Surmeier & Schumacker, 2013). The 
convergence of oxidative stress and mitochondrial dysfunction make SNpc dopaminergic 
neurons particularly vulnerable. Borrowing a concept from cancer biology where multiple hits 
by initiator carcinogens, promoter carcinogens, and loss of apoptotic signal balances are 
required for cancer progression and metastasis, the multiple hit hypothesis for PD etiology 
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focuses on environmental exposure as “primary hits” that initiate neuronal stress in 
combination with loss of protective pathways in neurons as “secondary hits”, resulting in 
dopaminergic neurodegeneration (Sulzer, 2007).  
 
Olfactory vector hypothesis 
Another hypothesis, the olfactory vector hypothesis for PD, attempts to correlate 
olfactory deficits, a symptom manifested in almost 90% of both Alzheimer’s disease (AD) and 
PD during early stages of these diseases (Richard L. Doty, 2008), with the initiation of AD and 
PD pathologies (R L Doty, Reyes, & Gregor, 1987; Ward, 1986; Wattendorf et al., 2009), with 
some proponents even suggesting that PD is primarily an olfactory disorder with 
accompanying motor dysfunctions during later stages (Hawkes, 1999). This hypothesis for PD 
pathogenesis takes into consideration that 1) clinical observation of PD found olfactory deficits 
“rivals or exceeds the prevalence rate of the defining motor signs of the disorder”; 2) findings 
that suggest pesticide exposure is a top risk factor for PD; 3) a number of viruses, aerosolized 
metals, chemicals, could be taken up by olfactory sensory neurons and enter the brain through 
the olfactory bulb, a circumventricular organ that allow toxicants to bypass much of the blood 
brain barrier. A number of studies indicating that MPTP treatment or LPS treatment 
administered through the nasal cavity better recapitulate motor and non-motor symptoms 
compared to intraperitoneal administration seem to support this hypothesis (D. S. Prediger et 
al., 2011; Qing He et al., 2013).  
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Animal Models of PD for Studying Gene-Environment Interactions 
 
Several animal models of PD have been developed in order to test hypotheses regarding 
PD pathogenesis and to evaluate therapeutic strategies devised against PD progression. MPTP 
is the most frequently used Parkinsonian toxicant applied in the generation of animal models 
of PD (Beal, 2001; Przedborski et al., 2001), with the obvious advantage that of MPTP was 
clinically observed in 1979 to produce a human model of the disease upon accidental injection 
(Davis et al., 1979; J. Langston et al., 1983).  
More recently, a genetic model of PD called MitoPark mice has been developed which 
recapitulate most of the characteristic behavioral symptoms of PD, including the slow 
progressive dopaminergic degeneration that takes place over a time course of months. This 
causes a gradual onset of motor function impairment seen in PD patients (Ekstrand et al., 2007). 
The animal model is constructed by conditionally knockout of mitochondrial transcription 
factor A (TFAM) in dopaminergic neurons using the Cre-loxP system, leading to reduced 
mitochondrial DNA expression, and respiratory chain deficiency (Ekstrand et al., 2007). 
Interestingly, using MitoPark mice, it was found that Mn exposure worsened depletion of 
striatal dopamine and accelerated the progressive nature of motor deficits already taking place. 
Importantly, using the MitoPark mice, Mn was found to aggravate the neuroinflammatory 
processes as indicated by increased IBA-1-immunoreactive microglia cells in the SN, 
strengthening the experimental evidence the interaction between PD susceptibility genes and 
environmental exposures. The MitoPark mouse genetic model of PD therefore represent a 
unique model for studying the interaction of genetic and environmental factors, and their 
contributions to the neurodegenerative process, during disease progression (Langley et al., 
2018).  
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Background and Literature Review II   
Current PD Experimental Therapy Landscape and the Potential of GDNF 
 
PD remain an incurable disease condition and the state-of-the art PD therapy remain 
focused on disease symptomatic management (Pires et al., 2017). L-DOPA, the precursor for 
dopamine, was discovered by Swedish scientist Arvid Carlsson in the 1950’s to mitigate motor 
symptoms in Parkinsonian mice, seminal findings to which the Nobel Prize in physiology or 
medicine was awarded in 2000. Decades since discovery of L-DOPA’s effects, it remains the 
strongest arsenal against PD disease symptoms (Mercuri & Bernardi, 2005). Currently, 
pharmacological remediation for countering the decrease in dopamine concentrations or 
receptor activity in the caudate putamen include dopamine agonists and monoamine oxidase B 
(MAO-B) inhibitors and Catechol-O-methyl transferase (COMT) inhibitors, both which inhibit 
degradation of dopamine, and are used many times in combination with L-DOPA 
administration.  
Although more choices in medications and combinations of medications have been 
recently made available, the fundamental treatment strategy of symptomatic management has 
remained the same. Despite an increasingly complex combination of therapies, once the 
“honeymoon” of L-DOPA period has waned, PD patients derive increasingly less efficacy 
(Rascol et al., 2003) and increasingly more side-effects (Smith, Wichmann, Factor, & Delong, 
2012) from the available treatments. Chronic use of L-DOPA leads to dyskinesia induced by 
stimulation of dopamine receptor 1 expressed by medium spiny neurons in the striatum. To 
mitigate dyskinesia induced by L-DOPA treatment, dopamine receptor agonists apomorphine, 
pramipexole and ropinirole are prescribed, either in place of L-DOPA, or more likely during 
later stages of PD, in combination with L-DOPA (Holloway et al., 2004). However, although 
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they reduce dyskinesia, they also increase orthostatic hypotension and psychiatric symptoms 
such as psychosis, depression. In the case of orthostatic hypotension, it affects 30% of the PD 
patients and is treated with L-Threo-dihydroxyphenylserine (L-DOPS) (S., M.V., A., & O., 
2013). In the case of PD-associated psychosis, it affects around half of advanced PD patients, 
and limited options include pimavanserin (Holloway et al., 2004). Surgical interventions for 
PD symptomatic control involves the implantation of deep brain stimulation (DBS) device into 
the brain of PD patients, commonly the internal pallidum or the subthalamic nucleus (Fang & 
Tolleson, 2017). An electrical wire is planted inside the target area, which applies intermittent 
direct electrical current, with frequencies above the native firing rates, thus generating an 
inhibitory effect on the target (Benazzouz & Hallett, 2000). However, major drawbacks, aside 
from being only available to selective patients, include surgical complications, occasional 
hardware failure, and worsening of neuropsychiatric side effects (Ughratdar, Samuel, & 
Ashkan, 2015). In late stage PD, treatment-resistant motor symptoms contribute to the burden 
of complications facing PD patients, for whom falls or accidental choking could be common 
(Hely, Morris, Reid, & Trafficante, 2005). Clearly, the current challenge is a fundamental 
treatment therapy that could slow or stop the progressive nature of the disease and restore 
dopaminergic innervation and function.  
 
Current Clinical Trials for Experimental Therapies  
Current disease-modifying clinical trials focus on three primary goals, which are (1) to 
compensate for dopamine deficiency or other neurodegenerative changes; (2) to provide 
trophic support to neurons and compensate for metabolic abnormalities; and (3) to replace lost 
dopaminergic neurons using cell-based therapies (Lang & Espay, 2018). A summary of clinical 
trials currently underway is listed in Table 2 (Athauda & Foltynie, 2016; Bergstrom, Kallunki, 
29 
& Fog, 2016; Brundin, Dave, & Kordower, 2017; Karuppagounder et al., 2014; Kingwell, 
2017; Mahul-Mellier et al., 2014; Schneeberger, Tierney, & Mandler, 2016; Surmeier, Obeso, 
& Halliday, 2017). 
 
Table 2. Current on-going clinical trials, showing the drug name, the mechanism of action, and 
the status of the trials. 
Drug name Main Mechanism of Action Status of Trial 
NPT200-11 Inhibition of alpha-synuclein misfolding Phase I 
PD01A/PD03A Immunization against alpha-synuclein Phase I 
R07046015 Immunization against alpha-synuclein Phase II 
BIIB054 Immunization against alpha-synuclein Phase II 
Nilotinib Inhibition of C-Abl /alpha-synuclein 
aggregation 
Phase II 
Isradipine Inhibition of Cav1 channels Phase III 
Inosine Elevation of urate levels in plasma or 
cerebrospinal fluid 
Phase III 
Deferiprone Iron chelator/crosses BBB to reduce iron 
levels in brain 
Phase III 
Exenatide Restoration of protein synthesis processes, 
autophagy, and mitochondrial biogenesis 
Completed 
AZD3241 irreversible inhibitor of myeloperoxidase Phase II 
Nicotine patches Protection of apoptosis for dopaminergic 
neurons  
Phase II 
EPI-589 (R-
troloxamide quinone) 
Increase in GSH levels in cells Phase II 
Stromal stem cells Release of pro-survival factors Phase I/II combined 
AAV-2 GDNF Neurotrophic factor for dopaminergic 
neuronal survival 
Recruiting for phase 
I 
 
As a hallmark during PD neurodegenerative process, alpha-synuclein aggregation has 
been the target of a number of clinical trials, with goals for its degradation or reduction of its 
protein synthesis, misfolding, and cell-to-cell transmission (Kalia, Kalia, & Lang, 2015). 
However, instead of focusing on early events, a critical downside to these clinical trials lie in 
that they focus on the formation of alpha-synuclein aggregation and Lewy body, a late-stage 
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event in the pathophysiology of PD. Moreover, since alpha-synuclein has been found to 
protective during early stage of disease, more concrete understanding of the role of alpha-
synuclein is needed to ensure successes of therapies targeting alpha-synuclein. Some studies 
focus on specific aspects of the neurodegenerative process as clinical endpoints, rather than 
improvements in patient UPDRS, for demonstration of efficacy. For example, AZD3241 is 
being evaluated in a phase IIa randomized placebo controlled multicenter positron emission 
tomography (PET) study for its effects on activated microglia in PD patients (Jucaite et al., 
2015). EPI-589 (R-troloxamide quinone) is being evaluated in phase II trial using the increases 
in cellular levels of antioxidant GSH as a biomarker and endpoint (clinical trial 
NCT02462603). Aside from ones listed in the table, Epigallocatechin gallate (EGCG) is also 
nearing clinical trial stage (Perni et al., 2017; Yan Xu et al., 2016). Lastly, glial cell-derived 
neurotrophic factor (GDNF) which has been evaluated in a number of high profile clinical 
trials but did not realize hoped-for results. It is currently under a phase II trial in association 
with the Michael J. Fox Foundation using an improved delivery method. The potential of 
GDNF as a therapeutic candidate is a topic which will receive special attention in the following 
sections.  
 
Glial-cell line Derived Neurotrophic Factor 
GDNF is the founding member of GDNF family of neurotrophic factors artemin, 
persephin and neurturin, which are members of the transforming growth factor-β superfamily 
(Airaksinen & Saarma, 2002). GDNF is a glycosylated homodimer, with a molecular weight 
of 33-45 kDa as a dimer and 16 kDa after deglycosylation (L. F. Lin et al., 1993). Synthesized 
as a 211-amino acid pre-proGDNF, it is cleaved by furin proteases prior to secretion as a 134-
amino acid mature protein.  
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Each of the four members of the GDNF family signal through multicomponent receptor 
complexes, by preferential binding of GDNF, neurturin, artemin, or persephin to 
glycosylphosphatidylinositol-anchored cell surface protein GFRα1, GFRα2, GFRα3, GFRα4, 
respectively. The GDNF-GFRα1 complex binds to the Ret tyrosine kinase, the GDNF co-
receptor, for transduction of intracellular signaling (Figure 1).  
 
Figure 1. Signaling mechanisms of GDNF family neurotrophic factors. GFRα receptors are 
preferentially located on lipid rafts, and the pairs GDNF-GFRα1, neurturin-GFRα2, artemin-
GFRα3, persephin-GFRα4 activate co-receptor Ret tyrosine kinase for signal transduction. 
Adapted from (Airaksinen & Saarma, 2002) 
 
Regulation of GDNF expression 
 
A number of factors could induce expression of GDNF, such as docosahexaenoic acid, 
imipramine, adenosine, apomorphine, dopamine, and riluzole (Y. Kim et al., 2011; L. Zhang 
et al., 2017). During development, GDNF support the growth of midbrain dopamine neurons 
and motoneurons, as well as peripheral neurons, including sympathetic, parasympathetic, 
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sensory and enteric neurons (Sariola, 2003). A number of transcription factors, Pax2, Eya1, 
Six1, Six2, Sall1, Foxc1, Wt1, and Hox11 could induce GDNF expression during kidney 
development. (Saavedra, Baltazar, & Duarte, 2008).  
During neuronal injury, the predominant amount of GDNF is secreted by glial cells for 
neuronal maintenance and survival (Saavedra et al., 2008). Compensatory induction of GDNF 
is observed in response to lipopolysaccharide (LPS) treatment in astroglioma cells (Appel, 
Kolman, Kazimirsky, Blumberg, & Brodie, 1997). In the dopaminergic system, Ret expression 
is required for modulation of protective effects, whereas the absence of Ret abolishes GDNF's 
neuroprotective and regenerative effect (Drinkut et al., 2016).  
In hippocampal and cortical neurons lacking Ret tyrosine kinase, the neuronal cell 
adhesion molecule (NCAM) is an alternative signaling receptor for GDNF family neurotrophic 
factors. GDNF-GFRα1 association with NCAM, instead of Ret, induces axonal growth in 
hippocampal and cortical neurons via binding to NCAM, leading to its interaction with focal 
adhesion kinase Fak (Paratcha, Ledda, & Ibáñez, 2003). Transcriptionally, GDNF can be 
upregulated by Nurr1, Pitx3 in cultured dopaminergic neurons. Activation of p44/42 ERK and 
PI3-K/AKT pathways have also been show to induce GDNF expression (Tanabe, Matsushima-
Nishiwaki, Iida, Kozawa, & Iida, 2012). GDNF can also be regulated by FGF2, via induction 
of EGR1 (Shin et al., 2009). Epigenetically, chronic stress could affect histone modifications 
and DNA methylation of the Gdnf promoter, leading to changes in GDNF expression (Uchida 
et al., 2011).  
GDNF is currently being assessed for its therapeutic potential in clinical trials, as 
detailed in the next sections. As one of the most studied neurotrophic factors in the brain, much 
knowledge has accumulated about its biology and its mechanisms of action. However, 
33 
transcription factors that drives its expression are not completely known, and even less is 
known about pharmacological agents that could modulate its expression. Yet, such agents 
could prove immensely helpful in activating GDNF or other neurotrophic factors in brains of 
PD patients.  
 
GDNF: a promising candidate for disease modifying therapy 
 
Discovery and early studies 
With early studies in 1993 that discovered GDNF in glioma cell lines, researchers 
quickly realized its potential as a potent and selective growth factor for mesencephalic 
dopaminergic neurons and a stimulator of neurite growth (L. F. Lin et al., 1993). By 1994, 
direct injection of GDNF had been used in unilateral 6-OHDA rat model of PD for its effects 
on amphetamine-induced contralateral rotational behavior, and showed a 4-fold decrease in 
contralateral rotational behavior in rats that received ipsilateral dopaminergic neuron 
degeneration (Hoffer et al., 1994). The next year, in 1995, studies injecting GDNF in the SN 
or in striatum of mice before MPTP injection found potent protection against MPTP-induced 
nigrostriatal lesion, and observed higher dopamine nerve terminal densities and dopamine 
levels (Tomac et al., 1995). By 1996, monkeys treated with MPTP were used to successfully 
show the potential of intraputamental injection of GDNF in both rescuing motor deficits and 
restoring striatal dopamine levels (Gash et al., 1996).  
 
First-in-human safety and tolerability studies (Rush Medical Center Chicago) 
Perhaps emboldened by the non-human primate study, the first-in-human study was 
done at Rush Medical Center in Chicago in 1999, led by Jeffrey Kordower, in a 65-year-old 
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PD patient, who received monthly intracerebroventricular injections of GDNF (J H Kordower 
et al., 1999). However, no improvements on motor symptoms were seen, and side effects 
included nausea, loss of appetite, tingling, intermittent hallucinations, and depression. 
Importantly, GDNF was thought to not have diffused into the deep layers of the brain 
(intraparenchymal diffusion). The results suggested that an alternative GDNF delivery system 
is needed. A second study in monkeys was reported in 2000, where lentivirus coding for GDNF 
was injected into the striatum and SN of young adult rhesus monkeys treated prior with MPTP. 
The lenti-GDNF was able to reverse functional deficits and completely prevented nigrostriatal 
degeneration (J. H. Kordower et al., 2000). The study had also found extensive anterograde 
and retrograde transport of GDNF, and it was realized later that GDNF retrograde transport to 
the SN was required for its protective effects (Tenenbaum & Humbert-Claude, 2017). A third 
study in 2002 subjecting MPTP-treated rhesus monkeys with chronic infusion of 5 or 15 
µg/day of GDNF using programmable pumps into the lateral ventricle or the striatum, had 
found restoration of the nigrostriatal dopaminergic system and significantly improved motor 
functions (Grondin et al., 2002).  
 
Intracerebroventricular GDNF injection (Phase I/II, open-label, led by Gary Nutt) 
Prompted by new efficacy data in primates, in the same year in 2002, a prominent 
Swedish neuroscientist, Patrick Brundin, called for a clinical trial evaluating GDNF as a PD 
therapy (Brundin, 2002). In a perhaps still premature attempt, the first controlled trial was 
conducted in 2003, led by Gary Nutt, to test the safety, tolerability, and biological activity of 
GDNF administered by an implanted intracerebroventricular (ICV) catheter in a dose-
escalation study in 50 PD patients for 8 months (Nutt et al., 2003). After the 8 months, some 
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patients became part of the open-label study extending exposure up to an additional 20 months, 
and some patients were in groups that received the maximum of 4,000µg GDNF. 
Unfortunately, the study did not achieve the efficacy that was hoped: motor UPDRS scores 
were not improved, and moreover, significant adverse effects, such as nausea and vomiting 
were common hours to several days after treatment with GDNF, and one person died after 
three weeks, from events unrelated to GDNF treatment.  
 
Direct putamenal GDNF injection (Phase I, open-label, Frenchay Hospital) 
Since the first-in-human study reported in 1999 had speculated that ICV-administered 
GDNF did not penetrate deep into the layers of brain into the SN and striatum, another study, 
led by Steve Gill, had reported in 2003 which tested safety and feasibility of direct putamenal 
injection of GDNF protein using catheters in 5 PD patients (Gill et al., 2003). The recombinant 
methionine human GDNF was produced by Amgen as liatermin or r-metHuGDNF, and had 
the sequence of mature GDNF with an N-terminal-tagged methionine. The results from this 
open label, phase I safety study were positive, with no serious clinical side effects and drastic 
improvements in motor symptoms. Positron emission tomography (PET) scans of 
[(18)F]dopamine uptake also showed improvements in putamen dopamine storage after 18 
months. However, since this study was an open label study, a randomized, controlled study is 
needed.  
 
Intraputamenal GDNF infusion (Phase II, randomized controlled trial, Amgen) 
 
Encouraged by results from previous open-label study, a phase II trial started in 2003 
and reported in 2006, led by Anthony E Lang at the Toronto Western Hospital, in association 
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with Amgen. A randomized controlled trial of 34 PD patients receiving continuous bilateral 
intraputamenal infusion of liatermin 15 at µ/day, or placebo, in each putamen, was conducted 
(Lang et al., 2006). Although patients did not develop severe side effects, no change in primary 
endpoint was seen and no change in UPDRS ratings were found. Additionally, some patients 
developed antibodies against GDNF. Although are no direct adverse effect from production of 
antibodies against GDNF during the treatment course, the neutralizing antibodies could render 
the treatment less effective, and depending on the epitopes that the antibodies targeted, could 
further decrease endogenous GDNF after treatment cessation.  
 
Unilateral intraputaminal GDNF infusion (Phase I, open-label, led by John Slevin) 
Another study was done in parallel for testing the safety and tolerability of a dose-
escalation regimen of administration of Amgen’s GDNF protein, increasing from 3 µg/day, to 
30µg/day, over a 6-month period. The delivery method used was unilateral intraputaminal 
GDNF infusion using a multiport catheter that delivered continuous infusion at 2µl/h, into the 
most affected putamen in the 10 patients with advanced PD (Slevin et al., 2005). At 24 weeks 
of treatment, UPDRS scores significantly improved, as did balance and gait. The only observed 
side effects were transient Lhermitte's sign, a tingling electric shock sensation produced by 
flexing the neck. The open-label study demonstrated the safety and potential efficacy of 
unilateral intraputaminal GDNF infusion and showed sustained effects after the withdrawal of 
treatment. But before a phase II trial could be conducted, Amgen halted all trials using GDNF, 
since the earlier phase II trial led by Anthony Lang did not meet primary endpoint of 
improvement in UPDRS, and toxicity in higher doses of GDNF was seen in non-human 
primates. A follow-up study of patients in the phase I open-label trial confirmed the previous 
37 
phase II trial; all benefits seen during treatment were lost after 1 year of GDNF infusions, 
UPDRS returned to patient baseline, and motor symptoms required higher levels of 
conventional antiparkinsonian drugs (Slevin et al., 2007). Further, GDNF neutralizing 
antibodies were also detected.  
 
GDNF family - Neurturin phase I/II trials 
 
Another GDNF family member, neurturin, was undergoing a number of clinical trials 
in parallel with GDNF. In 2008, the first safety and tolerability of intraputaminal delivery of 
adeno-associated virus serotype 2-neurturin (AAV2-neuturin/CERE-120) was conducted in 
PD patients by the pharmaceutical company Ceregene (Marks et al., 2008). In this open-label 
trial, the delivery method was found safe and feasible. But two years later, in 2010, Ceregene 
reported that the a double-blind, randomized, controlled trial of CERE-120 largely did not meet 
its primary endpoint (Marks et al., 2008), and importantly, brain tumors were found in both 
the AAV-neurturin treatment group and the AAV vector group, suggesting that the vector 
could be associated with tumorigenesis.  
Since the report also suggested that impaired axonal transport of neurturin from 
putamen to SN reduced the effectiveness of neurturin injection in striatum, SN-injection of 
AAV-neuturin was therefore assessed for functional efficacy in rats (Herzog et al., 2013), then 
in human (Bartus et al., 2013) for safety and feasibility of direct delivery into the SN, which 
reported in 2013. For a second double-blind, randomized, controlled trial reported in 2015 
(Warren Olanow et al., 2015), AAV-neurturin or placebo were delivered into both putamen 
and SN in 51 PD patients. Although there were no clinically meaningful adverse events, no 
significant differences were found between the groups in the evaluation of primary endpoint.  
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Despite the promising potential of GDNF and GDNF family member neurturin, side 
effects and efficiency in delivery remain big hurdles. To date, all attempts to develop GDNF 
or any other therapy as a cure for PD have failed. Candidate therapies shown to work in current 
animal models of PD had failed to modify the progression of disease and show improvements 
in human clinical endpoints. Two major aspects that undermined the efficacy of GDNF in 
humans have been attributed to difficulty in candidate drug evaluation in animal models and 
delivery of the drug into patients.  
 
Reasons for trial failures: animal model selection 
 
Currently, no single animal model of PD exists that is ideal for all types of studies. 
Administration of Parkinsonian toxicants such as 6-hydroxydopamine (6-OHDA) and MPTP 
in rodents and primates have been widely-used to elicit dopaminergic neuronal degeneration 
and motor symptoms, and have been tremendously useful in evaluating dopamine-based 
therapies that could potentially provide symptomatic management (Bezard, Yue, Kirik, & 
Spillantini, 2013; C. Warren Olanow & Kordower, 2009). However, dopamine-based therapies 
are themselves stopgap solution in finding a disease-modifying therapy.  
The MPTP model is the most commonly used model, and the most commonly used 
method employs acute administration of MPTP into animals to selectively kill dopaminergic 
neurons. However, in PD patients, dopaminergic neuronal death occurs in a backdrop of a 
slowly evolving neurodegenerative processes, with competing compensatory responses, and 
the acute administration of MPTP may not properly reflect the time-dependent, complex 
cascade of events relevance to what occurs in the brain of a PD patients. Instead, MPTP 
treatment in mice could have its own compensatory response different from that of PD patients. 
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For example, acute MPTP treatment could induce TH+ neurons to increase their branching as 
a compensatory response (D. D. Song & Haber, 2000).  
To reduce attrition of drug candidates, more accurate animal models would need to be 
employed to evaluate new neuroprotective therapies. To this end, transgenic models based on 
genes involved in the pathogenesis of PD found through human genetic studies have 
increasingly received more attention.  
 
Reasons for trial failures: delivery methods and side effects 
 
Purified GDNF protein was directly injected into the putamen of PD patients in the 
trials conducted by Amgen. In a separate study using the same protocol and procedures, 
Salvatore et al. had reported that unilaterally infused GDNF in the putamen of adult rhesus 
monkeys was concentrated around the delivery catheter, with concentration dropping 
exponentially in the tissues away from the catheter (Salvatore et al., 2006). The volume of 
distribution of GDNF around the catheter ranged between 87 to 369 mm3, which covers 2%-
9% of the total 3-4000 mm3 of the human putamen (Salvatore et al., 2006). Since GDNF protein 
has a limited diffusion range, an ideal delivery method, aside from pharmacological 
modulation of endogenous GDNF, would carry GDNF or GDNF-coding cDNA further away 
from the delivery site, into larger areas of the putamen and SN, for efficient protective effects. 
Although AAV2-mediated delivery of GDNF cDNA allow GDNF expression in wider areas 
of the putamen, as seen in the AAV2-neurturin trial, both AAV2-neuturin and vector were 
associated with tumorigenesis (Marks et al., 2008). Lastly, some patients had developed 
GDNF-neutralizing antibodies. Little is known about this process, but it is likely that excess 
GDNF injected into the brain is leaked from the CNS into the peripheries, where the exogenous 
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GDNF protein encounters immune cells in the peripheries. In summary, for the above reasons, 
pharmacological modulation of endogenous GDNF levels that could be tightly controlled 
might resolve issues associated with protein diffusion, leakage, and transgene tumorigenicity.  
 
Background and Literature Review III 
Prokineticin-2 
 
Structure of Prokineticins 
 
Prokineticin-1 and prokineticin-2 are a pair of secreted signaling neuropeptides 
discovered around thirty years ago. From the venom of the black mamba snake, a non-toxic 
cysteine-rich protein was isolated and named mamba intestinal toxin 1 (MIT-1), for its ability 
to potently contract guinea pig ileum (Schweitz, Pacaud, Diochot, Moinier, & Lazdunski, 
1999). Later it was found to be homologous with another protein isolated from the skin of the 
frog Bombina variegata named Bv8 (Mollay et al., 1999). Since both could potently induce gut 
motility, when the human homologs were cloned, the MIT-1 homolog was named Prokineticin-
1 (PK1), which maps to chromosome 1p21. The Bv8 homolog was named Prokineticin-2 
(PK2), which maps to chromosome 3p21.1, an unstable chromosomal synteny breakpoint 
region. PK1 (86 amino acids), and PK2 (81 amino acids) share 45% amino acid identity. 
Contained within the protein sequences are 19 peptides serving as secretion signal in the 
mature proteins.  
Prominent structural features and determinants include 10 crosslinked cysteine residues 
forming five disulfide bridges, which is important for the structural integrity of mature PK1 
and PK2, as highlighted in purple in Figure 2. The mature PK1 and PK2 proteins are predicted 
to have an approximate ellipsoid shape. Receptor binding are thought to involve the exposed 
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ends of N-terminus and C-terminus, of which the conserved N-terminus sequence of 6 amino 
acids AVITGA, and the C-terminal cysteine-rich domain, are indispensable for functional 
activation of the receptors (Figure 2). Mutations in the AVITGA sequence could abolish its 
activity, and substitution of alanine for methionine at the N-terminal produce PKR1 and PKR2 
antagonists. However, the AVITG peptides alone cannot activate the receptors (Bullock, Li, & 
Zhou, 2004). Mutations in cysteine residues of the C-terminal domain also result in PK1 and 
PK2 without biological activity (Bullock et al., 2004). 
A PK2 splice variant containing an extra 21 amino acids between exons 2 and 4, named 
PK2L, could undergo furin proteolytic cleavage of to produce PK2β, which has roughly 10-
fold lower potency in binding to PKR1 or PKR2 as compared to PK2, and showed selectivity 
for PKR1 (J. Chen et al., 2005). The function of the splice variant in PK2 signaling is still 
unclear. No splice forms of PK1 are currently found. The isoelectric point (pI) of PK2 is a 
relative basic 8.85, and pI of PK2L is 10.68, due to its extra 21 amino acids that are rich in 
lysine and arginine.  
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Figure 2. Multiple sequence alignment of mature protein sequences for human PK1 (red), 
human PK2 (yellow), frog PK2 homolog Bv8 (green), and snake PK1 (blue) reveals 10 
conserved cysteines in PK1 and PK2. PK1 and PK2 have 44% amino acid identity. The N-
terminal sequences (yellow highlighted region) before the first cysteine (AVITGA) is 
conserved among all species. 
 
PK1 and PK2 Signaling Through PKR1 and PKR2 
 
PK1 and PK2 bind to two cognate receptors prokineticin receptor 1 (PKR1), and 
prokineticin receptor 2 (PKR2) with similar affinity (D. C. Lin et al., 2002). The non-
mammalian homolog of PK1, MIT-1, is a PKR2-prefering agonist (L. Negri & Ferrara, 2018). 
In humans, PKR1 and PKR2 are located at chromosome 2p13.3, and 20p13, respectively. The 
prokineticin receptors are G protein-coupled receptors (GPCR), belonging to the family-A of 
GPCR, and are related to the neuropeptide Y receptor family, which has been found to 
stimulate migration of neuroprogenitor cells in the SVZ (Decressac et al., 2009). The 
sequences of both receptors are highly conserved, with nearly 85% identity, with most of the 
sequence variation appearing in the extracellular N-terminal region (D. C.-H. Lin et al., 2002). 
The structure of PKR1/PKR2 is shown in Figure 3. The endogenous peptide ligands PK1 and 
PK2 make contacts on the extracellular surface of the receptors with the second extracellular 
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loop, which is stabilized by a disulfide bond formed between two cysteine residues located on 
the first and second extracellular loops (L. Negri & Ferrara, 2018). 
 
Figure 3. PKR1 and PKR2 have 85% sequence similarity. The predicted structure of PKR1 
and PKR2 (differences shaded in black). The extracellular domain (N-terminus) and 
intracellular (C-terminus) are labelled. Seven transmembrane regions are shaded in grey boxes. 
The binding of PK1 or PK2 to either receptors may be coupled to Gq to induce calcium 
mobilization (Q Y Zhou, 2006), or Gs to induce cAMP accumulation (J. Chen et al., 2005), or 
Gi to activate p44/42 MAPK signaling (Ngan & Tam, 2008), indicating that multiple pathways 
are involved in prokineticin signaling depending on cell type. Figure 4 provides an overview 
of prokineticin signaling in the body primarily outside of CNS.  
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Figure 4. Summary of Prokineticin signaling in the body. Particularly in the enteric system, 
Prokineticin signaling could crosstalk with GDNF signaling to induce differentiation, and 
migration of ENS neurons. Each of the mentioned processes or associated disease conditions 
are explained in the text (adapted from Ngan & Tam, 2008).  
PK1 and PKR1 are more widely distributed in peripheral tissues such as reproductive, 
gastrointestinal, and blood systems than PK2 and PKR2, who are expressed more widely in 
the central nervous system (Michelle Y Cheng, Leslie, & Zhou, 2006). High levels of both 
PKR1 and PKR2 are seen in steroidogenic glands (ovary, testis, adrenal gland and placenta), 
and PKR2 knockout mice exhibit arrested spermatogenesis (Masumoto et al., 2006). 
Interestingly, in the fallopian tube, PKR1 expression is stimulated by nicotine exposure, via 
nicotinic AChRalpha-7 (Shaw et al., 2010).  
In the brain, neurons express both PKR1 and PKR2, with PKR2 expression 
predominant in the brain overall. Yet in astrocytes, PKR1 expression is predominant, with 
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minimal expression of PKR2 (Puverel, Nakatani, Parras, & Soussi-Yanicostas, 2009). The 
non-selectivity of the PKs and differential expression of PKR1 vs PKR2 suggests that the effect 
of the ligands PK1 and PK2 are mediated depending on the receptor that are present at the 
target tissues. For instance, corpus luteum-derived endothelial cells (LEC) express both PKR1 
and PKR2, whereas aorta endothelial cells (BAEC) and brain capillaries endothelial cells 
(BCEC) express only PKR1. In these tissue types, PK1 is mitogenic for LEC and BAEC 
endothelial cells, but has no effect on BCEC endothelial cells (Monnier & Samson, 2010). 
PK2 is expressed in the bone marrow, and responds to granulocyte colony-stimulating 
factor for inducing hematopoietic cell proliferation (Shojaei et al., 2007). Importantly, PK2 
expression can also be stimulated by hypoxia through HIF1α to induce growth and 
angiogenesis by endothelial cells. Similarly, PK2 can be activated by STAT3, which induces 
proliferative effects (Kujawski et al., 2008). Due to these mitogenic effects, PK2 is implicated 
in tumorigenesis and survival of tumors in hypoxic conditions. The PK2/PKR1 signaling axis 
promotes cardiomyocyte survival and angiogenesis, and in the mouse model of myocardial 
infarction, transient PKR1 transfection in the heart could protect the heart’s structure and 
function (Boulberdaa, Urayama, & Nebigil, 2011). Mechanistically, overexpressing PK2 or 
PKR1 activates AKT to protect cardiomyocytes against oxidative stress, and siRNA against 
PKR1 completely reversed the protective effects (Urayama et al., 2007). Further, loss of PKR1 
in mice leads to heart and kidney abnormalities due to mitochondrial defects (Nebigil, 2010).  
One of the earliest discovered properties of PK2 is its ability to induce hyperalgesia to 
pain stimulus when injected into paws of rats. The majority of dorsal root ganglion cells 
responding to stimuli co-express both PKR1 as well as the transient receptor potential vanilloid 
1 (TRPV1), and PKR1 receptor activation potentiates the activation of TRPV1, significantly 
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lowering the nociceptor threshold to physical and chemical stimuli (Lucia Negri et al., 2002). 
PKR1-null mice showed impaired acute nociception, compromising what is an essentially 
protective response against further injury.  
PK1 could induce differentiation of bone marrow cells into monocyte/macrophages 
(Dorsch et al., 2005), and is highly expressed in the endothelial cells of blood vessels and the 
ovaries to induce angiogenesis, giving it the alternative name endocrine gland vascular 
endothelial growth factor (EG-VEGF) (Fraser et al., 2005). A number of PK1, PKR1, PKR2 
polymorphisms are associated with recurrent pregnancy loss (Y. Cao et al., 2016; M.-T. Su et 
al., 2010; M. T. Su, Lin, Chen, & Kuo, 2014; Mei-Tsz Su et al., 2010). These and other studies 
had found that during pregnancy, the expression of EG-VEGF/PK1 and PKR1, PKR2 are 
controlled temporally in human placenta of the first and third trimester period. This expression 
pattern suggests their important roles, especially during human early pregnancy, when 
vascularization of the chorionic villi in the placenta is essential for successful pregnancy. The 
dynamic expression of PK1 may be regulated by estrogen, progesterone and human chorionic 
gonadotrophin, and has also been proposed to be regulated by HIF-1α via hypoxia-response 
element in the promoter region of PK1. Several polymorphisms, PROKR1 (I379V) 
and PROKR2 (V331M) conferred protection in recurrent pregnancy loss via decreased 
intracellular calcium influx and increased cell invasiveness (M. T. Su, Lin, Chen, Wu, & Kuo, 
2013). Cell proliferation, cell–cell adhesion, and tube organization are not affected, and the 
mechanisms of protection owing to the polymorphisms are not completely understood.  
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PK1-GDNF Signaling in the Enteric Nervous System 
 
In the enteric nervous system, PK1 is indispensable for the development of enteric 
neurons. PK1, but not PK2, is expressed in mouse embryonic gut during enteric nervous system 
development (Ngan et al., 2007). During this critical period, dysregulation in GDNF or PK1 
signaling in the enteric system causes in defects in proliferation and differentiation of neural 
crest stem cells, and cause a condition in humans known as Hirschsprung disease (Iwashita, 
Kruger, Pardal, Kiel, & Morrison, 2003). Mechanistically, the proliferative and differentiation 
effects of PK1 is potentiated by GDNF via upregulating PKR1 expression in enteric neural 
crest stem cells. Further, overexpression of PKR1 could rescue a lack of RET signaling, 
suggesting that PK1 and GDNF signaling pathways share some common downstream targets 
(Ngan et al., 2007).  
However, little is known about the involvement of prokineticin signaling with GDNF 
in the central nervous system during development, and even less during neurodegenerative 
processes. Since PK2, and not PK1, participates as key regulator of biological processes in the 
brain, the following sections will focus on the function of PK2 in the brain and during 
neurodegenerative processes.  
 
PK2 Signaling in the Brain 
 
PK2 transcriptional regulation by circadian rhythm  
 
In the brain, PK2 and PKR2 are both highly expressed in the hypothalamus, the limbic 
system, and olfactory bulbs. PK2 is also highly expressed in the suprachiasmatic nucleus 
(SCN), the regulator of circadian rhythm in mammals. Levels of PK2 expression oscillates 
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from the highest during the day to almost undetectable at night, and is entrainable by light 
(Michelle Y. Cheng et al., 2002). In vitro studies revealed that PK2 is under the control of first-
order clock-controlled genes, particularly the basic helix-loop-helix transcription factors 
(bHLH) CLOCK-BMAL1, which are master regulator of circadian rhythm. CLOCK-BMAL1 
could transcriptionally regulate PK2 gene expression by binding to enhancer-box (E-Box) 
element sequence (CACGTG) in the PK2 proximal promoter region. Soon it was also found 
that other bHLH transcription factors Ngn1 and MASH1/ASCL1 could also bind to the PK2 
promoter to regulate its effects on neurogenesis (C. Zhang et al., 2007), HIF1α, as a bHLH 
transcription factor, was also postulated to bind to the PK2 promoter.  
In vivo studies indicated that mice lacking the clock gene also have drastically reduced 
oscillation of PK2 expression in the SCN. Moreover, intracerebroventricular injection of PK2 
protein disrupts normal nocturnal locomotor activity in nocturnal mice. Interestingly, injection 
of PK2 into the arcuate nucleus, a target of SCN, could suppress feeding without affecting 
drinking. When injected into the subfornical organ, an indirect target of SCN via the 
paraventricular nuclei (PVN), PK2 stimulated drinking without affecting feeding (Lucia Negri 
et al., 2004). Therefore, PK2 output from the SCN could transmit the circadian rhythm of 
feeding and water regulation in the body. Studies in diurnal rats revealed similar temporal 
expression pattern as nocturnal mice, which seems to indicate that diurnality lies downstream 
of the SCN for rodents (Lambert, Machida, Smale, Nunez, & Weaver, 2005). However, PK2 
antagonist could produce opposite effects of the PK2 signaling on the arousal levels in the 
nocturnal mice and diurnal monkey, which could be attributable to the differential expression 
of receptors for PK2 in the intrinsically photosensitive retinal ganglion cells (ipRGC) that 
transmit photonic information to SCN for the two animals, therefore suggesting that diurnality 
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could lie upstream of the SCN starting from the response of ipRGC to light (Qun Yong Zhou 
et al., 2016).  
 
PK2 induces neurogenesis 
PK2 signaling is necessary for olfactory bulb neurogenesis and the continuing 
migration of neuroprogenitor cells (NPC) from the subventricular zone (SVZ) through the 
rostral migratory stream (RMS) during adulthood. PK2 is highly expressed in the olfactory 
bulbs, where it acts as a chemoattracant for SVZ-born neuroprogenitor cells migrating towards 
the olfactory bulb (Ng et al., 2005). In the SVZ, accumulation of pkr2 transcripts was detected 
in almost all migrating neuroblasts (Puverel et al., 2009). In the absence of PK2 signaling, it 
seems that the neuroprogenitors cells do not detach from the rostral migratory stream properly, 
or they are disoriented about the direction of migration (Winner & Winkler, 2015). In Pk2-/- 
mice, the olfactory bulbs do not develop normally and are less than half the size of wildtype 
controls, and exhibit multiple abnormalities in the various layers of the olfactory bulbs (Ng et 
al., 2005). Interestingly, during early development, the lack of organization of the olfactory 
bulb hinders the migration of a group of neurons, gonadotrophin-releasing hormone (GnRH) 
neurons, from the olfactory placode in the peripheries, through the olfactory bulb, to the 
hypothalamus, where they extend processes to the median eminence. The precise mechanisms 
that guide these small group of neurons through such long distances are unclear, but 
nonetheless, the lack of organization of the olfactory bulb obfuscates their migratory path. The 
failure of this group of neurons to migrate in turn results in a lack of gonadotrophin-releasing 
hormone normally secreted during puberty (Schwarting, Wierman, & Tobet, 2007). Thus, due 
to its crucial involvement in the morphogenesis of the mature olfactory bulb, loss of PK2 
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signaling arising from defects in either PK2 or PKR2 in humans causes a severe form of 
Kallmann syndrome, characterized by both anosmia and lack of puberty (S.-H. Kim, 2015). 
Similar to the case with PKR2 involvement in pregnancy, PKR2 polymorphisms could strongly 
influence disease severity. In three disease-associated mutations of the PKR2, W178S, G234D, 
and P290S, the mutant receptors are trapped in the cellular secretary pathway within the cell, 
never transported to the cell surface or properly integrated into the cell membrane (D. N. Chen, 
Ma, Liu, Zhou, & Li, 2014).  
 
PKR1/PKR2 Agonists and Antagonists 
 
While PK1 and PK2 make are endogenous and convenient agonists to the cognate 
PKR1 and PKR2 receptors, efforts have been made to synthesize smaller or more efficient 
agonists, and to look for antagonists of the receptors. Early studies had found that changes in 
the conserved N-terminal sequences result in the loss of agonist activity. The first antagonists 
were made such a way – substitution of alanine with methionine at position 1 created A1MPK1, 
and addition of a methionine to the N terminus created MetPK1 (Bullock et al., 2004).  
A chemical Prokineticin receptor antagonist, 6‐[(2‐Amino‐pyridin‐3‐ylmethyl)‐
amino]‐1,3‐bis‐(4‐methoxy‐benzyl)‐1H‐[1,3,5] triazine‐2,4‐dione, was able to block PK2-
induced increases in intracellular Ca2+ mobilization in CHO cells transfected with human 
PKR1 or PKR2 (Watson et al., 2012). No off-target effects were detected in a Novartis safety 
panel of 60 different receptors, suggesting a high-selectivity for prokineticin receptors.  
From patented chemical structures release by what was known as Janssen 
Pharmaceuticals, 3 related compounds, with general structure 1,3,5-triazin-4,6-diones, were 
synthesized and were shown to inhibit Bv8/PK2-induced intracellular Ca2+ mobilization 
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(Balboni et al., 2008). The most effective compound, triazine Compound 1, at 300 nM, was 
able to inhibit close to 96% of cells from responding to 1 nM of Bv8/PK2-induced intracellular 
Ca2+ mobilization, suggesting that these triazine compounds are potential pharmacological 
prokineticin receptor antagonists (Balboni et al., 2008).  
Recently, three more compounds, PKR-A, PKRA7, and A547 were synthesized and 
found to have antagonistic activities against either or both of the receptors. PKRA7, a PKR2-
preferring antagonist, has been found to have anti-tumor activity in glioblastoma and 
pancreatic cancer xenograft tumor models (Curtis et al., 2013). PKR-A is a receptor antagonist 
that blocks both PKR1 and PKR2. It belongs to a group of morpholine carboxamide 
prokineticin antagonists (Patent US7855201), and was found to inhibit PKR2 at a IC50 of 48.1 
± 4.6 nM, in CHO cells stably expressing PKR2 (M Y Cheng et al., 2012). An interesting case 
lies with A457, another morpholine carboxamide prokineticin antagonist. As previously 
mentioned, three disease-associated mutations of the PKR2 (W178S, G234D, and P290S), 
cause deficiency in trafficking, resulting in retention of PKR2 within the cellular secretory 
pathways (D. N. Chen et al., 2014). Using a different modeling methodology employing the 
use of Phyre2 (Protein Homology/Analog Y Recognition Engine), the PKR2 W178S, G234D, 
and P290S sequences were modelled. Interestingly, A457 dramatically increased cell surface 
expression and rescued the function of PKR2 with P290S mutation in a dose- and time-
dependent manner, withou de novo protein synthesis. Data showed that A457 could affect the 
conformation only around its binding site. It is therefore thought that P290S mutation causes 
a subtle distortion in transmembrane domain VI, and binding of A457 allosterically to the 
mutant receptor enables it to act as a pharmacological chaperone, to affect its conformation 
and correct the misfolding (D. N. Chen et al., 2014). 
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In the recent few years, the first PKR1 agonists were designed, synthesized, and 
characterized. A group based in France used a homology model computational screening 
method to screen a library of 250,000 compounds and found 10 potential hits, which were 
tested in vitro (Gasser et al., 2015). One compound was found to mobilize intracellular Ca2+, 
and activate AKT, ERK signaling. Thirty more compounds, named IS1 through IS30, were 
then synthesized based on this parent compound. The most potent derivative, IS20, was 
confirmed for its selectivity and specificity to PKR1. Using this compound, the group showed 
that IS20 prevented cardiac lesion formation after myocardial infarction, and improved cardiac 
function. In line with numerous previously published in vitro studies using endogenous PKR1 
agonists which confirmed PKR1’s proliferative effects in cardiomyocytes (Boulberdaa, 
Turkeri, et al., 2011; Boulberdaa, Urayama, et al., 2011; Nebigil, 2010; Urayama et al., 2007), 
IS20 was shown to promote proliferation of cardiac progenitor cells and neovasculogenesis in 
the heart (Gasser et al., 2015).  
We previously showed that PK2 mRNA was highly induced by TNFα in dopaminergic 
cell culture, and by neurodegeneration in animal models of PD. In MPP+ and MPTP classic 
Parkinsonian toxicant models, upregulation of PK2 in dopaminergic cells rescued MPP+-
induced cell death in cell culture and gene delivery of PK2 rescued MPTP-induced cell death 
in vivo [6]. Our data therefore supported the hypothesis that the upregulation of PK2 is a 
neuroprotective compensatory response relevant in PD-related neurodegeneration. Given the 
availability of PKR1 agonists, we aim to evaluate the therapeutic potential of PKR1 agonist in 
activating protective prokineticin signaling in animal model of PD. Clearly, prokineticin 
signaling is a complex network involving multiple modes of signal transduction in various cell 
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types, and it is our goal to further elucidate its mechanism of action, especially during 
neurodegenerative stress events.  
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Abstract 
While cell signaling mechanisms underlying neurotoxic injury have been actively 
studied in recent years, signaling molecules contributing to compensatory survival signaling 
are largely unknown. Recently, we reported that the secreted neuropeptide prokineticin-2 
(PK2) is upregulated during early stages of neurotoxic stress induced by MPP+, and plays a 
major compensatory protective function in nigral dopaminergic neurons in vitro and in vivo. 
To further study the transcriptional and molecular regulatory mechanisms of MPP+ and Mn-
induced PK2 upregulation, we performed in silico analysis of the PK2 promoter and revealed 
the presence of (early growth response-1) EGR1, HIF1α (hypoxia inducible factor 1), 
transcription factor E2F, and nuclear respiratory factor-1 (NRF1) putative binding sites. 
Importantly, we observed that MPP+ and Mn exposure increased HIF1α and EGR1 levels at 
early stages of neurotoxicity. Since overexpression of HIF1α or EGR1 upregulated PK2 
expression, these studies suggest that Mn regulates PK2 expression via EGR1 or HIF1α-
dependent pathway. A toxicologically relevant dose of Mn exposure by an oral route (30 mg/kg 
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for 30 days) significantly upregulated global PK2 levels in the brain, especially in the 
substantia nigra with concomitant increases in HIF1α transcription factor. Taken together, 
these results suggest that Mn upregulates PK2 levels to counter the early neurotoxic stress and 
that Mn-induced upregulation of PK2 expression is transcriptionally regulated by EGR1, 
HIF1α and NRF1. 
 
Introduction 
Parkinson’s disease (PD) is characterized by a progressive degeneration of 
dopaminergic neurons in the substantia nigra in the ventral midbrain, resulting in reduction of 
dopamine in the striatum and ensuing chronic deficits in motor functions (Kalia & Lang, 2015; 
Poewe, 2010). Clinically, nonmotor symptoms also exist, and manifests itself through 
olfactory deficits, depression, and constipation (Poewe, 2010). Following the Nobel-winning 
discovery of the role of dopamine precursor 3,4-dihydroxy-L-phenylalanine (L-dopa) in PD 
by the Swedish scientist Arvid Carlsson in the 1950’s (W & O, 1961), the standard-of-care for 
PD have continued to be the administration of L-DOPA for the management of motor 
symptoms, while having little impact on the progressively worsening neurodegeneration 
associated with the condition. In addition, symptoms such as difficulties with balance, 
swallowing, or nonmotor symptoms such as speech or cognition can be progressively resistant 
or unresponsive to L-DOPA therapy (Okun, 2012).  
Biochemically, the involvement of mitochondrial dysfunction have been recognized as 
a major contributor to disease pathology and progression (Ghosh et al., 2010; Gómez-Sánchez, 
Bravo-San Pedro, Gegg, González-Polo, & Fuentes, 2016; Jin et al., 2014; Keane, Kurzawa, 
Blain, & Morris, 2011; Mounsey & Teismann, 2010; Schapira & Gegg, 2011). Given that 
mitochondrial dysfunction has been increasing recognized as a central theme in other 
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neurodegenerative disease such as in Alzheimer’s and ALS (Cozzolino, Ferri, Valle, & Carrì, 
2013; Maruszak & Żekanowski, 2011; Von Lewinski & Keller, 2005; Yu et al., 2018), 
pathways that stimulate mitochondrial biogenesis represent druggable targets against 
neurodegeneration.  
Mn can accumulate in the brain, a major organ of Mn toxicity during overexposure. 
The disruption of the nigrostriatal pathway of the basal ganglia system in prolonged Mn 
overexposure causes a severe neurological disorder similar to Parkinson’s disease named 
Manganism (Cawte, Hams, & Kilburn, 1987). Manganism is characterized clinically by 
extrapyramidal symptoms resembling Parkinson’s disease, with depression, postural 
instability, bradykinesia, micrographia, and a characteristic cock-walk caused by dystonia of 
the legs (Cersosimo & Koller, 2006; Olanow, 2004; Perl & Olanow, 2007).   
The involvement of oxidative stress has also been recognized as a major contributor to 
Parkinsonism progression. In the substantia nigra, the pro-inflammatory tumor necrosis factor 
alpha (TNFα) could induce both protein kinase C delta (PKCδ)-mediated upregulation of 
reactive oxygen species (ROS), and microglial NADPH oxidase-mediated free radicals 
generation (Gordon, Singh, et al., 2016; Langley et al., 2018). Furthermore, ROS could prevent 
degradation of hypoxia-inducible factor-1alpha (HIF1α) under normoxic conditions (Park et 
al., 2003), and DHB, a HIF1α stabilizer, was shown to be neuroprotective in a MPTP model 
of PD (D. W. Lee et al., 2009), suggesting that HIF1α could naturally be a compensatory 
mechanism for neurons under hypoxic stress as well as oxidative stress. Studies in choroidal 
neovascularization (CNV) indicated that HIF1α expression is regulated by AKT 
phosphorylation (Yang et al., 2009), while in in cell cultures of PD, phosphorylation and 
activation of PI3K/AKT pathway could rescue neurodegeneration of dopaminergic neurons 
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during neurotoxic stress, which stimulates neurotrophic factor upregulation and counters 
neurodegeneration by inhibition of pro-apoptotic signals. Therefore, although much focus had 
been on deciphering the process of neuronal cell death, increasing efforts have more recently 
been placed on identifying early compensatory responses to neurodegeneration. 
Prokineticin-2 (PK2) is a signaling neuropeptide that regulates wide-ranging functions 
as gut motility, angiogenesis hematopoiesis, estrous cycle progression, and nociception (Hu et 
al., 2006; Negri & Lattanzi, 2012; Negri, Lattanzi, Giannini, & Melchiorri, 2007; Ngan & Tam, 
2008; Soderhall, Kim, Jiravanichpaisal, Lee, & Soderhall, 2005; Xiao et al., 2014). In the 
central nervous system (CNS), PK2 could also participates in neurogenesis (Ng et al., 2005). 
Furthermore, PK2 expression can be transactivated via basic helix-loop-helix (bHLH) 
transcription factors binding to several Enhancer-box (E-box) elements in its proximal 
promoter region. Bmal, a bHLH transcription factor part of the core component of circadian 
rhythm pacemaker, targets PK2 as one of its approximately 150 sites (Hatanaka et al., 2010), 
and activates PK2 gene expression via binding to E-box elements in its promoter as a 
heterodimer in a cyclic, rhythmic manner, resulting in its secretion from the suprachiasmatic 
nucleus (Cheng et al., 2002; J. Da Li, Hu, & Zhou, 2012; Menet, Pescatore, & Rosbash, 2014; 
Zhang et al., 2007; Q Y Zhou, 2006; Qun Yong Zhou & Cheng, 2005). 
The mitogenic effects of PK2 in the peripheries have been well characterized 
(Keramidas, Faudot, Cibiel, Feige, & Thomas, 2008; Kisliouk et al., 2005; LeCouter et al., 
2003; LeCouter, Zlot, Tejada, Peale, & Ferrara, 2004; Podlovni et al., 2006), but its role in 
CNS have been less well studied (Koyama et al., 2006; Ng et al., 2005), especially during 
neurodegeneration. During an initial screening of early gene expression changes in responses 
to neuroinflammation, we had previously discovered that PK2 became highly upregulated in 
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response to pro-inflammatory factors, which upon subsequent examination in PD animal 
models, were upregulated in nigral dopaminergic neurons preceding the onset of motor deficits 
and participated in an early, protective compensatory response to neurodegeneration (Gordon, 
Neal, et al., 2016). Mechanistic studies later showed that PK2 signaling protected against the 
Parkinsonian neurotoxicant MPP+ by countering oxidative stress, mitochondrial dysfunction 
and dopaminergic degeneration. However, the upstream mechanisms that induces PK2 
upregulation during neurodegeneration remains incompletely understood, and our goal is to 
integrate PK2’s role into the current understanding of compensatory, pro-survival signaling 
networks during neurodegeneration.  
During early stages of neurotoxicity, compensatory responses that counter pro-
apoptotic signals, stimulate mitochondrial biogenesis, are likely governed by complex 
networks of transcription factors. We hypothesized that PK2 gene expression is regulated by a 
number of such transcription factors which are known to associate with pro-survival responses 
and mitochondrial biogenesis. In this study, we examined the regulation of PK2 gene by the 
toxicant-responsive transcription factor EGR1, mitochondrial regulator NRF1, as well as pro-
survival factor HIF1α during response to Parkinsonian toxicant MPP+ and Mn. We found that 
during neurotoxic stress, EGR1, NRF1, and HIF1α could positively regulate PK2 gene 
transcription possibly by binding to putative EGR1, NRF1, or HIF1α binding sites, 
respectively. The expression of the PK2 is reduced by disruption of EGR1 or HIF1α signaling 
in dopaminergic neurons. Our results indicate that PK2 is a major downstream target of EGR1, 
NRF1, and HIF1α transcription factors during neurotoxic stress.  
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Results 
We had previously shown that PK2 upregulation is a protective, compensatory 
response to neurodegeneration, and over expression could induce mitochondrial biogenesis 
(Gordon, Neal, et al., 2016). Here, we seek to elucidate PK2’s transcriptional regulation during 
neurotoxic stress. 
Figure 1. Neurotoxicant MPP+ upregulates PK2 and induces PK2 promoter 
activity in dopaminergic neurons. Parkinsonian toxicant MPP+ has a EC50 of roughly 300µM 
during a 24h treatment in cultured dopaminergic neurons, and induces significant caspase 
activation at 8h (Gordon, Neal, et al., 2016). Quantitive PCR assay showed that Parkinsonian 
toxicants MPP+, Mn, as well as HIF1α stabilizer DHB, could induce mRNA expression in 
MN9D cell (Figure 1A). Quantitive PCR assay also showed that MPP+ treatment at 300µM in 
MN9D cultured mouse dopaminergic neurons upregulates PK2 gene expression during early 
neurotoxic stress, peaking at 3 hours post treatment, an early event that precedes dopaminergic 
cell death (Figure 1B). Western blot assay similarly showed early increases in PK2 protein 
level at 3h that remained high at 12h (Figure 1C). This suggests that PK2 is an early responder 
to MPP+ neurotoxicity. However, it is unclear if PK2 upregulation was only due to mRNA 
stabilization and posttranslational modifications on mature protein, or if PK2 expression was 
also regulated by transcriptional control during neurotoxic stress. Therefore, to determine if 
MPP+ could induce PK2 transcriptional activation, we cloned a 1kb fragment of the proximal 
promoter immediately upstream of the human PK2 gene putative transcription start site into a 
promoterless Nanoluc vector plasmid construct (pNL) encoding a nanoluciferase reporter. We 
found that MPP+ increased PK2 promoter activity in MN9D dopaminergic cell host transfected 
with the PK2 promoter construct, increasing luciferase activity at 3h and 6h-post treatment by 
2-fold, which indicates that PK2 response to MPP+ can be controlled at the level of 
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transcription (Figure 1D). These experiments indicate that neurotoxicant such as MPP+ can 
increase level of PK2 by inducing its transcription.  
Figure 2. In silico analyses reveal conserved, methylated sequences 1kb upstream 
of proximal PK2 promoter, and a wide range of transcription factors associated with 
metabolic processes, cellular processes, cellular biogenesis, and transcription factors 
regulating response to stimuli. PK2 has been shown to participate in a compensatory, 
protective response during neurotoxic stress against neurodegeneration (Gordon, Neal, et al., 
2016). While the downstream effects of PK2 on MAPK/ERK signaling has been elucidated, 
little is known about the upstream events and mechanisms that lead to PK2 upregulation during 
neurotoxicity. Previous studies had found that positive regulation of PK2 gene could be 
achieved by transcriptional factor binding to E-Box, which are present in multiple copies 
within 1kb upstream of the transcription start site (Cheng et al., 2002; Cheng, Bittman, Hattar, 
& Zhou, 2005; J.-D. Li et al., 2006; Qun Yong Zhou & Cheng, 2005). Since induction of PK2 
transcription during neurotoxic stress cannot be expected to be wholly elicited by circadian 
rhythm-responsive genes, we sought to analyze the proximal PK2 promoter region and 
comprehensively predict putative transcription factor binding sites. Firstly, to determine a 
putative promoter region, we utilized the ECR browser (ecrbrowser.dcode.org), to compare 
human PK2 promotor sequences with other species, which revealed that 1kb upstream of the 
transcription start site is conserved across rodents and canines (Figure 2A). Analysis of 
promoter CpG islands using EMBOSS CpGplot found increased CpG around -400 to +1 
relative to transcription start site (Figure 2B), and MethPrimer analysis (L. C. Li & Dahiya, 
2002) found two CpG islands near -400 to +1 of the transcription start site (Figure 2C). These 
software analyses for appearance of CpG suggest the presence of a core promoter region 
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(Deaton & Bird, 2011; Saxonov, Berg, & Brutlag, 2006). To comprehensively predict putative 
transcription factor binding sites, the 1kb upstream promoter sequences was uploaded into the 
MatInspector software (Cartharius et al., 2005; Quandt, Frech, Karas, Wingender, & Werner, 
1995) from Genomatix (Figure 2D). Using Matrix Similarity cutoff > 0.66, (indicating high 
confidence of putative transcription factor binding site), MatInspector database and algorithms 
identified 77 transcription factors that could bind to 1kb upstream proximal promoter for the 
PK2 gene (Table 1). 
 
 
Table 1. Genomatix’s MatInspector output for transcription factors predicted to bind to 1kb 
PK2 upstream proximal promoter.  
 
 
Gene Name Gene Description 
ZF04 C2H2 zinc finger transcription factors 4 
DEAF Homolog to deformed epidermal autoregulatory factor-1 from D. melanogaster 
HDBP Huntington's disease gene regulatory region binding proteins 
RU49 Zinc finger transcription factor RU49, zinc finger proliferation 1 - Zipro1 
PAX1 PAX-1 binding sites 
AHRR AHR-arnt heterodimers and AHR-related factors 
NF1F Nuclear factor 1 
CTCF 
CTCF and BORIS gene family, transcriptional regulators with 11 highly 
conserved zinc finger domains 
ZICF Members of ZIC-family, zinc finger protein of the cerebellum 
PLAG Pleomorphic adenoma gene 
ZF5F ZF5 POZ domain zinc finger 
HAND Twist subfamily of class B bHLH transcription factors 
RXRF RXR heterodimer binding sites 
AP1R MAF and AP1 related factors 
HOMF Homeodomain transcription factors 
SORY SOX/SRY-sex/testis determinig and related HMG box factors 
KLFS Krueppel like transcription factors 
BNCF Basonuclein rDNA transcription factor (PolI) 
GCMF Chorion-specific transcription factors with a GCM DNA binding domain 
RORA v-ERB and RAR-related orphan receptor alpha 
SPZ1 Testis-specific bHLH-Zip transcription factors 
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Table 1. Continued 
EGRF EGR/nerve growth factor induced protein C & related factors 
ZF02 C2H2 zinc finger transcription factors 2 
SP1F GC-Box factors SP1/GC 
RREB Ras-responsive element binding protein 
GLIF GLI zinc finger family 
E2FF E2F-myc activator/cell cycle regulator 
MAZF Myc associated zinc fingers 
SRFF Serum response element binding factor 
HIFF Hypoxia inducible factor, bHLH/PAS protein family 
FKHD Fork head domain factors 
NEUR NeuroD, Beta2, HLH domain 
RP58 RP58 (ZFP238) zinc finger protein 
MYOD Myoblast determining factors 
HNF1 Hepatic Nuclear Factor 1 
PBXC PBX1 - MEIS1 complexes 
43374 Octamer binding protein 
MYT1 MYT1 C2HC zinc finger protein 
EBOX E-box binding factors 
HES Vertebrate homologues of enhancer of split complex 
CREB cAMP-responsive element binding proteins 
ZF08 C2H2 zinc finger transcription factors 8 
NR2F Nuclear receptor subfamily 2 factors 
XBBF X-box binding factors 
NFAT Nuclear factor of activated T-cells 
CAAT CCAAT binding factors 
NGRE "Negative" glucocoticoid response elements 
NRSF Neuron-restrictive silencer factor 
ZF06 C2H2 zinc finger transcription factors 6 
GRHL Grainyhead-like transcription factors 
ETSF Human and murine ETS1 factors 
NRF1 Nuclear respiratory factor 1 
RBPF RBPJ - kappa 
BARB Barbiturate-inducible element box from pro+eukaryotic genes 
MYBL Cellular and viral myb-like transcriptional regulators 
MOKF Mouse Krueppel like factor 
MTEN Core promoter motif ten elements 
AP2F Activator protein 2 
TF2B RNA polymerase II transcription factor II B 
CHRE Carbohydrate response elements, consist of two E box motifs separated by 5 bp 
HASF HIF-1 ancillary sequence family 
SMAD Vertebrate SMAD family of transcription factors 
SREB Sterol regulatory element binding proteins 
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Table 1. Continued 
OAZF Olfactory associated zinc finger protein 
XCPE 
Activator-, mediator- and TBP-dependent core promoter element for RNA 
polymerase II transcription from TATA-less promoters 
AP1F AP1, Activating protein 1 
P53F p53 tumor suppressor 
VTBP Vertebrate TATA binding protein factor 
CDXF Vertebrate caudal related homeodomain protein 
OVOL OVO homolog-like transcription factors 
NOLF Neuron-specific olfactory factor 
CP2F CP2-erythrocyte Factor related to drosophila Elf1 
PAX3 PAX-3 binding sites 
AP4R AP4 and related proteins 
MTF1 Metal induced transcription factor 
PAX9 PAX-9 binding sites 
WHNF Winged helix binding sites 
 
 
 
The PANTHER (Protein ANalysis THrough Evolutionary Relationships) 
Classification System for Gene Ontology(Mi, Muruganujan, & Thomas, 2013; Thomas et al., 
2003), can be used to classify gene functions into broad categories (Mi, Muruganujan, 
Casagrande, & Thomas, 2013; PANTHER, 2016). We found that among the putative 
transcription factors that regulate biological processes, transcription factors that regulate 
metabolic processes represents 25% of all transcription factors and cellular processes 
represented 25% of transcription factors, two of the most enriched ontology terms (Figure 2E. 
Developmental processes represented 10.7%, cellular component organization or biogenesis 
represented 7.1%. Transcription factors that regulate response to stimuli represented 10.7%, 
biological regulation represented 7.1%, and multicellular organismal process represented 
22.2%. Number of genes that correspond to each category is listed as a histogram (Figure 2F) 
However, not all putative transcription factors were predicted to express in the CNS. Therefore, 
to narrow our focus and avoid false positives, we filtered the names of predicted transcription 
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factors using MatInspector’s database to search for known expression in a specific tissue organ. 
When filters for specific expression in CNS was applied, 23 transcription factors remained, 
and they were classified according to function (Table 2). 
 
Table 2. Putative PK2 proximal promoter binding-transcription factors that are known to 
express in the CNS.   
 
Regulation of proliferation and differentiation  
EGRF Early Growth Response/nerve growth factor induced protein C  
GLIF GLI zinc finger family 
HASF HIF-1 ancillary sequence family 
HIFF Hypoxia inducible factor, bHLH/PAS protein family 
MYT MYT1 C2HC zinc finger protein 
NRSF Neuron-restrictive silencer factor 
PLAG Pleomorphic adenoma gene 
RP58 RP58 (ZFP238) zinc finger protein 
BRN Brn-5 POU domain factors 
GRHL Grainyhead-like transcription factors 
NRF1 Nuclear respiratory factor 1 
Cell development and maintenance  
CLOX CLOX and CLOX homology (CDP) factors  
E2F E2F-myc activator/cell cycle regulator  
HESF Vertebrate homologues of enhancer of split complex  
IRX Iroquois homeobox transcription factors  
SORY SOX/SRY-sex/testis determinig and related HMG box factors  
Regulator of cell survival 
P53 p53 tumor suppressor  
DEAF Homolog to deformed epidermal autoregulatory factor-1  
MOKF Mouse Krueppel like factor  
CTCF CTCF and BORIS gene family, transcriptional regulators 
Regulation of circadian rhythm  
EBOX E-box binding factors  
RORA v-ERB and RAR-related orphan receptor alpha 
Regulation of metal homeostasis  
MTF1 Metal induced transcription factor 
 
The PANTHER classification for gene ontology was used again to analyze the resultant 
genes. Of the putative transcription factors binding to the PK2 proximal promoter that are 
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known to express in the CNS, transcription factors associated with cellar process represented 
23.8% and metabolic process represented 23.8%, again two of the most enriched gene 
ontology. Biological regulation represented 9.5% of transcription factors, cellular component 
organization or biogenesis represented 4.8%, developmental process represented 14.3%, 
multicellular organismal process represented 9.5%, and transcription factors that regulate 
response to stimulus represented 14.3% of transcription factors (Figure 2G, H).  
The in silico analyses collectively suggested that transcription factors involved with 
cellular processes and metabolic processes are the most over-represented gene ontology terms. 
This is in line with currently known roles for PK2, such as cellar process of cell-cell 
communication, and metabolic process resulting in cellular growth (Q. Y. Zhou & Meidan, 
2008). We had shown previously that PK2 is responsive to neurotoxic stress, and at early stages 
of toxicity, it acts to compensate for the pro-apoptotic signals by inducing anti-apoptotic BCL-
2 and mitochondrial biogenesis. Interestingly, regulation of stimulus and biogenesis are also 
represented in the unbiased analysis of transcription factors, possibly providing mechanisms 
for regulation of PK2 during neurotoxic stress. The unbiased analyses provided a starting point 
for further analysis and validation. 
Figure 3. PK2 may be a target gene for Early Growth Response family of 
transcription factors (EGRs), Nuclear Respiratory Factor 1 (NRF1), Hypoxia-inducible 
factor1 (HIF1α), and E2F-myc activator/cell cycle regulator. Putative transcription factors 
that regulate cell proliferation/differentiation, or cell development/maintenance are over-
represented in Table 2, suggesting that PK2, as a downstream target of these transcription 
factors, may be highly involved in the corresponding cellular functions. PK2 may be 
downstream target of proliferation-associated Early Growth Response family of transcription 
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factors (EGRs), mitochondrial biogenesis-inducing Nuclear respiratory factor 1 (NRF1), pro-
survival Hypoxia-inducible factor alpha (HIF1α), and E2F-myc activator/cell cycle regulator 
(E2F).  
The bHLH transcription factors MASH1 and Ngn1 were reported to positively regulate 
PK2 gene expression by binding to E-box elements in the proximal promoter, and HIF1α was 
speculated to interact with the PK2 promoter via similar mechanisms (Zhang et al., 2007; Q Y 
Zhou, 2006). Additional putative HIF1α binding sites in the proximal promoter revealed by in 
silico analysis in the present study further might suggest a role of HIF1α in PK2 gene 
regulation.  
The corresponding conserved core binding sites on 1kb PK2 promoter is shown in 
Figure 3A. To test if PK2 upregulation during neurotoxic stress is modulated through EGRs, 
NRF1, or HIF1α, we treated MN9D dopaminergic neurons with Parkinsonian toxicant MPP+ 
or manganese, as well as oxidative stress-inducing hydrogen peroxide (Cantu, Schaack, & 
Patel, 2009). Western blot analysis showed that MPP+, Mn, or hydrogen peroxide drastically 
increased EGR1 protein level within 6h post-treatment, suggesting that EGR1 is responsive to 
neurotoxic stress (Figure 3B). PK2 mRNA was rapidly induced by MPP+ within 30 minutes 
and is sustained at 6h (Figure 3C). These studies suggest that EGR1, NRF1, E2F and HIF1α 
co-regulate with PK2 expression during a mitochondrial inhibition-induced neurotoxicity and 
oxidative stress-induced neurotoxicity.   
Figure 4. Overexpression of EGRs, NRF1, HIF1α, or E2F1 in MN9D 
dopaminergic neurons induces PK2 promoter activity. Cotransfection of 1kb PK2 proximal 
promoter nanoluciferase reporter construct (3ug) with plasmid vector encoding wildtype 
EGR1, EGR2, EGR3, NRF1, HIF1α, HIF2α, E2F, or empty vector (9ug) for a total of 12ug 
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total transfected vector DNA. Promoter assay analyzing the expression and activity of 
nanoluciferase driven by the PK2 1kb proximal promoter indicated that members of the EGR 
family could stimulate PK2 promoter activity (Figure 4A). Similarly, NRF1 and HIF1α, also 
stimulated promoter activity (Figure 4B, 4C). Since the α subunit of HIF1 (HIF1α) is tightly 
controlled by prolyl hydroxylase, which under normoxic conditions, prevents its accumulation 
(Tennant et al., 2009), we used a prolyl hydroxylase inhibitor, DHB (ethyl 3,4 ‐
dihydroxybenzoic acid) to stabilize HIF1α protein (Lomb, Straub, & Freeman, 2007; Siddiq et 
al., 2005) in MN9D dopaminergic neurons. While DHB treatment alone induced a moderate, 
50% increase in promoter activity compared to mock treatment, DHB treatment in combination 
with HIF1α overexpression produced more than 200% increase in promoter activity (Figure 
4C). Additionally, mutant HIF1α with defective PAS domain did not stimulate the PK2 
promoter activity (Figure 4C). Since HIF2 is also needed for dopaminergic neuron survival in 
the SNpc(Smeyne, Sladen, Jiao, Dragatsis, & Smeyne, 2015), and some studies suggest that 
HIF2 might regulate prolonged hypoxic gene activation(Holmquist-Mengelbier et al., 2006), 
therefore we also tested and confirmed that HIF2 could upregulate PK2 promoter activity 
(Figure 4D). Overexpression of E2F drastically stimulated PK2 promoter activity, with nearly 
3500% increase (Figure 4E). MatInspector analysis also revealed that two EGR1 binding sites 
overlapped with NRF1 binding sites (-64/-60, and -131/-129), and it could be speculated that 
EGR1 and NRF1 could synergistically stimulate PK2 gene expression. Therefore, in a separate 
study, we co-transfected PK2 promoter construct together with both EGR1 and NRF1 plasmid 
vectors. The amount of EGR1 and NRF1 plasmid vector DNA were reduced in half (4.5ug), 
so the total amount of transfected plasmid DNA is consistent across the study (12ug total). As 
controls, we transfected the same amount of EGR1 or NRF1 (4.5ug) for this experiment (for a 
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total of 7.5ug). As expected, we found increased promoter activity with EGR1 or NRF1-
transfected cells compared to empty vector control.  
To further confirm if overexpression of EGR1, NRF1, HIF1α or E2F1 could induce 
PK2 gene expression, MN9D dopaminergic neurons were separately transfected with plasmid 
DNA encoding cDNAs of these transcription factors for 16h, to allow for expression of plasmid 
DNA. Analysis using qPCR showed that EGR1 overexpression induced PK2 gene expression 
approximately 4.5-fold of control, while NRF1 overexpression induced > 3-fold of control, 
HIF1α overexpression induced > 4-fold of control, and E2F overexpression induced > 5-fold 
of control (Figure 4F-4I). Collectively, this set of experiments indicate that EGRs, NRF1, 
HIF1α, HIF2α, or E2F could induce PK2 gene expression, and transcription factors EGR1 and 
NRF1 could together could synergistically activate PK2 gene expression.  
Figure 5. Promoter sequence most proximal to transcription start site induces 
highest level of transcription activity. Next, to find the promoter region most efficient in 
stimulating transcription of downstream PK2 gene, we sequentially deleted 250 bases from the 
5’ 1kb promoter, eventually leaving only the most proximal -250/+1. Promoter assay analyzing 
the basal activity of the sequential deletions found 5’ truncation that leaves only 250 bases 
most proximal to the transcription start site remaining had surprisingly increased basal 
promoter activity to over 150% compared to the basal activity of 1kb promoter activity (Figure 
5A). These promoter truncation studies indicate that 250 bases most proximal to the 
transcription start site is most effective in activating basal level of transcription, and that 
negative regulatory elements are speculated to bind to -750/-250 region. Further evidence using 
HIF1α overexpression plasmid DNA (or vector control plasmid) co-transfected with each of 
the truncated promoter regions also indicated that -250/+1 region was most effective in 
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stimulating HIF1α overexpression induced promoter activity (Figure 5B). Collectively, these 
experiments suggest a core promoter region adjacent to the gene transcription start site which 
could be effectively activated by HIF1α transcription factor.  
Figure 6. PK2 may be a major downstream target of EGR1 transcription factor 
to mediate EGR1-induced effects during neurotoxic insult. 
EGR1 have been found to be neuroprotective during ischemia induced neurotoxic stress 
(Wenfang Lai et al., 2015), and stimulates tyrosine hydroxylase expression in dopaminergic 
neurons (Akiba, Jo, Akiba, Baker, & Cave, 2009; Fukuchi et al., 2010; Stefano, Al Sarraj, 
Rössler, Vinson, & Thiel, 2006; Verma, Lim, Han, Nagarajah, & Dawe, 2007). HIF1α has 
been shown to be neuroprotective in models of PD and also ischemia (Feng et al., 2014; D. W. 
Lee et al., 2009; Y. C. Lee, Chang, Wu, & Huang, 2018; Lomb et al., 2007). We first wanted 
to assess the functional effect of EGR1 downregulation during neurotoxic stress. We created a 
stable EGR1 knockdown N27 dopaminergic cell line, by using CRISPR-cas9. MTS assay 
showed that EGR1 knockdown N27 cells were more vulnerable to MPP+ compared to wildtype 
N27 cells (Figure 6A). Similarly, we created a PK2 knockdown dopaminergic cell line in a 
fashion similar to the creation of EGR1 knockdown N27 cells. MTS assay showed that PK2 
knockdown N27 cells were more vulnerable to MPP+ compared to wildtype N27 cells (Figure 
6B). 
Since EGR1 knockdown could affect PK2 expression during MPP+ treatment, we then 
showed that inhibition of EGR1 and HIF1α drastically reduces PK2 gene transcription during 
MPP+ treatment. Since MPP+ induces EGR1 upregulation (Figure 3) to induce PK2 
upregulation (Figure 1, Figure 4), we next wanted to test whether EGR1 knockdown could 
affect PK2 expression during MPP+ treatment. We engineered a stable EGR1 knockdown 
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dopaminergic cell line by using lentiviral-mediated transduction of CRISPR cas-9 and gRNA 
in rat dopaminergic cell line (N27), which has high transduction efficiency.  
Quantitive PCR of stable EGR1 knockdown treated with control or MPP+ saw 
dampened MPP+-induced PK2 response in EGR1 knockdown cells, and showed that that 
EGR1 knockdown disrupted normal PK2 gene expression during neurotoxic stress. (Figure 
6A). With MPP+ treatment, scrambled control N27 cells had increased PK2 gene expression 
of approximately 3.5-fold of control 6h post-treatment, as expected, while PK2 expression in 
EGR1 knockdown N27 cells was approximately 2-fold of control level at 6h post-treatment 
(Figure 6A), suggesting that EGR1 knockdown disrupted normal PK2 gene expression during 
neurotoxic stress. However, the time-course study with EGR1 knockdown cells revealed that 
MPP+-induced PK2 mRNA expression was not reduced in the early stages of neurotoxicity (up 
to 6h) and was only significantly reduced in later stages of neurotoxicity (6-12h) (Figure 6A). 
Therefore, it was speculated that another transcription factor was responsible for the early 
induction of PK2 gene expression.  
Then, to simulate a condition that inhibited both EGR1 and HIF1α, EGR1 knockdown 
N27 was treated with PX-12 (1-methylpropyl 2-imidazolyl disulfide), an anti-cancer 
compound that reduces HIF1α protein levels (Kim, Coon, Baker, & Powis, 2011; Welsh et al., 
2003), to inhibit HIF1α transcriptional activity in neurons. In N27 cells with EGR1 inhibited 
via knockdown and HIF1α inhibited via PX-12, PK2 gene expression was drastically reduced 
starting almost immediately at 2h, during which time PX-12 starts to inhibit HIF1α (Figure 
6B). Together, these studies suggest a pattern of PK2 gene regulation, with HIF1α inducing 
immediate PK2 upregulation, and EGR1 participation is required to sustain PK2 upregulation 
pass the immediate stage into the early stage and onwards. It is likely that HIF1α, EGR1, and 
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NRF1 transcription factors working in synergy or in combination could therefore achieve high 
level, sustained PK2 expression.  
In summary, EGR1 knockdown disrupted and reduced normal PK2 gene expression 
during neurotoxic stress, which is found to result in reduced cell viability. Further, the effect 
of PK2 knockdown on cell viability was similar to the effect of EGR1 knockdown. Considering 
EGR1 downstream regulation of PK2 gene expression (Figure 4), this suggest that PK2 could 
be a major downstream target for EGR1.  
Figure 7. PK2, HIF1α, and EGR1 levels are dysregulated during Parkinsonian 
toxicant-induced neurotoxic stress in mouse model of Parkinsonism. Manganese (Mn) was 
used as a Parkinsonian toxicant for in vivo validation of our cell culture findings. Mn-induced 
parkinsonism has been recognized since 1837 (Couper, 1837; Guilarte, 2010; Racette et al., 
2017), and Mn has been used as a mouse model for PD since 1973 (Villalobos et al., 2009). 
Fundamental cellular pathology such as mitochondrial dysfunction and oxidative stress 
occurring during Mn-overexposure are strikingly similar to these underlying 
neurodegenerative processes which also occurs in PD. To test if PK2, HIF1α, or EGR1 are 
involved in Mn-induced neurotoxicity, we treated Swiss Webster mice with oral gavage of Mn 
(30mg/kg/day) for 30 days (Figure 8A). At the end of the treatment, mice were sacrificed, and 
the striatum, substantia nigra (SN) were dissected from the brain.  
Western blot analysis of brain tissue found that in the SN, Mn treatment induced PK2 
upregulation as well as HIF1α upregulation, while EGR1 levels remained steady (Figure 8B). 
Surprisingly, in the striatum, PK2 is significantly downregulated, with co-downregulation of 
both HIF1α and EGR1 (Figure 8C). It is noteworthy that the most significant cell death has 
been reported in the striatum and the adjacent globus palladus during Mn toxicity 
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(Latchoumycandane et al., 2005; Olanow, 2004; Peres et al., 2016). Together, these studies 
indicate that PK2 expression is largely co-regulated with the expression of HIF1α and EGR1 
in vivo during neurotoxic stress.  
In summary, EGR1, HIF1α, NRF1, and PK2 upregulation are induced in response to 
neurotoxicant MPP+ or Mn treatment in cell culture studies. Promoter studies show that EGR1, 
HIF1α, and NRF1 could induce PK2 promoter activity, gene transcription, and protein 
upregulation. EGR1 knockdown and HIF1α inhibition studies indicates a dampened PK2 
upregulation in response to MPP+. Together, these studies suggest that neurotoxic stress could 
induce the upregulation of EGR1 and HIF1α which then stimulate the downstream PK2 as 
compensatory protective response, by transcriptionally activating PK2 gene expression. 
Furthermore, initiation of high level, sustained PK2 expression likely involves several 
transcriptional factors working in synergy or in combination.  
 
Discussion 
We had previously shown that PK2 could mitigate the production of ROS, bolster 
mitochondrial biogenesis, and counter pro-apoptotic signals in dopaminergic neurons. Despite 
these recent advances in understanding of PK2’s functions, its role and its transcriptional 
regulation during neurotoxic stress remain incompletely understood. In this study, we analyzed 
the PK2 proximal promoter for clues of its transcriptional activation. Using the in silico 
analysis as a starting point, we found putative transcription factors EGR1, NRF1, HIF1α, and 
E2F could respond to neurotoxic stress in dopaminergic cell cultures, and further validated 
their effects on PK2 promoter activity. Using CRISPR cas9-based knockdown and chemical 
inhibition of HIF1α, we found that EGR1 and HIF1α are major regulators of PK2 gene 
expression during MPP+-induced PK2 upregulation. Lastly, we found that PK2 expression 
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generally co-regulated with EGR1 and HIF1α in Mn overexposure animal models of 
neurotoxic stress.  
Since the discovery of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a 
potent dopaminergic system-specific neurotoxicant in human patients around 1987, it has been 
used to create PD models in animals (Langston, 1987). Its functional metabolite, MPP+, has 
since been used in cell culture to for dopaminergic neurotoxicant as a potent mitochondrial 
complex I inhibitor. The accumulation of MPP+ causes the collapse of mitochondrial potential, 
activation of caspase-3, and the ensuing apoptosis.  
Successes against MPTP-induced dopaminergic neuronal cell loss and striatal 
innervation have been found via treatment with FG-4592 and 3,4-dihydroxybenzoate (DHB) 
(D. W. Lee et al., 2009; X. Li et al., 2018), both prolyl hydroxylase inhibitors and hence HIF1α 
stabilizers. Treatment with DHB was shown to rescue mitochondrial dysfunction, a major 
mechanism of DHB-mediated protective effects. Treatment with FG-4592 produced similar 
effects. Our previous finding indicated that PK2 could induce proliferator-activated receptor-
γ coactivator 1α (PGC-1α) in the activation of mitochondrial biogenesis and respiration, 
therefore it could be speculated that HIF1α activation of PK2 could help in mediating PGC-
1α’s protective effects. Further studies need to be conducted to confirm the mechanism of a 
putative HIF1α-PK2-PGC-1α axis. Additionally, we found that HIF2 overexpression could 
induce PK2 promoter activity. Molecular suppression of HIF-2α increases the basal sensitivity 
to oxidative death (Nanduri et al., 2009). HIF2 governs prolonged hypoxic gene activation 
(Holmquist-Mengelbier et al., 2006) and promotes iron absorption in mice (Mastrogiannaki et 
al., 2009). Interestingly, MTF1, a transcription factor with a putative binding site on the PK2 
promoter, is involved in metal homeostasis in response to heavy metals such as cadmium, zinc, 
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copper, and silver. These transition metals induce MTF-1 translocation into the nucleus to bind 
to the Ferroportin1 (FPN1) promoter (Troadec, Ward, Lo, Kaplan, & De Domenico, 2010). 
The dysregulation of FPN1 has recently been implicated in the pathogenesis of PD (Xu, 
Kanthasamy, Jin, & Reddy, 2016). 
Several lines of evidence suggest that EGR1 is important for neuronal plasticity, 
dopaminergic neuronal maintenance and tyrosine hydroxylase expression (Kress & 
Wullimann, 2012; Papanikolaou & Sabban, 2000). Its upregulation is attributed to a number 
of neuroprotective regimens ranging from the anti-ROS actions of resveratrol (Han, Zheng, 
Bastianetto, Chabot, & Quirion, 2004) to anti-inflammatory, anti-oxidative, and anti-apoptotic 
properties of salidroside (W. Lai et al., 2015), and its downregulation has been associated with 
decreased cognition in dementia (Gersten et al., 2009). In addition, EGR1, EGR2, EGR3, and 
EGR4 are co-upregulated with brain-derived neurotrophic factor (BDNF) after treatment with 
pridopidine in Huntington disease mouse models (Kusko et al., 2018). Furthermore, 
erythropoietin (EPO), a neuroprotective cytokine in models of ischemic injury, induced EGR1, 
EGR2, EGR4 expression and directly activated EGR2 (Mengozzi et al., 2012). Importantly, 
MAPK/ERK signaling pathway could activate EGR1 to stimulate neurite outgrowth in a 
traumatic brain injury model (Chasseigneaux et al., 2011; Plummer, Van den Heuvel, 
Thornton, Corrigan, & Cappai, 2016). Lastly, EGR1 activates high levels of glial-cell derived 
neurotrophic factor (GDNF), a neurotrophic factor necessary for maintenance of dopaminergic 
neurons, by directly binding to the Gdnf promoter (Shin et al., 2009).   
The presence of putative binding site for neuron-restrictive silencer factor could 
suggest that PK2 might be involved in processes of axon sprouting in neurons. NRSF represses 
expression of neuronal genes in nonneuronal cells and in neuronal progenitor cells (NPC) 
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(Huang, Myers, & Dingledine, 1999; Jones & Meech, 1999). NRSF binds to target genes and 
recruit histone deacetylases, making DNA more basic and tighter association of histone to 
DNA thereby less accessibility to transcription factors (Chen, Paquette, & Anderson, 1998; 
Naruse, Aoki, Kojima, & Mori, 1999). Through this mechanism, NRSF also negatively 
regulates the activity of neuropilin-1, which is a positive regulator of axon branching promoted 
by the actions of VEGF and EGF (Kurschat, Bielenberg, Rossignol-Tallandier, Stahl, & 
Klagsbrun, 2006). These lines of evidence suggest that this balancing control aims to prevent 
the expression of PK2 and other co-regulated neurogenesis-associated genes such as 
neuropilin-1 until the precise moment that they are needed. In the same vein, vertebrate 
homologues of enhancer of split complex (HES) is another bHLH TF that was predicted to 
bind to the PK2 promoter. HES1 is critically important for neurogenesis (Dearden, 2015); 
decreasing expression of HES promote the expression of proneural genes, while reducing the 
pool of neural stem cell. Thus, HES1 works to provide a delicate balance between neurogenesis 
of new neurons and maintenance of neural stem cell pool, by repressing proneural identity. It 
has been known that PK2 is indispensable for olfactory bulb neurogenesis owing to its 
chemoattractant properties. However, the expression of PK2 is differentially upregulated as 
neuronal progenitor cells differentiate into functional neurons, and the upstream events which 
results in the cell’s decision to precisely upregulate PK2 at the most opportune moment 
remains unclear. Factors such as NRSF and HES involved in suppressing neuronal genes could 
provide such fine control of PK2 expression.  
Deletion of the -750/-250 region of the promoter increases promoter activity, indicating 
possible negative regulatory elements in this region. Given PK2’s compensatory, protective 
role in neurodegeneration, this represents a target for PK2 transcriptional regulation and 
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therapeutic intervention. Understanding the upstream transcription factors induced by 
neurotoxic stress that activate protective, compensatory PK2 upregulation is crucial in devising 
a potential strategy for slowing and reverse the progression of neurodegeneration such as PD. 
 
Materials and Methods 
Promoter Cloning and Promoter Assay. Three kilobases of PK2 promoter sequence 
contained in a proprietary plasmid was obtained from Switchgear promoter company and 
verified through sequencing. One kilobase of the promoter sequence upstream of the predicted 
transcription start site was then subcloned into Promega’s pNL1.1 luciferase vector. Luciferase 
promoter assay: MN9D cells were grown in 12 well plates overnight and co-transfected with 
PK2 promoter plasmid (pNL1.1-PK2) and selected transcription factors. Cells were harvested 
and prepared according to Promega Nanoluc Luciferase Assay kit protocol and the promoter 
assay was performed using manufacture’s protocols. 
Animal handling. All animal procedures were approved by Iowa State University’s 
Institutional Animal Care and Use Committee (IACUC). All mice were housed under a 12-h 
light cycle in a climate-controlled mouse facility (22±1 °C) with food and water available ad 
libitum. Male C57B/6 mice were pre-screened during behavioral assessments for normal 
baseline performance before being randomly assigned to experimental groups. Animals were 
not wounded or otherwise exhibited conditions that could affect behavior, and are taken off the 
study if any conditions have manifested which could affect behavioral measurements. 
Investigators involved with data collection and analysis were not blinded to group allocation.  
Behavior monitoring. All groups were monitored for behavior using the automated 
VersaMax system software connected to motion-detection hardware (VersaMax monitor, 
model RXYZCM-16, and analyzer, model VMAUSB, AccuScan, Columbus, OH). Each 
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animal was put in one chamber fitted with motion-detection hardware, and allowed to 
acclimate for 2 minutes, after which its spontaneous locomotor activities (horizontal activity, 
vertical activity, and speed) were recorded for 10 minutes.  
Western blot. Dissected brain regions were collected in Eppendorf tubes and flash 
frozen. To isolate total protein, RIPA buffer with sodium orthovanadate, Protease and 
Phosphatase Inhibitor Cocktail (Thermo Fisher 78440) was added to each tube, and 
homogenized using a tissue homogenizer. Dissolved total lysate was centrifuged at 12,000g 
for 60 minutes, to remove cellular debris. Normalized protein samples were loaded into each 
well and were separated by sodium dodecyl sulfate (SDS) gel electrophoresis (100V, 90 
minutes), using AnykD Mini-PROTEAN resolving gel (Bio-Rad, #4569035). Proteins on SDS 
gels were then transferred to a nitrocellulose membrane (26V, overnight) and blocked for 1h 
using fluorescent western blocking buffer (Rockland Immunochemicals). Primary antibodies 
were diluted in blocking buffer with 0.05% Tween 20, were then added to the membranes and 
incubated overnight at 4 °C. Next day, primary antibodies were taken off, and blots were 
washed (7 times, 5 minute each) in wash buffer comprising PBS containing 0.05% Tween 20 
(PBST). Secondary antibody (infrared dye-tagged) was added for 1 h. Blots were further 
washed in PBST for 3 more times, and once in PBS. β-Actin was used as a loading control. 
Membranes were scanned using the Odyssey IR imaging system (LI-COR) and digital images 
were captured via LI-COR Odyssey imager. Densitometric analysis was done using ImageJ 
software. 
Immunohistochemistry. Cells were fixed in 4% paraformaldehyde blocked with BSA 
and Triton-X to permeabilize the cell membranes. Primary antibodies were used as follows: 
rabbit anti-TH (1:1600 dilution), rabbit anti-PK2 (1:500 dilution), goat anti-GDNF (1:500 
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dilution), goat anti-IBA1 (1:1000), rabbit anti-GFAP (1:1000 dilution). Alexa Fluor 
Fluorescent Secondary Antibodies from ThermoFisher were used against primary antibodies 
for fluorescent images. For DAB staining, HRP-conjugated secondary antibodies were used 
against primary antibodies, and VECTASTAIN Elite ABC HRP Kit (VectorLabs) was used 
for conjugation of HRP to secondary antibodies. DAB was used for color development.  
SYBR Green qRT-PCR. To obtain total RNA, tissue lysis buffer from Absolutely 
RNA Miniprep kit (Agilent Technologies) was added to dissected brain regions with addition 
of beta-mercaptoethanol as reducing agent to preserve RNA. A tissue homogenizer was used 
to dissolve tissue into the lysis buffer, and lysates were processed according to kit 
manufacturer’s instructions. Isolated total RNA from each sample was quantified using 
Nanodrop instrument to determine RNA concentration and purity. First strand cDNA synthesis 
was performed using Affinity Script qPCR cDNA synthesis system (Agilent Technologies) 
with 1µg of total RNA in the reaction mixture. Real-time PCR was performed with the 
RT2 SYBR Green master mix (Qiagen) using diluted cDNA, and qPCR mouse primer sets 
were purchased from Qiagen (Quantitect primer mix). The 18S rRNA gene (mouse) was used 
as normalization of each sample as the housekeeping gene. The amount of each template was 
optimized empirically to maximize efficiency without inhibiting the PCR reaction. After the 
last cycle of the qPCR run, dissociation curves were run to ensure a single amplicon peak was 
obtained, indicating primer specificity. The results are reported as fold change in gene 
expression with the ΔΔCt method, using the threshold cycle (Ct) value for the housekeeping 
gene and for the respective gene of interest in each sample. Control animals serve as the 
baseline for fold change.  
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Lentivirus production. PK2 lentivirus expression vector was obtained from Origene, 
and the MISSION Lentiviral Packaging Mix was obtained from Sigma (SHP001) and used 
according to manufacturer’s protocols. Briefly, the PK2 lentivirus expression vector was mixed 
with the Packaging Mix, and co-transfected into 293FT cells to package the virus. After 24h 
post-transfection, the supernatant, which contain the virus, was collected. The second 
harvesting of virus was done 48h post-transfection. The Lenti-X™ p24 Rapid Titer Kit from 
Clontech (632200) was used to titer the lentivirus.  
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Figures 
 
Figure 1. Neurotoxicant MPP+ upregulates PK2 and induces PK2 promoter activity in 
dopaminergic neurons. A. Parkinsonian toxicants MPP+, Mn, as well as HIF1α stabilizer DHB, 
could induce PK2 mRNA expression as found by quantitive PCR. MN9D cultured mouse 
dopaminergic neurons were treated with MPP+, Mn, or DHB dissolved in ddH2O. After 4h of 
treatments, cells from each flask were harvested and processed for RNA isolation. B. 
Quantitive PCR assay also showed that a MPP+ treatment at 300µM upregulates PK2 gene 
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expression during early neurotoxic stress, peaking at 3 hours post treatment. MN9D cultured 
mouse dopaminergic neurons were treated with MPP+ dissolved in ddH2O. After the respective 
time points (0h, 1h, 3h, and 12h) cells from each flask was harvested and processed for RNA 
isolation. C. Western blot assay (top) and densitometric analysis (bottom) showed early 
increases in PK2 protein level at 3h, 6h, and 12h-post treatment. MN9D cells were treated and 
harvested similarly, and processed for western blot. Beta-actin was used as internal loading 
control. D. MPP+ increased PK2 promoter activity in MN9D dopaminergic cell host transiently 
transfected with the PK2 promoter construct, increasing luciferase activity at 3h and 6h-post 
treatment by 2-fold. MN9D cells were transfected the previous day with PK2 promoter 
construct, and 24h later, treated with MPP+ for 0h, 1h, 3h, 6h. Cells were harvested at 
designated timepoints and processed for promoter reporter assay.  
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Figure 2. In silico analyses reveal conserved, methylated sequences 1kb upstream of 
proximal PK2 promoter, and a wide range of transcription factors associated with metabolic 
processes, cellular processes, cellular biogenesis, and transcription factors regulating response 
to stimuli. A. Using ECR Browser to find conserved sequences between human PK2 promotor 
sequences and other species, 1kb upstream of the transcription start site has been found to be 
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conserved across rodents and canines. B. Analysis of promoter CpG islands using EMBOSS 
CpGplot found increased CpG around -400 to +1 relative to transcription start site. C. 
MethPrimer analysis found two CpG islands near -400 to +1 of the transcription start site. D. 
Upstream 1kb promoter sequences was uploaded into the MatInspector software from 
Genomatix. Transcription factors are summarized in Table 1 and Table 2.  E, F. Pie chart and 
histogram of broad categories of genes found in Table 1, as classified by the PANTHER 
Classification System for Gene Ontology. G, H. Pie chart and histogram of broad categories 
of genes found in Table 2, a shorter list of genes expressed in the CNS, as classified by the 
PANTHER Classification System for Gene Ontology. 
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Figure 3. PK2 may be a target gene for Early growth response family of transcription 
factors (EGRs), Nuclear respiratory factor 1 (NRF1), Hypoxia-inducible factor 1 (HIF1α), and 
E2F-myc activator/cell cycle regulator. A. Putative transcription factor core binding sites on 
1kb PK2 promoter. B. Western blot analysis showed that MPP+, manganese, or hydrogen 
peroxide drastically increased EGR1 protein level within 6h post-treatment. C. PK2 mRNA 
was rapidly induced by MPP+ within 30 minutes and is sustained at 6h. These data suggest that 
EGR1 is responsive to neurotoxic stress.  
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Figure 4. Overexpression of EGRs, NRF1, HIF1α, or E2F1 in MN9D dopaminergic 
neurons induces PK2 promoter activity. A. Promoter reporter assay revealed that co-
transfection of 1kb PK2 proximal promoter nano-luciferase reporter construct (3ug) with 
plasmid vector encoding wildtype EGR1, EGR2, EGR3, could induce PK2 promoter activity. 
Members of the EGR family could stimulate PK2 promoter activity, with approximately 400% 
increase for EGR1 overexpression, approximately 150% increase for EGR2 overexpression, 
and over 1000% for EGR3 overexpression. B. NRF1 also stimulated promoter activity by 
approximately 550%. C. HIF1α overexpression moderately but significantly induced PK2 
promoter activity. DHB treatment and DHB treatment in combination with HIF1α 
overexpression produced more than 200% increase in promoter activity. Additionally, mutant 
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HIF1α with defective PAS domain did not stimulate the PK2 promoter activity. D. 
Overexpression of HIF2α could stimulate approximately 300% increase in PK2 promoter 
activity. E. HIF2α Overexpression of E2F drastically stimulated PK2 promoter activity, with 
nearly 3500% increase. F-I. Analysis using qPCR showed that EGR1 overexpression induced 
PK2 gene expression approximately 4.5-fold of control, while NRF1 overexpression induced 
> 3-fold of control, HIF1α overexpression induced > 4-fold of control, and E2F overexpression 
induced > 5-fold of control.  
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Figure 5. Promoter sequence most proximal to transcription start site induces highest 
level of transcription activity. A. Promoter assay analyzing the basal activity of the sequential 
deletions found that 5’ truncation of 250 bases reduced promoter activity to approximately 
50% of 1kb promoter, while a further 5’ truncation of 250 bases marginally restored the basal 
promoter activity. The -250/+1 promoter sequences most proximal to the transcription start 
site had surprisingly increased basal promoter activity to over 150% compared to the basal 
activity of 1kb promoter activity. B. HIF1α overexpression plasmid DNA (or vector control 
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plasmid) co-transfected with each of the truncated promoter regions also indicated that HIF1α 
stimulated 200% promoter activity when co-transfected with -750/+1 truncated promoter, and 
strong activation at close to 250% was seen comparatively when co-transfected with -500/+1 
truncated promoter, and nearly 300% as compared to vector control plasmid. 
 
 
 
 
 
 
99 
 
Figure 6. PK2 may be a major downstream target of EGR1 transcription factor to 
mediate EGR1-induced effects during neurotoxic insult. A. MTS cell viability assay showed 
that EGR1 knockdown exacerbates MPP+-induced cell death. While treatment with 300µM 
MPP+ resulted in approximately 60% viability after 24h in wildtype N27 cells, only 
approximately 40% of N27 cells were viable after EGR1 knockdown. B. MTS cell viability 
assay showed that PK2 knockdown also exacerbates MPP+-induced cell death, with cell 
survival similar to EGR1 knockdown. C. Inhibition of EGR1 drastically reduces PK2 gene 
transcription. PK2 gene expression in scrambled control or EGR1 knockdown N27 cells were 
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treated with control or MPP+. EGR1 knockdown in rat dopaminergic cell line, N27 cells, was 
made by using lentiviral-mediated transduction of CRISPR cas-9 and gRNA. The qPCR 
analysis showed that basal level of PK2 gene expression reduced approximately 30% in EGR1 
knockdown N27 cells. With MPP+ treatment, scrambled control N27 cells had increased PK2 
gene expression of approximately 3.5-fold of control 6h post-treatment, as expected, while 
PK2 expression in EGR1 knockdown N27 cells was approximately 2-fold of control level at 
6h post-treatment. D. Inhibition of EGR1 and HIF1α together drastically reduces PK2 gene 
transcription. EGR1 knockdown N27 was treated with PX-12 to inhibit HIF1α transcriptional 
activity in neurons. In N27 cells with EGR1 inhibited via knockdown and HIF1α inhibited via 
PX-12, PK2 gene expression was drastically reduced starting almost immediately at 2h.  
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Figure 7. PK2, HIF1α, and EGR1 levels are dysregulated during Parkinsonian toxicant-
induced neurotoxic stress in mouse model of Parkinsonism. A. Treatment paradigm of Mn, 
which was used as a Parkinsonian toxicant for in vivo validation of our cell culture findings. 
Swiss Webster mice was treated with oral gavage of Mn (30mg/kg/day) for 30 days. At the 
end of the treatment, mice were sacrificed, and the striatum, substantia nigra (SN) were 
dissected from the brain. B. Western blot analysis of SN (top panel) and striatum (bottom 
panel), in mice treated with Mn. In SN, PK2, and HIF1α are upregulated, while EGR1 levels 
remained steady. In the striatum, PK2 is significantly downregulated, with co-downregulation 
of both HIF1α and EGR1. 
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Abstract 
Over exposure to manganese (Mn) causes manganism, a neurological disorder with 
symptoms similar to Parkinson's disease. However, the cellular mechanism by which Mn 
impairs the dopaminergic neurotransmitter system remains unclear. While much focus has 
been placed on cell death processes underlying the neurotoxic effect of Mn, early neuronal 
response to Mn exposure deserves more attention. Here we found that the dopaminergic 
neurotoxicant Mn rapidly induce PK2 during the early stages of Mn neurotoxic stress in an 
N27 dopaminergic cell model. To better understand the functional role of PK2 upregulation, 
we created stable PK2-expressing dopaminergic cells by delivering PK2 myc-tagged cDNA 
into mouse dopaminergic MN9D cells. Interestingly, PK2-overexpressing cells exposed to 
manganese showed significant protection against neurotoxicity relative to vector control cells, 
suggesting a neuroprotective role for PK2 in dopaminergic neurons. The protective effect was 
both dose- and time-dependent. Furthermore, the PK2 receptor blocker PC7 attenuated the 
PK2-induced neuroprotective effects in PK2-overexpressing cells. Overexpressing PK2 
103 
protected against manganese-induced apoptosis as measured by Annexin 5 and caspase-3 
activation. We also found that mitochondrial integrity was well maintained in PK2-
overexpressing cells relative to vector cells following exposure to Mn. Preliminary results also 
showed that key proteins involved in mitochondrial functions, including BCL2, PGC1-α and 
TFAM levels, were preserved in PK2-overexpressing cells during neurotoxic stress. 
Collectively, our results suggest that neurotoxic insults upregulate PK2 in dopaminergic 
neurons to protect against the early stages of neurotoxicity. Finally, observed the effect of Mn 
treatment on PK2 expression using a GENSAT PK2 GFP transgenic mouse model. During 
early exposure to Mn (30 mg/kg for 10 days, oral), PK2 levels were significantly upregulated 
in the SN while slightly decreasing in striatum. Prolonged exposure to Mn (30 mg/kg for 30 
days) significantly upregulated PK2 levels in the brain, especially in the substantia nigra. 
Interestingly, in the striatum, where Mn-induced cell death mainly occurs, decreased PK2 
levels were noted. Significant amount of methylation of the PK2 promoter region is also 
observed in the striatum. Combined with cell culture studies, the differential regulation of PK2 
in the striatum and substantia nigra might suggest a possible neuroprotective role of PK2 in 
the SN during early exposure to Mn. Taken together, these results suggest that Mn upregulates 
PK2 levels to counter early neurotoxic stress in vitro and in vivo.  
 
Introduction 
 Manganese (Mn) is an essential trace element in all known living organisms. It is 
required for cellular maintenance and participates in such fundamental cellular processes as 
metabolism of fats and carbohydrates, regulation of blood sugar, and calcium absorption 
(Erikson, Syversen, Aschner, & Aschner, 2005). It is also a cofactor for glutamine synthetase, 
arginase, pyruvate decarboxylase, serine/threonine phosphatase, and superoxide dismutase 2 
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(SOD2) (Christianson, 1997; Rokad et al., 2017; Takeda, 2003). Mn exists in various chemical 
forms including several oxidation states (Mn2+, Mn3+, Mn4+) (Rask, Miner, & Buseck, 1987; 
Reaney & Smith, 2005), a versatile chemical property which enabled its industrial usage in 
making glass and ceramics, adhesives, welding, paint, gasoline anti-knock additives” and 
medical device batteries (Loranger & Zayed, 1995; Nduka, Onyenezi Amuka, Onwuka, 
Udowelle, & Orisakwe, 2016; Sriram et al., 2014).  
Wide range of industrial uses consequently increases risks of overexposure to Mn for 
workers such as welders and miners in occupational settings. Routes of overexposure are 
mainly through dermal absorption and inhalation. Despite its essential role in multiple 
metabolic functions, Mn can accumulate in the brain, a major organ of Mn toxicity during 
overexposure. Excessive Mn efficiently crosses the blood brain barrier and blood-
cerebrospinal fluid barrier, to preferentially concentrate in globus pallidus and striatum in 
monkeys (Dastur DK, Manghani DK, 1971; Fujii, 1975) and humans (Aschner, 2006; Aschner, 
Guilarte, Schneider, & Zheng, 2007; Sarkar et al., 2018; Wooten, Aweda, Lewis, Gross, & 
Lapi, 2017; Yokel, 2009). The disruption of the nigrostriatal pathway of the basal ganglia 
system in prolonged Mn overexposure causes a severe neurological disorder similar to 
Parkinson’s disease named manganism (Cawte, Hams, & Kilburn, 1987). manganism is 
characterized clinically by extrapyramidal symptoms resembling Parkinson’s disease, with 
depression, postural instability, bradykinesia, micrographia, and a characteristic cock-walk 
caused by dystonia of the legs (Cersosimo & Koller, 2006; Olanow, 2004; Perl & Olanow, 
2007).  Tremor is less commonly seen compared to Parkinson’s disease, and are postural or 
kinetic in nature, rather than resting (Casamajor, 1913; Mena, Marin, Fuenzalida, & Cotzias, 
1967). Furthermore, Mn overexposure are more detrimental to younger individuals, who 
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generally accumulate greater Mn levels in the CNS (Campbell, 2005; Grandjean & Landrigan, 
2006; Rodier, 1995; Zheng, Aschner, & Ghersi-Egea, 2003). They are more vulnerable to its 
toxicity during brain development, and may be predisposed to later-life neurological disorders 
by Mn overexposure (Erikson, Thompson, Aschner, & Aschner, 2007; Hafeman, Factor-
Litvak, Cheng, van Geen, & Ahsan, 2007; Moreno, Streifel, Sullivan, Legare, & Tjalkens, 
2009). Neuropathologically, it is characterized by lesions found in globus pallidus and striatum 
downstream in the nigrostriatal pathway (Olanow, 2004; Perl & Olanow, 2007), causing 
nigrostriatal disruption and extrapyramidal symptoms (ATSDR Toxicological Profile for Mn).  
The effects of Mn on the dopaminergic system remain controversial and the cellular 
mechanism by which Mn impairs the dopaminergic neurotransmitter system remains unclear 
in adults and children (El-hady & Galal, 2018; Gandhi, Sivanesan, & Kannan, 2017; Lao et 
al., 2017). Some studies suggested increase in dopamine with acute exposures of Mn, while 
chronic exposures to Mn in experiments using nonhuman primates as well as PET scans of 
welders suggested that Mn could inhibit the normal function of dopaminergic neurons by 
marked inhibition (> 50% on average) dopamine release in the striatum. Such prolonged 
exposure then causes cell death in the globus pallidus of the striatum (Perl & Olanow, 2007).  
Mn can be transported into the cell via the actions of the divalent meta transporter 
DMT1, the transferrin receptor (Tfr), and SLC39 zinc transporters, as well as ATP13A2, 
among which DMT1 and Tfr are the most well-studied (Aschner & Aschner, 1990; Eide, 2004; 
Heilig et al., 2006; Kim et al., 2015). Within the cell, Mn causes impairment in iron 
homeostasis, excitotoxicity, oxidative stress, and mitochondrial dysfunction (Afeseh Ngwa et 
al., 2011; Harischandra, Jin, Anantharam, Kanthasamy, & Kanthasamy, 2015; Sarkar et al., 
2018). A major cellular storage of Mn is the mitochondria, where Mn preferentially 
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accumulates via the Ca2+ uniporter. At excessive levels, Mn causes dissipation of the 
mitochondrial membrane potential (Allshire, Bernardi, & Saris, 1985; Gavin, Gunter, & 
Gunter, 1999; Rao & Norenberg, 2004). In detailed electron microscopy micrographs, neurons 
in mice nasally administered Mn for one month showed swollen mitochondria, and 
disorganization of the inner membrane system (Villalobos et al., 2009). Mn exposure has been 
used as a mouse model for PD since 1973 (Villalobos et al., 2009), with mitochondrial 
dysfunction and oxidative stress occurring in manganism being strikingly similar to the 
underlying neurodegenerative processes occurring in PD. This suggests that toxicity involving 
mitochondria could be common in both manganism and PD.  
Furthermore, recent studies had found Mn overexposure could induce aberrant 
epigenetic changes such as changes in histone acetylation (Guo et al., 2018), DNA 
hypermethylation or hypomethylation during development for genes regulating neurogenesis 
(Wang et al., 2013) and during neurodegeneration for genes regulating cell survival (Chahrour 
et al., 2008; A. Kanthasamy et al., 2012; Tarale et al., 2016, 2017; Wang et al., 2013; Yang 
Qiao, Hua Shao, Jack Ng, 2015). Therefore, downregulation of key protective genes caused by 
aberrant methylation could be a major culprit in Mn-induced neurotoxicity.  
Prokineticin-2 (PK2) is a secreted neuropeptide that binds to two cognate receptors 
prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). The PK2 signaling cascade 
through PKR1 or PKR2 regulates diverse physiological processes including hematopoiesis, 
reproductive functions, pain perception and angiogenesis in the peripheries. In the brain, PK2 
is a chemoattractant during olfactory bulb neurogenesis, and is also an output molecule of the 
suprachiasmatic nucleus in the hypothalamus, oscillating in levels of expression to transmit 
circadian rhythm into nearby structures (Cheng et al., 2002; Hu et al., 2006; Li et al., 2006; 
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Lin et al., 2002; Ng et al., 2005; Qun Yong Zhou & Cheng, 2005). Recently we have reported 
that PK2 is upregulated in human PD patient post-mortem brains. We showed that in MPTP-
induced and MitoPark genetic mice models of PD, PK2 is upregulated as a compensatory 
response to protects against dopaminergic degeneration (Gordon et al., 2016). Importantly, we 
previously found that PK2 protects against oxidative stress, mitochondrial dysfunction, and 
promotes mitochondrial biogenesis, by reducing mitochondrial fragmentation, increasing 
mitochondrial length and number, and bolstering expression of TFAM, PGC1α.   
Since mitochondrial dysfunction is central in both PD and manganism, elucidating the 
role of PK2 in mitochondria during Mn toxicity could shed light on mitochondrial dysfunction 
in both pathological conditions. We hypothesized that PK2 might be involved in compensatory 
responses in early Mn-induced neurotoxicity. In the current study, we found that PK2 is 
upregulated during Mn-induced neurotoxicity, and showed that PK2 is a compensatory 
protective response against Mn-induced neurotoxicity in cell cultures. PK2 overexpression 
conferred protection against oxidative stress, enhanced mitochondrial biogenesis, while 
blocking PK2 signaling nullified protective effects. Importantly, we found that PK2 is 
upregulated in the substantia nigra of mice during subacute and subchronic exposures of Mn, 
but is downregulated in the striatum, possibly due to PK2 promoter hypermethylation in the 
striatum induced by Mn toxicity.  
Although progress in understanding of mechanisms of toxicity for Mn overexposure 
has been made since its initial observation in James Couper in 1837, currently there is no cure 
against manganism (Chen, Chakraborty, Peres, Bowman, & Aschner, 2015; Dobson, Erikson, 
& Aschner, 2004; Nielsen, Larsen, Ladefoged, & Lam, 2017; Tarale et al., 2016; Tjalkens, 
Popichak, & Kirkley, 2017). The situation is made dire due to a lack of response to L-DOPA 
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for motor symptoms present in manganism patients (Bowler, Koller, & Schulz, 2006; Koller, 
Lyons, & Truly, 2004). Current developments of potential therapies in preclinical testing 
involve stem cell transplantation strategies (de Moura, Afadlal, & Hazell, 2018). Given 
neuroprotective properties of PK2, differential regulation of PK2 leading to downregulation of 
PK2 in the striatum could represent a mechanism of Mn toxicity as well as a point of 
intervention as therapies for manganism patients.  
 
Results 
Figure 1. Neurotoxicant Mn treatment induces PK2 upregulation in N27 
dopaminergic cells. From a neuroinflammation PCR array, we initially had found that the 
expression of PK2 in dopaminergic cells treated with TNFα 7-fold was increased 7-fold. 
Thereafter, we had discovering its role in mediating cell survival in Parkinsonian toxicant 
MPP+-induced dopaminergic neuron degeneration. We then hypothesized that PK2 could also 
mediate neuronal survival in Mn-induced neurotoxicity. We first treated cultured N27 rat 
dopaminergic neurons with a biologically relevant dose of Mn, 300µM in the form of MnCl2, 
and the classic Parkinsonian toxicant MPP+, as well as a HIF1α stabilizer, 3,4-
dihydroxybenzoate (DHB). Mn treatment induced PK2 mRNA expression 4h post-treatment 
of Mn as assessed by qPCR (Figure 1A). Mn was able to induce sustained increase in protein 
levels of PK2 at 6h to 12h post treatment (Figure 1B). This suggests that PK2 signaling is 
implicated in Mn-induced cellular responses.  
Figure 2. Stable PK2 overexpression in dopaminergic cell line protects against 
Mn-induced cytotoxic cell death. We engineered MN9D mouse dopaminergic cell line to 
overexpress PK2 by stable transfection of plasmid vector carrying human PK2 cDNA and a 
small 1.2 kD myc-tag, to confirm the role of PK2 during Mn-induced neurodegeneration. 
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Representative western blot and densitometric analysis of 3 western blot runs for human PK2 
indicates high expression in of PK2 in MN9D dopaminergic cells after stable transfection 
(Figure 2A, 2B). Immunostaining of PK2-myc using antibody against the myc tag found 
increased PK2-myc in the cytosol (Figure 2C). PK2, as a signaling neuropeptide, can be 
secreted outside of the cell (Bullock, Li, & Zhou, 2004; Q. Y. Zhou & Meidan, 2008). 
Coincidentally, immunostaining for the myc tag also found significant amount of PK2-myc in 
the Golgi apparatus, possibly undergoing posttranslational modifications for secretion outside 
of the cell. Since high constitutive overexpression could lead to receptor downregulation, we 
assessed level of PKR2, a receptor for PK2 on dopaminergic neurons, in vector and PK2 
overexpressing cells. Interestingly, western blot immunostaining of PKR2 found that it is not 
affected in its protein levels by PK2 overexpression, indicating that constitutive overexpression 
of PK2 does not lead to unwanted downregulation of the receptor (Figure 2D).  
After establishing the stable PK2 overexpression dopaminergic cell line, in our next set 
of studies, we assessed the protective effects of PK2 overexpression during Mn-induced 
neurodegeneration. Vector and PK2 overexpression cells were treated with increasing doses of 
Mn ranging from 0µM to 500µM which were added to growth media with reduced serum (2% 
FBS) for 24 hours. MTS assay analysis showed that while PK2 overexpression caused little 
change in cell viability in control conditions without Mn treatment, PK2 overexpression 
significantly increased cell metabolic activity associated with cell viability in almost all doses 
of Mn (Figure 2E). Cell viability in PK2 overexpression cells was close to 15% higher as 
compared to vector cells, when treated with 300µM Mn for 24 hours (Figure 2E).  However, 
blocking with PC-7, a GPCR blocker, abolished any protective effects afforded by PK2 
overexpression (Figure 3F). Flowcytometry analysis showed that Mn 300µM treatments, in 
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vector cells induced ANNEXIN-5 in approximately 55% of vector cells, in comparison to 35% 
of PK2-overexpressing cells, indicating less PK2 overexpression cells undergoing apoptosis 
when treated with Mn (Figure 2G). This set of experiments indicates that constitutive PK2 
expression could protect neurons during Mn-induced stress, and the protective effects are 
mediated through secreted PK2. 
Figure 3. Stable PK2 overexpression in dopaminergic MN9D cells protects against 
Mn by reducing caspase activation and increasing BCL-2 levels. Our next set of 
experiments attempted to elucidate the mechanism of PK2 overexpression-mediated 
protection. Caspase-3 activation is a major pathway of apoptosis that could lead to PKCδ 
proteolytic cleavage and apoptotic cell death of dopaminergic neurons exposed to Mn 
(Anantharam, Kitazawa, Wagner, Kaul, & Kanthasamy, 2002; Latchoumycandane et al., 
2005). By using a fluorescent, substrate-based assay, caspase-3 activity was found to 
drastically increase in vector cells 16h post-Mn treatment, while PK2-overexpression reduced 
caspase-3 activity to close to caspase-3 activity levels in control cells (Figure 3A). Since 
upregulation of Bcl-2 could promote anti-apoptotic effects in dopaminergic neurons during 
toxic insult (Gordon, Anantharam, Kanthasamy, & Kanthasamy, 2012; A. G. Kanthasamy et 
al., 2003; Kitazawa et al., 2005a; Kitazawa, Anantharam, Kanthasamy, & Kanthasamy, 2004), 
we sought to determine the expression of Bcl-2 in vector or PK2 overexpression cells treated 
with or without Mn. We found PK2 overexpression significantly increased gene expression of 
Bcl-2 in qPCR assay (Figure 3B). While Mn treatment significantly reduced Bcl-2 gene 
expression, PK2 overexpression preserved Bcl-2 gene expression in cells treated with Mn for 
8h (Figure 3B). Western blot assay (top) and densitometric quantification (bottom) had found 
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increased Bcl-2 protein levels in PK2 overexpression cells and preserved Bcl-2 protein levels 
during Mn treatment, while decreasing Bax (Figure 3C-3E).  
Figure 4. PK2 overexpression protects MN9D cells against Mn-mediated 
mitochondrial dysfunction, while knockdown of PK2 exacerbates Mn-induced 
mitochondrial dysfunction. Mitochondria’s role in the etiology of neurodegenerative 
diseases, as well as a target of intervention, have become increasing recognized (Dranka et al., 
2014; Jin et al., 2014). We had previously found that PK2 could bolster mitochondrial 
biogenesis against MPP+-induced mitochondrial dysfunction, here we found that while Mn 
treatment for 24h drastically decreases mitochondrial content, PK2 overexpression could 
restore Mn-induced decreases in mitochondrial content, as stained by MitoTracker dye (Figure 
4A). Quantitative-PCR analysis of mitochondrial DNA content (mDNA) showed a significant 
decrease in mDNA in cells treated with Mn for 24h, while PK2 overexpression significantly 
increased mDNA in cells treated with Mn (Figure 4B). Western blot analysis showed that after 
treatment with Mn, PK2 overexpression also preserves mitochondrial levels of PGC1alpha and 
TFAM, transcription factors which are important regulators of mitochondrial-transcribed 
genes. (Figure 4C). To assess the effect of PK2 downregulation on mitochondrial function, we 
generated a N27 rat dopaminergic cell line defective in PK2 expression using a CRISPR-Cas9 
lentivirus system. The CRISPR-Cas9 system is driven by the activity of the Cas9 protein. The 
expression of Cas9 tagged with GFP in N27 cells is shown in Figure 4D. This lentiviral-
mediated expression of the CRISPR-Cas9 system induced a drastic reduction of PK2 mRNA 
in N27 cells, as analyzed using qPCR (Figure 4E), and protein level as assessed by western 
blot assay using antibody against PK2 (Figure 4F). PK2 knockdown exacerbated mitochondrial 
damage induced by Mn treatment. Seahorse Mito-stress test of Mn-treated CRISPR-Cas9-
112 
mediated PK2 knockdown or control knockdown in N27 cells (Figure 4G) shows lower oxygen 
consumption rate in PK2 knockdown cells (Figure 4H) and lower basal oxygen consumption 
rate (Figure 4I), as well as lower ATP production (Figure 4J). Compared to vector cells, PK2 
knockdown N27 cells also exhibit a stressed phenotype (Figure 4K). This set of experiments 
suggests that PK2 could preserve and maintain mitochondrial function even during Mn-
induced cellular stress while PK2 downregulation aggravates Mn-induced stress.  
Figure 5. Subacute and subchronic Mn treatment in mice increase PK2 levels in 
SN but not striatum. A biologically relevant dose of Mn in the form of MnCl2 (30mg/kg body 
weight) or vehicle was given daily via oral gavage to C57B/6 mice for 10 days (Figure 5A). 
After the subacute treatment, the mice were sacrificed, and brains dissected. Western blot 
analysis showed that in the SN, PK2 level was induced significantly (Figure 5B) whereas in 
the striatum, PK2 level was consistent (Figure 5C). This suggests that PK2 upregulation is an 
early response to Mn-induced neurotoxicity, and that PK2 is differentially regulated in the SN 
and the striatum.  
Next, to better observe PK2 expression, we obtained Swiss Webster transgenic mice 
that expressed eGFP driven by the PK2 gene promoter. Mn in the form of MnCl2 (30mg/kg 
body weight) or vehicle were given daily via oral gavage to eGFP-PK2 Swiss Webster mice 
for 30 days (Figure 5D). Mn-treated mice exhibited decreased locomotor activity as recorded 
by VersaMax software (Figure 5E). Specifically, Mn-treated mice exhibited lower horizontal 
activity, vertical activity, and total distance (Figure 5F). Interestingly, we also observed 
decreased social discrimination in mice treated with Mn, using the sniff test (Figure 5G), which 
measured a decrease in average number of visits to a zone with opposite sex’s bedding in Mn-
treated mice and average time spent in zone with opposite sex’s bedding (Figure 5H).  
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Post-mortem analysis of biochemical changes in mice treated with Mn showed 
increased dopamine and decreased dopamine metabolites Dopac and HVA in Mn-treated mice 
as measured by HPCL, suggesting of decreased turnover of dopamine and a dysregulation of 
the dopamine metabolic pathway (Figure I). EGFP expression as driven by PK2 expression 
was generally increased in brains of mice treated with Mn, as measured by fluorescence 
intensity of eGFP using in-vivo imaging (Figure 5J). However, following dissection of the 
brain, western blot analysis showed that PK2 level was found to be decreased in the striatum 
of mice treated with Mn, whereas increases in olfactory bulb (OB) and SN were seen (5K). 
This suggests that PK2 is also upregulated during subchronic exposure to Mn, and that PK2 is 
also differentially regulated in the SN and the striatum. This interesting result had led us to 
assess the mechanism of differential regulation of PK2 in the striatum. Since Mn could 
epigenetically alter gene expression in dopaminergic cells in culture (Gandhi et al., 2017) and 
expression of PD-related genes (Tarale et al., 2017), we sought to assess the methylation status 
of the PK2 gene promoter in the cortex and striatum in mice treated with vehicle or Mn. Mn 
treatment induced a lower ratio of methylated to unmethylated PCR products in cortex tissues, 
suggesting decreased methylation of PK2 promoter region in the cortex, presumably allowing 
for higher transcriptional factor access to promoter and transcription of associated PK2 gene 
(Figure 5L). In the striatum tissues, however, PK2 promoter methylation status remains 
relatively unchanged (Figure 5M). This suggests that the failure to increase PK2 expression in 
the striatum could be due to epigenetic changes induced by Mn treatment. This set of 
experiments showed that Mn could exert its toxic effects through downregulation of PK2 gene 
expression in the striatum by inducing methylation of the PK2 promoter region.  
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Discussion 
Although chronic exposure to excessive Mn produces a neurotoxic insult to the basal 
ganglia neurotransmitter system that culminates in Mn-induced Parkinsonism, the cellular and 
molecular mechanisms leading to neurotoxicity, especially early neuronal response to Mn 
exposure, are largely unknown and deserves more attention.  
The mechanism causing the selective accumulation of Mn in basal ganglia, or why 
pallidal neurons are selectively vulnerable to Mn intoxication, is unclear (Bouabid, Tinakoua, 
Lakhdar-Ghazal, & Benazzouz, 2016). The mechanism of Mn toxicity in inducing cellular 
apoptosis is also not completely clear, but have generally been attributed to Mn’s capacity to 
cause oxidative stress, disrupt mitochondrial functions, and induce aberrant epigenetic changes 
in the genome (Kitazawa et al., 2005b; Latchoumycandane et al., 2005; Tarale et al., 2017; D. 
Zhang, Kanthasamy, Anantharam, & Kanthasamy, 2011). Mn could also exert neuronal 
toxicity by impairing key signaling molecules that control the balance between pro- and anti-
apoptotic signaling. Although various proapoptotic signaling pathways that occur during 
neurotoxic stress have been elucidated, only a few studies have characterized signaling 
molecules that can protect neurons against toxic insults. 
Recently, we reported that the prokineticin-2 (PK2) protein, a recently discovered 
mammalian homolog of mamba snake venom, plays a major compensatory protective function 
in nigral dopaminergic neurons. Here we found that the dopaminergic neurotoxicant Mn 
rapidly induce PK2 during the early stages of Mn neurotoxic stress in an N27 dopaminergic 
cell model. We showed that PK2 is a compensatory, protective response against Mn toxicity, 
and that overexpression of PK2 could protect against Mn-induced cell death. In light of Mn’s 
role in mitochondrial dysfunction, we showed that overexpression of PK2 protects against Mn-
induced mitochondrial dysfunction while knockout of PK2 exacerbates these effects. 
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Importantly, we found that PK2 is differentially regulated in the striatum in relation to other 
regions experiencing less degeneration during Mn toxicity, likely to be caused by Mn-induced 
hypermethylation of PK2 promoter region in the striatum.  
While pathophysiological differences exist in the diagnosis of PD and manganism, the 
underlying cellular mechanism of toxicity are overlapping. Mn mimics the action of MPP+ in 
selectively inhibiting mitochondrial complex I in neurons (Gavin et al., 1999; Hirata, Kiuchi, 
& Nagatsu, 2001; Malecki, 2001) by accumulating via mitochondrial Ca2+ uniporter (S. Zhang, 
Zhou, & Fu, 2003) to induce caspase 3 and 9 activation, major contributors to the execution of 
neuronal apoptosis leading to cell death (Choi et al., 2007; Smith, Fernandes, Go, & Jones, 
2017; Uchida, Oh-Hashi, Kiuchi, & Hirata, 2012; L. Zhang, Sang, Liu, & Li, 2012). BCL-2, 
an anti-apoptotic protein localized on the outer mitochondrial membrane, could suppress 
caspase-3 activation induced by Mn toxicity (Anantharam et al., 2002; Latchoumycandane et 
al., 2005), DNA fragmentation, and PKCδ activation during neurodegeneration in cell culture 
models of PD (Fabisiak, Kagan, Ritov, Johnson, & Lazo, 1997; Kitazawa, Anantharam, & 
Kanthasamy, 2001; Yang et al., 1998). Therefore, in PD models, PK2-mediated upregulation 
of Bcl-2 could promote anti-apoptotic effects in dopaminergic neurons during toxic insult 
(Gordon et al., 2012; A. G. Kanthasamy et al., 2003; Kitazawa et al., 2005a, 2004). Our current 
study suggests that PK2 could preserve and maintain mitochondrial function even during Mn-
induced cellular stress, while PK2 downregulation renders the cell susceptible to Mn-induced 
stress. In this study, we found downregulation of PK2 in striatum, pointing to a possible 
mechanism of selective vulnerability to Mn intoxication.   
The preferential accumulation of Mn in the globus pallidus and striatum likely will also 
affect the subventricular zone (SVZ) along the lateral ventricle of the striatum, a major site of 
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neurogenesis in the adult brain. A recent study found that Mn caused an initial increase in early 
stages of neurogenesis in the SVZ, but due to Mn-induced toxicity, only 33% of new SVZ-
derived neuroprogenitor cells (NPCs) survive to differentiate into functional neurons, 
compared to 64% in controls (Bresjanac & Antauer, 2000). Mn also exacerbates decreased 
neurogenesis and neuronal differentiation in the SVZ of MitoPark mouse model of PD 
(Langley et al., 2018). PK2 is a downstream target of Mash1 (C. Zhang et al., 2007) during 
neuronal differentiation as NPCs mature into neurons, a reduction of PK2 in the basal ganglia 
could therefore cause an accumulation of NPCs at the early stages of neurogenesis, and a 
reduction of NPCs undergoing neuronal differentiation in the SVZ to replace lost functional 
neurons in the striatum. Recent findings suggest that BDNF, an important trophic factor 
involved in neurogenesis (Bath, Akins, & Lee, 2012; Liu & Nusslock, 2018), was decreased 
in the striatum of non-human primates and mice chronically exposed to Mn, as well as primary 
cortical and hippocampal neuron cultures treated with Mn (Stansfield, Bichell, Bowman, & 
Guilarte, 2014). This raises the possibility that BDNF and PK2, which are both involved in 
olfactory bulb neurogenesis (Uranagase, Katsunuma, Doi, & Nibu, 2012; Yuan, 2008),  are co-
regulated in the long term in the striatum. It is also possible that the initial increase in 
neurogenesis is a compensatory response to acute Mn overexposure. If the exposure continues, 
however, the compensatory response is likely to be exhausted, with resultant decreases in 
neurogenesis in SVZ and cell loss in basal ganglia.  
Some studies found that brain dopamine levels are initially elevated and then depleted 
by Mn toxicity (Cotzias, Miller, Papavasiliou, & Tang, 1976), suggesting that an initial 
compensatory response in the nigrostriatal system being overwhelmed. In our study, PK2 was 
upregulated in the SN after a subacute (10 days) Mn treatment, at a time during which no motor 
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impairments were detected. In the striatum, we saw an initial stabilization of PK2 level which 
later decreased. However, further studies are needed to clarify the role of PK2 in response 
against acute Mn exposure in striatum and the rest of the brain.  
Current understanding of Mn toxicity in the brain attributes it on a function of its 
distribution; its preferential accumulation in the striatum causes damage to striatum while 
sparing the SN. However, upregulation of PK2 during early Mn neurotoxicity suggests that 
toxicity is not only limited to striatum, and might suggest PK2’s compensatory, protective role. 
PK2 upregulation in many regions relatively spared by Mn-induced toxicity contrasts with its 
downregulation in striatum, suggesting that the striatum did not participate in this 
compensatory response.  
In light of the mechanism of Mn toxicity by way of interference with mitochondrial 
energy production, and given PK2’s role in mitochondrial biogenesis, failure to upregulate 
PK2 expression in the striatum due to Mn-induced PK2 promoter methylation could represent 
a major mechanism of toxicity, as well as a point of intervention by methods to upregulate PK2 
expression in the affected regions.  
Given that mitochondrial dysfunction has been increasing recognized as a central theme 
in other neurodegenerative disease aside from manganism and PD, such as in Alzheimer’s and 
ALS (Cozzolino, Ferri, Valle, & Carrì, 2013; Maruszak & Żekanowski, 2011; Von Lewinski 
& Keller, 2005; Yu et al., 2018), understanding the role of PK2 in Mn toxicity could shed 
insight on mitochondrial dysfunction for a multitude of neurodegenerative diseases. 
Furthermore, current standard of care for manganism is limited to devising ways of reducing 
Mn by dietary intake, chelation therapy with metal chelators, and symptomatic management 
of dystonia (Kwakye, Paoliello, Mukhopadhyay, Bowman, & Aschner, 2015; Peres et al., 
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2016; Rodan LH, Hauptman M, D’Gama AM, Qualls AE, Cao S, Tuschl K, Al-Jasmi F, 
Hertecant J, Hayflick SJ, Wessling-Resnick M, Yang ET, Berry GT, Gropman A, Woolf AD, 
2018). Since a large portion of small molecules target a GPCR, PK2’s two cognate GPCRs, 
PKR1 and PKR2, represent clinically relevant druggable targets for pharmacological 
modulation of PK2 signaling using recombinant protein or chemical agonists.  
In summary, exposure to Parkinsonian toxicants MPP+ and Mn induces PK2 
upregulation in dopaminergic neuronal cells. Functional studies show over-expressing PK2 
protect manganese-induced cytotoxic and apoptotic cell death. Mechanistic studies show that 
in PK2-overexpressing cells, pro-survival factors as well as factors important for mitochondrial 
health are preserved relative to vector control cells during neurotoxic insult. Manganese 
increases PK2 levels in the brain of GENSAT Swiss Webster mice, and decreases in the 
striatum. Overall, these results indicate that PK2 signaling represents a potential therapeutic 
target against Mn-induced neurotoxicity.  
 
Materials and Methods 
Animal handling. All animal procedures were approved by Iowa State University’s 
Institutional Animal Care and Use Committee (IACUC). All mice were housed under a 12-h 
light cycle in a climate-controlled mouse facility (22±1 °C) with food and water available ad 
libitum. Male C57B/6 mice were pre-screened during behavioral assessments for normal 
baseline performance before being randomly assigned to experimental groups. Animals were 
not wounded or otherwise exhibited conditions that could affect behavior, and are taken off the 
study if any conditions have manifested which could affect behavioral measurements. 
Investigators involved with data collection and analysis were not blinded to group allocation.  
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Behavior monitoring. All groups were monitored for behavior using the automated 
VersaMax system software connected to motion-detection hardware (VersaMax monitor, 
model RXYZCM-16, and analyzer, model VMAUSB, AccuScan, Columbus, OH). Each 
animal was put in one chamber fitted with motion-detection hardware, and allowed to 
acclimate for 2 minutes, after which its spontaneous locomotor activities (horizontal activity, 
vertical activity, and speed) were recorded for 10 minutes.  
Western blot. Dissected brain regions were collected in Eppendorf tubes and flash 
frozen. To isolate total protein, RIPA buffer with sodium orthovanadate, Protease and 
Phosphatase Inhibitor Cocktail (Thermo Fisher 78440) was added to each tube, and 
homogenized using a tissue homogenizer. Dissolved total lysate was centrifuged at 12,000g 
for 60 minutes, to remove cellular debris. Normalized protein samples were loaded into each 
well and were separated by sodium dodecyl sulfate (SDS) gel electrophoresis (100V, 90 
minutes), using AnykD Mini-PROTEAN resolving gel (Bio-Rad, #4569035). Proteins on SDS 
gels were then transferred to a nitrocellulose membrane (26V, overnight) and blocked for 1h 
using fluorescent western blocking buffer (Rockland Immunochemicals). Primary antibodies 
were diluted in blocking buffer with 0.05% Tween 20, were then added to the membranes and 
incubated overnight at 4 °C. Next day, primary antibodies were taken off, and blots were 
washed (7 times, 5 minute each) in wash buffer comprising PBS containing 0.05% Tween 20 
(PBST). Secondary antibody (infrared dye-tagged) was added for 1 h. Blots were further 
washed in PBST for 3 more times, and once in PBS. β-Actin was used as a loading control. 
Membranes were scanned using the Odyssey IR imaging system (LI-COR) and digital images 
were captured via LI-COR Odyssey imager. Densitometric analysis was done using ImageJ 
software. 
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Immunohistochemistry. Cells were fixed in 4% paraformaldehyde blocked with BSA 
and Triton-X to permeabilize the cell membranes. Primary antibodies were used as follows: 
rabbit anti-TH (1:1600 dilution), rabbit anti-PK2 (1:500 dilution), goat anti-GDNF (1:500 
dilution), goat anti-IBA1 (1:1000), rabbit anti-GFAP (1:1000 dilution). Alexa Fluor 
Fluorescent Secondary Antibodies from ThermoFisher were used against primary antibodies 
for fluorescent images. For DAB staining, HRP-conjugated secondary antibodies were used 
against primary antibodies, and VECTASTAIN Elite ABC HRP Kit (VectorLabs) was used 
for conjugation of HRP to secondary antibodies. DAB was used for color development.  
SYBR Green qRT-PCR. To obtain total RNA, tissue lysis buffer from Absolutely 
RNA Miniprep kit (Agilent Technologies) was added to dissected brain regions with addition 
of beta-mercaptoethanol as reducing agent to preserve RNA. A tissue homogenizer was used 
to dissolve tissue into the lysis buffer, and lysates were processed according to kit 
manufacturer’s instructions. Isolated total RNA from each sample was quantified using 
Nanodrop instrument to determine RNA concentration and purity. First strand cDNA synthesis 
was performed using Affinity Script qPCR cDNA synthesis system (Agilent Technologies) 
with 1µg of total RNA in the reaction mixture. Real-time PCR was performed with the 
RT2 SYBR Green master mix (Qiagen) using diluted cDNA, and qPCR mouse primer sets 
were purchased from Qiagen (Quantitect primer mix). The 18S rRNA gene (mouse) was used 
as normalization of each sample as the housekeeping gene. The amount of each template was 
optimized empirically to maximize efficiency without inhibiting the PCR reaction. After the 
last cycle of the qPCR run, dissociation curves were run to ensure a single amplicon peak was 
obtained, indicating primer specificity. The results are reported as fold change in gene 
expression with the ΔΔCt method, using the threshold cycle (Ct) value for the housekeeping 
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gene and for the respective gene of interest in each sample. Control animals serve as the 
baseline for fold change.  
Lentivirus production. PK2 lentivirus expression vector was obtained from Origene, 
and the MISSION Lentiviral Packaging Mix was obtained from Sigma (SHP001) and used 
according to manufacturer’s protocols. Briefly, the PK2 lentivirus expression vector was mixed 
with the Packaging Mix, and co-transfected into 293FT cells to package the virus. After 24h 
post-transfection, the supernatant, which contain the virus, was collected. The second 
harvesting of virus was done 48h post-transfection. The Lenti-X™ p24 Rapid Titer Kit from 
Clontech (632200) was used to titer the lentivirus.  
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Figures 
 
 
Figure 1. Neurotoxicant manganese treatment induces PK2 upregulation in N27 
dopaminergic cells. A. Upregulation of PK2 mRNA with neurotoxicant Mn, MPP+ at 300µµM, 
as well as HIF1α stabilizer, DHB at 200µM, following their treatments for 4h. At the end of 
132 
the treatment, cell pellets were collected and processed for RNA isolation using Trizol. B. 
Upreguation of PK2 protein levels with Mn treatment time course of baseline, 6h, 8h, 10h, and 
12h. At the end of treatment, cell pellets were collected and processed for western blot (top). 
Anti-PK2 and anti-β-actin were used to probe for PK2 and β-actin levels, and the results are 
analyzed using ImageJ software (bottom). Early upregulation of PK2 levels were seen at 6h 
post-treatment, and is sustained to 12h. Experiments were repeated twice with n = 3. Data 
represented as mean +/- s.e.m. and asterisks denote a significant (*P<0.05 and **P<0.01 and 
***P<0.005) difference between control and treatment groups using one-way ANOVA with 
Tukey post-test comparison.  
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Figure 2. Stable PK2 overexpression in dopaminergic cell line protects against Mn-
induced cytotoxic cell death. A. MN9D mouse dopaminergic cell line was transfected with 
PK2 overexpression vector by stable transfection of plasmid vector carrying human PK2 
135 
cDNA and a small myc-tag. After transfection, cells were put in growth media supplemented 
with neomycin/G418 to kill cells without transgene expression. Western blot runs for human 
PK2 indicates high expression in of PK2 in MN9D dopaminergic cells after stable transfection. 
B. Densitometric quantification of western blot analysis from A using ImageJ after 
normalization with beta-actin. Experiments were repeated three times. Data represented as 
mean +/- s.e.m. and asterisks denote a significant (*P<0.05 and **P<0.01 and ***P<0.005) 
difference between control and treatment groups using one-way ANOVA with Tukey post-test 
comparison. C. Localization of PK2, Myc-tag was determined by fluorescent immunostaining. 
Nuclei was stained by Hoechst dye (blue). Images were taken using 60x lens. E. MTS assay 
of Mn-treated Vector and PK2 overexpression cells, with control levels as percent control. 
Cells were treated with increasing doses of Mn ranging from 0µM to 500µM which were added 
to growth media with reduced serum (2% FBS) for 24 hours. F. Similarly, MTS assay of Mn-
treated Vector and PK2 overexpression cells, but with addition of PC-7, a GPCR blocker that 
could block PKR2. G. Flowcytometry analysis of vector and PK2 cells treated with control or 
Mn. ANNEXIN-5 and propidium Iodide stains were used to determine percentage of cells that 
are in live, early apoptotic, late apoptotic, or dead stages 24h after Mn treatment. H. statistical 
analysis of data obtained from the flowcytometry experiment. Experiments were repeated 
twice with n = 3. Data represented as mean +/- s.e.m. and asterisks denote a significant 
(*P<0.05 and **P<0.01 and ***P<0.005) difference between control and treatment groups 
using one-way ANOVA with Tukey post-test comparison.  
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Figure 3. Stable PK2 overexpression in dopaminergic MN9D cells protects against Mn 
by reducing caspase activation and increasing BCL-2 levels. A. Caspase assay of vector and 
PK2 cells treated with either control or Mn for 16h. After treatment, cell pellets were collected 
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and processed for caspase assay, using Ac-DEVD-AMC caspase-3 as a fluorogenic substrate 
to assess caspase-3 activity. B. RT-PCR assay for Bcl-2 mRNA expression in vector and PK2 
cells, treated with either control or Mn for 24h, with 18S as internal standard for normalization. 
C. Western blot for BCL-2 in Vector and PK2 cells treated with control, MPP+, or Mn for 8h. 
Experiments were repeated twice with n = 3. Data represented as mean +/- s.e.m. and asterisks 
denote a significant (*P<0.05) difference between control and treatment groups using one-way 
ANOVA with Tukey post-test comparison.  
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Figure 4. PK2 overexpression protects MN9D cells against Mn-mediated 
mitochondrial dysfunction, while knockdown of PK2 exacerbates Mn-induced mitochondrial 
dysfunction. A. Mitochondrial staining using MitoTracker dye staining for vector and PK2 
cells treated with Mn for 24h revealed that mitochondrial staining were increased in PK2 cells. 
B. RT-PCR analysis of mitochondrial DNA content (mDNA). Vector and PK2 cells are treated 
with control or Mn, and after 24h of treatment, cell pellets were processed. RT-PCR using 
140 
primers specific for mDNA cytochrome B revealed increased mDNA content in PK2 cells. C. 
Western blot analysis of mitochondrial levels of PGC1alpha and TFAM in vector and PK2 
cells after treatment with control or Mn.  
D. Activity of the CRISPR-Cas9 protein was assessed by green fluorescence, and the 
expression of Cas9 tagged with GFP in N27 indicates successful transduction of lentivirus in 
N27 cells. E. RT-PCR using rat PK2 primers found significantly reduced PK2 mRNA in PK2 
knockout cells. F. Western blot analysis of PK2 protein level indicated significant reduction in 
PK2 protein in PK2 knockout cells. G. Seahorse Mito-stress test of CRISPR-Cas9-mediated 
PK2 knockdown in N27 cells. Vector cells and PK2 Knockdown cells were plated in Seahorse 
assay cell culture plate, and treated with control or Mn for 24h. H. CRISPR-Cas9-mediated 
PK2 knockdown in N27 cells shows lower oxygen consumption rate. I, J. PK2 knockdown 
N27 cells have lower basal oxygen consumption rate and lower ATP production. K. Compared 
to vector cells, PK2 knockdown N27 cells also exhibit a stressed phenotype. Experiments were 
repeated twice with n = 3. Data represented as mean +/- s.e.m. and asterisks denote a significant 
(*P<0.05) difference between control and treatment groups using one-way ANOVA with 
Tukey post-test comparison.  
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Figure 5. Subacute and subchronic Mn treatment in mice increase PK2 levels in SN but 
not basal ganglia. A. Schematic of treatment paradigm for C57B/6 mice given Mn in the form 
of MnCl2 (30mg/kg body weight) or vehicle, daily via oral gavage for 10 days. B, C. Western 
blot analysis for PK2 protein level in the SN and striatum. Wildtype C57B/6 mice brains were 
dissected after treatment and processed into lysates. Antibodies for PK2 were used to probe 
for PK2 protein level and beta-actin was used a loading control.  PK2 levels were significantly 
higher after Mn treatment in the SN, but did not change in the striatum. D. Treatment paradigm 
for control and Mn treatment. Mn, in the form of MnCl2 (30mg/kg body weight) or vehicle, 
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were given daily via oral gavage to eGFP-PK2 Swiss Webster mice for 30 days. E. A 
representative VersaPlot tracing of locomotor activity on open-field generated by VersaMax 
software. Mn-treated mice exhibited decreased locomotor activity. F. Mn-treated mice 
exhibited lower horizontal activity, vertical activity, and total distance traveled on open field. 
G. Representative heat map of tracked location of rodent’s head, generated by AnyMaze 
software. The social discrimination test involved planting bedding from opposite-sex on one 
end the of the long rectangular cage (zone 2), and rodent’s own bedding on the other end (zone 
1). The number of times and the amount of time each mouse visits zone 1 or zone 2 and stays 
in the zone is recorded. H. Quantification of number of visits to zone 1 and zone 2 in mice in 
control or Mn treatment groups. I. HPLC analysis of dopamine, as well as dopamine 
metabolites DOPAC and HVA. After treatment course, the mice were sacrificed and brains 
dissected. The striatum was processed for HPLC. Increased dopamine and decreased 
metabolites were found, suggesting of decreased turnover of dopamine and a dysregulation of 
the dopamine metabolic pathway. J. Kodak in-vivo imaging revealed EGFP expression as 
driven by PK2 expression. After treatment, mice were sacrificed and whole brains were taken 
for imaging. K. Western blot analysis of PK2 protein level. PK2 level was found to be 
decreased in the striatum of mice treated with Mn, whereas increases in olfactory bulb (OB) 
and SN were seen. L. Methylation status of PK2 promoter region in the cortex after control or 
Mn treatments. Methylation-specific PCR was performed on cortex samples from mice treated 
with control or Mn and run on a agrose gel. M = methylated PCR product, U = unmethylated 
PCR product. After Mn treatment, a lower ratio of methylated to unmethylated PCR products 
were seen, presumably allowing for higher transcriptional factor access to promoter and 
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transcription of associated genes. M. PK2 promoter methylation remains relatively unchanged 
in the striatum. 
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Abstract 
Despite a wealth of preclinical studies establishing neuroprotective and 
neurorestorative properties of glial cell-line derived neurotrophic factor (GDNF) in animal 
models of PD, a number of phase II clinical trials utilizing direct intracranial injection of GDNF 
protein and AAV-mediated Gdnf gene transfer did not achieve efficacy that was hoped for. 
Setbacks from recent clinical trials might prompt a rethinking of the strategy which focused on 
ectopic expression of GDNF targeted towards neurons. Devising strategies to elevate GDNF 
expression by means other than genetic manipulation is the current challenge. We have 
previously found that prokineticin signaling is a compensatory protective response against 
dopaminergic neuronal degeneration during PD. Here we show that GDNF has significant 
crosstalk with prokineticin signaling in astrocytes. A small molecule, IS20, could activate 
prokineticin signaling to induce secretion and increased gene expression of GDNF from 
astrocytes in culture via activation of prokineticin receptor 1 (PKR1) preferentially expressed 
by astrocytes. Further, noninvasive administration of the blood-brain-barrier-permeable 
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lipophilic IS20 through intranasal delivery could pharmacologically modulate GDNF levels in 
brain and in the nigrostriatal system in C57B/6 mice. Importantly, IS20 treatment yielded 
significant neuroprotective and neurorestorative effects in MPTP-induced and MitoPark 
genetic mouse models of PD. Our results indicate that the full clinical benefit of GDNF could 
be leveraged by pharmacological modulation using IS20.  
 
Introduction 
Parkinson's disease (PD) is the second most common neurodegenerative disease that 
affects around 1% of the world's aging population. This disease is characterized by progressive 
degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNpc) in the 
ventral midbrain, leading to subsequent dopamine loss within the striatum, resulting in severe 
motor impairment that includes akinesia, rigidity, and tremor (Barzilai & Melamed, 2003; 
Jarraya et al., 2009). Since the 1950s following the Nobel-winning discovery of the role of 
dopamine precursor 3,4-dihydroxy-L-phenylalanine (L-DOPA) in Parkinsonian animals by 
Swedish scientist Arvid Carlsson, the current standard-of-care treatment strategy for PD has 
continued to be the oral administration of L-dopa, which increases the availability and 
concentration of dopamine in the striatum to alleviate motor symptoms, but has little effects 
on nonmotor symptoms (Meissner et al., 2011; W & O, 1961). Since no disease-modifying 
therapy has been developed (Won et al., 2016), the progressive nature of the disease demands 
dosage titration involving high doses of L-dopa, resulting in an array of motor fluctuations and 
other severe complications including dyskinesia over time in the majority of patients (Jarraya 
et al., 2009).  
Glial-cell derived neurotrophic factor (GDNF) has been well documented to participate 
in the development and maintenance of various neuronal systems in the body, including 
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development of neuronal system in the kidney, enteric nervous system (ENS), and the central 
nervous system (CNS). Since its discovery in 1992 (O’Malley, Sieber, Black, & Dreyfus, 
1992), GDNF has been one of the most potent neurotrophic factors discovered to date with 
protective properties on the dopaminergic system (L. F. Lin, Doherty, Lile, Bektesh, & Collins, 
1993). Dopaminergic neurons express both GDNF receptor GFRα1 and GDNF co-receptor 
RET, through which GDNF promotes regeneration and survival of SN dopaminergic neurons. 
GDNF was also found to increase dopamine content and uptake, while stimulating neurite 
extension, and increase in tyrosine hydroxylase (TH) in cell culture models (Beck et al., 1995; 
L. F. Lin et al., 1993). In vivo studies provide evidence that GDNF is necessary for maintenance 
of dopaminergic neurons during later stages of development and throughout adulthood. 
Supporting this notion, conditional knockout of GDNF in mice starting at 1 month of age 
results in selective decrease of TH immunoreactivity and a 60-70% loss of DA neurons in 
midbrain at 7 months of age, further indicating that under normal conditions, GDNF is 
indispensable for DA neuron survival (Pascual et al., 2008). 
Numerous preclinical studies using rodent and primate models of PD has demonstrated 
the potential of GDNF as a treatment for PD (Bilang-Bleuel et al., 1997; Björklund, Rosenblad, 
Winkler, & Kirik, 1997; J. H. Kordower et al., 2000; Tseng, Baetge, Zurn, & Aebischer, 1997) 
However, initial clinical trials delivering recombinant GDNF protein using intracranial 
administration failed to diffuse into deeper layers of the brain and slow down 
neurodegeneration or improve motor function (Domanskyi, Saarma, & Airavaara, 2015). 
While recent improvements in GDNF delivery has shown moderate efficacy (Gill et al., 2003), 
it still does not overcome the difficult challenge of long-term GDNF delivery into the brain. 
GDNF gene therapy using AAV-mediated gene delivery can overcome the hurdle of targeted 
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delivery, and was proven safe in phase I clinical trial, but ultimately showed no efficacy in 
phase II (Blits & Petry, 2016; Remy, 2014; Tenenbaum & Humbert-Claude, 2017). 
Furthermore, in the current configuration, AAV-mediated gene delivery is irreversibly 
integrated into genome of target cells, and is thus inherently less controllable than classical 
pharmacotherapies (Tereshchenko, Maddalena, Bähr, & Kügler, 2014). Failures of current 
GDNF trials underscore the importance of comprehending the events upstream of GDNF 
signaling pathway and deconvoluting other signaling pathways in crosstalk with GDNF. The 
control of endogenous GDNF expression would constitute a powerful target in 
neuropharmacology (Caumont, Octave, & Hermans, 2006). Devising strategies to elevate its 
expression by means other than genetic manipulation is the current challenge that should 
warrant increased translational research efforts (Ibáñez & Andressoo, 2017). 
Setbacks of current AAV-mediated dopaminergic GDNF gene delivery trials might 
demand a rethinking of the strategy, including expressing GDNF in striatal astrocytes. 
Astrocytes secrete neurotrophic factors NGF, BDNF, and GDNF (Dougherty, Dreyfus, & 
Black, 2000), and are the major source of GDNF in brains of PD patients (Drinkut, 
Tereshchenko, Schulz, Bähr, & Kügler, 2012; Mogi et al., 2001). Astrocyte’s role in 
maintaining a healthy environment for proper functioning of neurons has been increasingly 
recognized, yet their potential as a source of nigral GNDF and as therapeutic targets has not 
been sufficiently leveraged. 
Initially identified from a nontoxic component of black mamba snake venom (Laustsen, 
Lomonte, Lohse, Fernández, & Gutiérrez, 2015), the Prokineticins are shown to crosstalk 
extensively with GDNF signaling pathway in the peripheral nervous system during 
development of ENS (Enomoto et al., 1998; Ngan et al., 2007, 2008; Young et al., 2001), and 
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defects in either signaling pathways produce the rare genetic condition Hirschsprung disease 
(Ruiz-Ferrer et al., 2011). GDNF and prokineticin crosstalk during the development of ENS 
raises the possibility that the prokineticin signaling pathway is also in similar crosstalk with 
GDNF in the CNS. Interestingly, both GDNF and PK2 have been shown to be strong 
chemoattractants for axons during neurogenesis/neuritogenesis, and PK2 is required for 
complete olfactory bulb (OB) development. Importantly, we previously found that PK2 
upregulation mediates a protective, compensatory response through activation of AKT, ERK 
pathway and increasing mitochondria biogenesis during neurodegeneration (Gordon et al., 
2016). AAV2/5-mediated delivery of PK2 could protect against neurodegeneration induced by 
Parkinsonian toxicants in the SN and striatum. However, until now, there is no evidence for a 
fundamental relationship between PK2/PKR1 and GDNF/RET signaling in the CNS and the 
nigrostriatal system. Intriguingly, PKR1 was also found to be mainly expressed in astrocytes, 
raising the possibility that GDNF could be co-upregulated with the prokineticin pathway in 
brain astrocytes. Moreover, the predominant expression of PKR1 compared to PKR2 in 
astrocytes(Koyama et al., 2006) suggests that astrocytes could be preferentially targeted using 
receptor agonists with specificity to PKR1. Thus, using a lipophilic small molecule receptor 
agonist specific to PKR1 (Gasser et al., 2015), IS20, we hypothesized that positive modulation 
of the expression and secretion of GDNF in astrocytes of the nigrostriatal system can be 
achieved via pharmacological activation of PK2/PKR1 signaling. Subsequently, this could 
promote trophic effects on the dopaminergic system to yield neuroprotective and 
neurorestorative effects in PD models.  
In the present study, we report that 1) PK2/PKR1 signaling represents a novel, 
druggable pathway that could modulate GDNF expression in the CNS, particularly in the 
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astrocytes, 2) the upregulation of GDNF through PK2/PKR1 signaling could be 
pharmacologically induced by intranasal delivery of the PKR1 receptor chemical agonist IS20, 
and 3) IS20 could rescue DA neurons and neuronal projections against neurodegeneration in 
genetic and chemically-induced mouse models of PD. In contrast to long-term uncontrolled 
continuous expression driven by intracerebral injections of GDNF viral vectors, which led to 
unwanted compensatory responses (B. Georgievska, 2004; Biljana Georgievska, Kirik, & 
Björklund, 2002; Sajadi, Bauer, Thöny, & Aebischer, 2005), intranasal IS20 administration 
showed no such responses, nor any overt toxicity in mice for the course of treatment. Therefore, 
by pharmacologically modulating the amount and duration of endogenous GDNF expression 
using small molecule IS20 treatment, GDNF's established clinical benefits could be fully 
harnessed with non-invasive procedures and minimum unwanted compensatory responses.  
 
Results 
Figure 1. Prokineticin receptor 1 is activated by recombinant PK2 protein and 
receptor agonist IS20. To examine whether the PK2 agonist IS20 can positively modulate 
GDNF expression, our initial set of experiments was conducted to confirm that IS20 is able to 
activate PKR1, similar to recombinant PK2 (rPK2) protein. PKR1 has been reported to be 
expressed on the membrane of dopaminergic neurons and type 1 astrocytes in the nigrostriatal 
system. Once activated, PKR1 initiates downstream signaling activation that culminates in the 
rise of Ca2+ in the cytosol (Ngan & Tam, 2008). To facilitate the analysis of PKR1 activation, 
we used a CHO cell line stably expressing PKR1. The PKR1-overexpressing cells were treated 
with 10 µM IS20 or 100 nM rPK2, and PKR1 activation was monitored by measuring 
intracellular Ca2+ mobilization in real time over 180 seconds using a Fluo-4 NW calcium assay 
kit. In silico modeling of binding to PKR1 protein reveals that both rPK2 (Fig. 1A) and IS20 
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(Fig. 1C) can bind to PKR1 with high affinity. As shown in Fig. 1B, upon treatment with rPK2, 
intracellular Ca2+ concentration rapidly rises and peaks at 20 seconds post-treatment, 
suggestive of a Gαq1 mechanism of PKR1 activation (Fig. 1B). Similarly, after treatment with 
10 µM of IS20, Ca2+ concentration rises but slowly peaks at 180 seconds post-treatment (Fig. 
1D), suggesting that IS20 induces a similar magnitude but relatively delayed activation of 
PKR1 compared to rPK2. 
Figure 2. PK2 agonist IS20 and recombinant PK2 upregulate GDNF expression 
in U373 human astrocyte cells. Next, to examine the effects of PK2 signaling activation on 
GDNF expression in astrocytes we first treated U373 human astrocyte cells with rPK2 and 
found that treatment with 25 nM rPK2 was able to induce GDNF protein expression to 1.6-
fold above control (Fig. 2A), and mRNA level to nearly 3-fold above control (Fig. 2B). The 
rPK2-induced upregulation of GDNF mRNA was completely attenuated with co-treatment of 
the Prokineticin receptor antagonist PC-7 (Fig. 2B). Furthermore, using an ELISA kit, we 
showed that the release of GDNF in media was significantly increased by rPK2 (25 nM). To 
confirm these findings, we infected U373 cells with lentivirus expressing PK2-GFP fusion 
protein or GFP control virus. Although we only achieved a modest increase in PK2 levels (Fig. 
2D), Lenti-PK2-GFP-infected cells exhibited a 1.7-fold increase in PK2 protein levels as 
compared to Lenti-GFP-infected control cells (Fig. 2E).  Importantly, time-course treatment of 
U373 cells with 10 µM IS20 induced maximal GDNF mRNA expression at 1 h; this 
upregulation declined over the subsequent 5 h (Fig. 2G). To assess any receptor-specific effects 
of IS20 on GDNF production, we overexpressed PKR1 by transiently transfecting increasing 
amounts of PKR1 expression vector (0.5-15 µg) in U373 astrocytes and the transfected cells 
were treated with 10µM IS20 for 4h. As shown in Fig. 2H, ectopic expression of PKR1 dose-
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dependently stimulated IS20-induced upregulation of GDNF mRNA, and the optimal 
stimulation (5-fold) was saturated between 5-15 µg PKR1 expression plasmid. Next, we 
generated a stable PKR1 overexpression U373 cell line and found that PKR1 overexpression 
cells exhibited an increased expression of GDNF mRNA and immunoreactivity, and treatment 
with IS20 (3-10 µM) further potentiated this upregulation (Fig. 2I-J). More importantly, when 
a CRISPR-Cas9 guide RNA against PKR1 was used to knock down PKR1 (Fig. 2K) in U373 
astrocytes, IS20 was no longer able to modulate GDNF expression level (Fig.2L), further 
demonstrating that IS20-induced GDNF expression is highly dependent on PKR1 receptor 
binding and activation.  
Figure 3. IS20 protects against MPP+-induced cell death and preserves 
mitochondrial energetics in dopaminergic neuronal cells. Having discovered that IS20 is a 
potent inducer of GDNF in astrocytes, we further evaluated whether the IS20-induced 
upregulation and secretion of astrocyte-derived GDNF could functionally protect 
dopaminergic neuronal cells under insults from the classic Parkinsonian toxicant MPP+. U373 
astrocytes were incubated with or without IS20, and the astrocyte conditioned media (ACM) 
was collected and added to N27 dopaminergic neuronal cells, with co-treatment with or 
without MPP+ (100-300 µM) for 24 h. As shown in Fig. 3A, addition of IS20 ACM 
significantly increased the cell viability in MPP+-treated N27 cells compared to the control 
ACM/MPP+-treated cells. Next, we investigated whether this protection was mediated through 
preservation of mitochondrial respiration. Seahorse analysis revealed that in addition to 
slightly increasing the basal respiration of untreated N27 cells (Fig. 3B, red and blue bars), 
IS20 ACM remarkably attenuated MPP+-induced reduction in oxygen consumption rate, basal 
respiration, reserve capacity, and ATP production (Fig. 3B-E), suggesting a post-mitochondrial 
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mechanism at least partly contribute to the protection conferred by IS20 ACM. Lastly, we 
utilized mouse primary striatal neurons to validate the neuroprotective effects of IS20 ACM. 
We included the ACM collected from U373 astrocytes treated with IS21, a compound known 
not to activate PKR1, to further determine the specificity of IS20. As depicted in Fig. 3F, IS20 
ACM but not IS21 ACM promoted the cell survival in MPP+-exposed mouse primary striatal 
neurons as determined by MTS assays. All together, these studies suggest that U373s treated 
with IS20 could secrete factors that protect dopaminergic neuronal cells against MPP+-induced 
neurotoxicity. 
Figure 4. IS20 upregulates GDNF expression in primary mouse astrocytes and 
midbrain organotypic slice cultures. Next, we used cultured primary mouse astrocytes from 
prenatal mouse pups to validate the findings obtained from U373 astrocyte cells. A time-course 
study of the effects of 10 µM IS20 treatment on the expression of GDNF mRNA (Fig. 4A) and 
the release of GDNF protein (Fig. 4B) over a 8-h period revealed rapid upregulation of GDNF 
mRNA and release, most prominent at 2h and 3h post-treatment, respectively, which gradually 
declined over time back to the levels slightly above those of control groups. To further 
determine the effect of the concentration of IS20 on GDNF mRNA expression and protein 
release, we undertook a concentration response study using a range of 0.3-30 µM of IS20. As 
shown in Fig. 4C-D, the maximal response was achieved for an IS20 concentration of 10 μM 
on both GDNF mRNA expression and protein release. GDNF protein levels in the IS20-treated 
whole cell lysates also increased concomitantly in a time- and dose-dependent manner (Fig. 
4E), demonstrating that GDNF is both upregulated and secreted by primary astrocyte cells 
following IS20 treatment. Supporting this, treatment of primary mouse astrocytes with 10µM 
of IS20 for 8 h can increase GDNF immunoreactivity in western blot (Fig. 4F). Some of the 
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primary mouse astrocytes that were isolated were separately stained for GFAP to confirm that 
they were indeed astrocytes (Fig. 4G). 
Interestingly, mRNA expression of GDNF and its predominant cell surface receptor in 
the dopaminergic system, GFRα1, were co-upregulated 3 h post-10 μM IS20 treatment (Fig. 
4G), indicating that the increased gene expression and protein secretion of GDNF also can lead 
to an upregulation of its receptor in the same cells, possibly establishing a positive feedback 
loop which helps to increase GDNF upregulation and secretion. To further evaluate the effect 
of IS20 on GDNF expression, we treated organotypic midbrain slice cultures prepared neonatal 
mouse pups. In line with the above findings, IS20 treatment for 4 h in cultured organotypic 
slices increased GDNF mRNA expression (Fig. 4H) and protein levels (Fig. 4I). Taken 
together, these results demonstrated that GDNF is highly upregulated and secreted in primary 
mouse astrocytes and midbrain organotypic slice cultures following IS20 treatment 
Figure 5. IS20 administration induces GDNF expression and release in C57 black 
mice. Next, we determined the bioavailability of IS20 in the brain after intraperitoneal injection 
or intranasal administration, and looked for its biological effects in the brain. Wildtype C57 
black mice were intraperitoneally injected with DMSO or IS20 at 10 mg/kg body weight for 8 
h, and GDNF protein levels in the brain and serum were examined by Western blot and ELSA, 
respectively. As shown in Fig. 5A-B, we observed a significant increase in GDNF protein 
levels in nigral lysates with a concurrent increase in serum. Intranasal administration allows 
for small, relatively lipophilic compounds intended for the CNS to non-invasively bypass much 
of the blood-brain-barrier (Hernando et al., 2017), thus increasing compound bioavailability in 
the CNS while reducing exposure to peripheral tissues. Given this information, in a second 
study, we therefore determined to examine the bioavailability of the lipophilic IS20 and its 
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effect on GDNF expression following intranasal administration of 3 mg/kg IS20. A lower dose 
(3 mg/kg) was chosen because intranasal administration has been shown to concentrate 
lipophilic compounds more efficiently in the brain than intraperitoneal injections. Using liquid 
chromatography/mass-spectrometry (LC/MS), our pharmacokinetic study found that the 
concentration of intranasally injected IS20 accumulated to be 4 ng/mg tissue in the brain at 30 
minutes, gradually decreased to 1.5 ng/mg tissue at 90 minutes and to less than 0.8 ng/mg 
tissue at 6 h, indicating that intranasally injected IS20 was able to cross the blood brain barrier 
and accumulate in the brain. Interestingly, 24 h post IS20 treatment, the brain level of IS20 
was highly maintained. Similar to intraperitoneal injection of IS20, at 3 and 6 h post-intranasal 
administration of IS20, qPCR assays showed significant increases in GDNF mRNA expression 
in SN and striatum (Fig. 5D). ELISA detected concurrent increases in GDNF protein in both 
brain lysates and serum (Fig. 5E), and the maximal response was observed at 30 minutes post 
IS20 treatment. GDNF mediates pro-survival effects through its preferred receptor GFRα1, a 
GPI, and its co-receptor RET, a receptor tyrosine kinase that transduces intracellular signals, 
and decreased expression of RET has been shown to cause progressive degeneration of the 
nigrostriatal system (Sariola, 2003; Tenenbaum & Humbert-Claude, 2017). Intriguingly, IS20 
modestly but significantly increased the expression of GFRα1 and RET mRNAs in whole brain 
(Fig. 5F). Collectively, these data show that both minimally-invasive intraperitoneal delivery 
and non-invasive intranasal delivery of IS20 could upregulate GDNF and GDNF receptors in 
the mouse brain. 
Figure 6. IS20 protects against MPTP-induced dopaminergic cell death in C57 
black mice and restores GDNF expression. Since intracranial delivery of exogenous 
recombinant GDNF has shown effective neuroprotection (Wang, Lin, Chiou, Williams, & 
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Hoffer, 1997), we hypothesized that the early induction of GDNF in striatum induced by 
intraperitoneally administered IS20 was sufficient to protect dopaminergic neurons against 
chemical-induced neurodegeneration. To test this hypothesis, we intraperitoneally injected 
C57BL/6 mice with the classic Parkinsonian toxicant MPTP, followed by an intraperitoneal 
injection of IS20, each day for 5 days. Since we wish to evaluate the effect of IS20 during 
neurodegeneration and not as a preventative measure, IS20 was administered 1 h after MPTP 
administration. After 5 days of the MPTP and IS20 co-injections, we injected only IS20 for 7 
more days (Fig. 6A). GDNF gene expression in the striatum was then analyzed by qPCR, 
which confirmed that MPTP treatment alone mildly reduced GDNF gene expression, and that 
IS20 co-treatment modestly but significantly restored GDNF gene expression in mice that 
received MPTP injections (Fig. 6B). Also, IS20 treatment alone upregulated GDNF gene 
expression in mice as anticipated in coherence with the above-mentioned in vitro and in vivo 
pharmacodynamics experiments (Fig. 6B). Importantly, HPLC analysis of striatum 
homogenates showed that IS20 treatment modestly but significantly attenuated the MPTP-
induced depletion of dopamine and its metabolites HVA and DOPAC (Fig. 6C-E). Finally, to 
further determine the effects of IS20 on the lesioned nigral-striatal system and to confirm the 
functional effects of IS20-induced GDNF upregulation on the preservation of dopaminergic 
system, TH immunohistochemistry and stereological counts of TH-positive dopaminergic 
neurons were performed on caudate-putamen and substantia nigra (SN) cryosections obtained 
from mice in each group. As expected, MPTP significantly reduced the number of TH-positive 
dopaminergic neurons in the SN. However, IS20 co-treatment significantly restored TH-
positive neuron count in MPTP-treated mice (Fig. 6F-G). TH immunohistochemistry analysis 
also showed that IS20 treatment significantly preserved dopaminergic nerve fibers damaged 
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by MPTP treatments (Fig. 6G, representative sections from each group shown). These results 
suggest that IS20 treatment is protective against MPTP-induced neurochemical deficits 
resulting from MPTP-induced dopaminergic neurotoxicity, possibly through enhanced GDNF 
signaling.  
Figure 7. IS20 protects against dopaminergic neurodegeneration in Mitopark PD 
model. We next tested if intranasal administration of IS20 could restore behavioral and motor 
functions in the MitoPark mouse model. Starting at 15 weeks, MitoPark mice exhibited 
significant and drastic reduction in locomotor activity as shown by representative Versaplot 
maps (Fig. 7A) and slowed horizontal activity (Fig. 7B). However, after 14 days, MitoPark 
mice that received IS20 intranasal administration performed mildly better in horizontal activity 
compared to vehicle control, and by day 28 post treatment, MitoPark mice that received IS20 
performed significantly better (Fig. 7B-C). Taken together, these sets of experiments showed 
that IS20 intranasal delivery could significantly protect against dopaminergic neuronal cell loss 
and behavioral deficits in the MitoPark genetic model of PD. 
Figure 8. IS20 protects against dopaminergic neurodegeneration in the Mitopark 
mouse model of PD. Because dopaminergic degeneration in the MPTP model requires an 
acute neurotoxic insult and follows a rapid disease course, we next used the MitoPark mice, a 
chronically progressive neurodegenerative mouse model of PD to verify if intranasal 
administration of IS20 in a longer-term (4 week) treatment regimen protects against 
dopaminergic neurodegeneration in a more gradual and progressive model. The MitoPark 
mouse model is a genetic model of PD rendered by conditional knockout of mitochondrial 
transcription factor A (TFAM) driven by the Cre/Loxp system in dopaminergic neurons, which 
results in close recapitulation of PD symptoms, including a steady, progressive loss of 
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dopaminergic neurons over several months, with the accompanying loss of motor capacity 
starting at around age 12-14 weeks, as well as non-motor symptoms including olfactory deficits 
and depression. Mice born in the same litter but does not have conditional knockout of TFAM 
and DAT exhibited no deficits, and serve as ideal health controls. MitoPark mice aged 13 
weeks, the average onset of motor symptoms, were randomly chosen for treatment with vehicle 
or IS20 for 4 weeks. Similar to mice treated with MPTP, GNDF gene and protein expression, 
as measured by qPCR and Western blot, respectively, in substantia nigra (SN) of MitoPark 
mice were significantly reduced compared to their litter mates (Fig. 8A-B). Importantly, 
treatment with IS20 significantly increased GDNF gene expression and protein levels in 
MitoPark mice (Fig. 8A-B). Moreover, TH protein levels in the (SN) of MitoPark mice were 
significantly restored after treatment with IS20 (Fig. 8B), whereas PKR1 levels were not 
affected. Since astrocyte-derived GDNF could reduce microglia-induced neuroinflammation 
(Chen et al., 2015; Rocha, Cristovão, Campos, Fonseca, & Baltazar, 2012), we also looked for 
microglia activation by immunostaining IBA1 in the SN MitoPark mice treated with vehicle 
or IS20. IBA1 immunoreactivity was significantly reduced in MitoPark mice by IS20 treatment 
(Fig. 8C), suggesting that IS20 treatment also prevents microglial activation in the SN of 
MitoPark mice. To confirm the functional effects of IS20-indudced GDNF upregulation on 
dopaminergic neurodegeneration in MitoPark mice, brain sections from 16-wk MitoPark mice 
were immunostained with TH to detect dopaminergic neurons. Intranasal IS20 treatment 
significantly preserved the dopaminergic neuronal cell bodies in SN and dopaminergic 
neuronal fibers that projected into the striatum of MitoPark (Fig.8E-F).  DAB immunostaining 
and stereological counts of TH-positive dopaminergic neurons further showed significantly 
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higher neuronal counts (Fig. 7G-H) in the SN of IS20-treated MitoPark mice compared to 
vehicle-treated MitoPark mice.  
Figure 9. IS20 activates p44/42, AKT pathways and induces pro-survival NRF2, 
BCL2 gene expression. Since phosphorylation of AKT could induce GDNF upregulation, we 
sought to find effects of IS20 on cellular signal transduction in primary mouse astrocytes. IS20 
rapidly induced AKT phosphorylation and p44/42 phosphorylation (Fig. 9A). Further, IS20 
induced early expression of Nrf2 (Figure 9B) and Bcl2 (Fig. 9C). In C57B/6 mice, IS20 8h 
after IP injection induced AKT phosphorylation in striatum and heart, the organ in which the 
protective effects of IS20 was originally found (Figure 9D). These experiments suggest that 
mechanistically, IS20 could induce signaling transduction known to induce GDNF 
upregulation, and induce other neuroprotective factors.  
 
Discussion 
In this study, we demonstrated the potential for a small-molecule PKR1 receptor 
agonist to induce GDNF expression and to achieve neuroprotective and neurorestorative 
effects in two rodent models of PD. In particular, we showed that activation of PKR1 signaling 
through IS20 treatment quickly causes GDNF secretion and gene expression in cultured 
astrocytes and organotypic slices. In C57B/6 mice, intranasally administered IS20 successfully 
crosses the blood brain barrier to reach maximum concentration in around 30 minutes and 
induce GDNF serum release and gene expression in the nigrostriatal system. In a subacute 
MPTP mouse model of PD, IS20 protects dopaminergic neurons against MPTP-induced 
neurodegeneration and increases dopamine levels in the striatum of MPTP-treated mice. 
Furthermore, we showed that, in transgenic MitoPark mice, 4-week intranasal IS20 
administration induces GDNF and TH levels in the SN, reduces microglial activation and 
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protects against dopaminergic neurodegeneration, and these protective effects translate to 
functional improvements in locomotor activity in MitoPark mice. These findings suggest that 
pharmacological modulation of GDNF signaling could be achieved with minimum side effects 
using intranasal administration of a PKR1 receptor agonist, IS20.  
PK2 activates PKR1 at EC50 4.3 +/- 1.3 nM and PKR2 at EC50 7.3 +/- 2.8 nM(D. C.-
H. Lin et al., 2002). The apparently similar receptor affinities (Zhou, 2006) suggest that 
downstream effects induced by PK2 are determined by the expression levels of PKR1 and 
PKR2 on cell surface (Attramadal, 2009). We previously have shown that PK2 signals through 
PKR1 and PKR2 in neurons to rapidly increase intracellular Ca2+ and induce phosphorylation 
of AKT and p44/42, leading to increases in BCL2 protein levels and mitochondrial biogenesis 
(ref). We also developed an efficient AAV2/5-mediated gene delivery system, which produced 
robust, stable expression of PK2 in the striatum and protected substantia nigra neurons from 
MPTP-induced neurodegeneration. In astrocytes, activation of prokineticin signaling is likely 
modulated by the predominant expression of PKR1 (Koyama et al., 2006). Our current study 
shows that the PKR1 receptor agonist IS20 rapidly increases intracellular Ca2+ and induces 
phosphorylation of AKT and p44/42 in astrocytes (Figure 10). Activation of AKT is a known 
pathway that results in secretion and upregulation of endogenous GDNF. Since both 
prokineticin and GDNF signaling depend on AKT and ERK signaling in the dopaminergic 
neurons to mediate protective effects (Gordon et al., 2016; Sariola, 2003), it is therefore 
possible that prokineticin and GDNF signaling crosstalk here to mediate IS20’s pro-survival 
effects. Indeed, blocking AKT and p44/42 using API and PD98059, respectively, in neurons 
treated with PK2 protein nullifies protective effects, while blocking p44/42 using PD98059 
prevented GDNF release from rat glioma cells (Tanabe, Matsushima-Nishiwaki, Iida, Kozawa, 
162 
& Iida, 2012). These data further suggest that prokineticin and GDNF signaling converge at 
AKT and p44/42 in dopaminergic neurons to promote neuronal survival.  
Recently, it was revealed that GDNF is upregulated by ischemia (K Yamagata et al., 
2002) and astrocyte-derived GDNF could protect neuronal cultures from cell death in cases of 
cellular mitochondrial damage (C.-H. Lin et al., 2006; K Yamagata et al., 2002). PK2 is also 
upregulated by hypoxia in primary cortical culture models of ischemia, induces proliferation, 
survival and migration of capillary endothelial cells in hypoxic stress, and supports 
mitochondrial biogenesis under MPP+-induced oxidative stress (Cheng et al., 2012; LeCouter 
et al., 2003). These previous findings support our hypothesis that PK2 is co-regulated with 
GDNF in the brain. Other reports also found that PK2 signaling has significant crosstalk with 
GDNF signaling in the development of the enteric nervous system (Ngan et al., 2008). Both 
PK2 and GDNF are strong chemoattractants for projecting axons during neurogenesis and 
neuritogenesis. Conditional knockout of PKR1 leads to heart and kidney disorders due to 
deficits in angiogenesis, cell pro-survival signaling, mitochondrial, and progenitor cell 
functions in these organs (Boulberdaa et al., 2011). GDNF and PK2 signaling in these cellular 
functions suggest a possible crosstalk between them in both peripheral nervous system and the 
central nervous system. 
Previous GDNF clinical trials concluded that although the potential for GDNF-based 
therapy remains high, two challenges need to be overcome: proper selection of animal PD 
models during preclinical testing and unwanted compensatory reactions or side-effects 
associated with GDNF delivery (Taylor et al., 2013). MPTP is the most frequently used 
Parkinsonian toxicant applied in the generation of animal models of PD (Beal, 2001; 
Przedborski et al., 2001), with the obvious advantage that of MPTP was clinically observed in 
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1979 to produce a human model of the disease upon accidental injection (Davis et al., 1979; 
Langston, Ballard, Tetrud, & Irwin, 1983). However, although subacute MPTP treatment (3-5 
daily injections) in rodents could manifest neuropathology in PD, it does not follow the 
progressive nature of the disease in humans or reliably reproduce behavioral deficits that 
recapitulate the human disease in rodents (Rommelfanger et al., 2007; Schober, 2004; 
Tillerson, Caudle, Reverón, & Miller, 2002). MPTP injections leave striatal dopaminergic 
neuron projections intact, capable of retrograde-transporting GDNF to neuron soma in the SN. 
Yet, recent clinical data observed in post-mortem brains of PD patients 5 years post-diagnosis 
revealed that TH-positive dopaminergic innervations from the caudate-putamen completely 
disappeared, questioning the effectiveness of delivering GDNF only in the striatum of 
advanced PD patients, as employed by clinical trials conducted by Amgen (Lang et al., 2006; 
Nutt et al., 2003; Tatarewicz et al., 2007) and others (Slevin et al., 2005, 2007). MitoPark mice 
used in the current study, in comparison, had similarly lost striatal projections at 17 weeks, 
recapitulating conditions seen in advanced PD patients, thereby allowing critical assessments 
of preclinical functional endpoints. Early studies that achieved neuroprotective effects 
indicated that GDNF administration by intranigral injection could mitigate neuronal cell loss, 
but did not protect against loss of projections (LeCouter et al., 2003; Mandel, Spratt, Snyder, 
& Leff, 1997). Intrastriatal injection of AAV-GDNF could protect against degeneration of both 
neuronal cell body and projections, provided that it is administered before neuronal cell loss 
(Kirik, Rosenblad, Bjorklund, & Mandel, 2000). This is presumably because to achieve full 
effectiveness, GDNF must be retrograde-transported to dopaminergic neuron soma for RET 
signaling to mediate pro-survival effects (Tenenbaum & Humbert-Claude, 2017). Results from 
past studies using only acute neurodegeneration models which suggested that targeting the 
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striatum was both necessary and sufficient are confounded when a lack of axon transport 
deficiencies in the model is taken into consideration (Herzog et al., 2013). Therefore, high 
GDNF expression in striatum is less effective if GDNF retrograde-transport is disrupted due 
to significantly degenerated dopaminergic neuronal projects. In this case, increasing GDNF 
level in both striatum and SN might prove to be more effective in mediating GDNF-induced 
pro-survival effects (Marks et al., 2010). Indeed, success have been achieved by using AAV2-
mediated neurotrophic factor gene transfer in both striatum and nigra (Kirik et al., 2000; Jeffrey 
H. Kordower et al., 2006). In our current study, IS20-induced GDNF expression level was 
upregulated in both striatum and substantia nigra of MitoPark mice, allowing astrocyte-
secreted GDNF to protect both dopaminergic projections in striatum as well as neuron soma 
in SN. Significantly more striatal projections are preserved in MitoPark mice treated with IS20 
(Figure 9). Together, these data indicate that performing preclinical studies in animal models 
that recapitulate the progression of PD pathology could increase success rate of translational 
research for PD and reduce attrition of candidate therapies. 
Most current GDNF gene delivery trials use AAV2, which has low immunogenicity 
and has proven safe for use in humans, but transduces predominantly neurons (Carter, 2001; 
Ruitenberg, Eggers, Boer, & Verhaagen, 2002; Towne, Pertin, Beggah, Aebischer, & 
Decosterd, 2009). However, in the injured brain, GDNF production is mainly regulated by 
astrocytes and not by neuronal cells (Bresjanac & Antauer, 2000; Nakagawa & Schwartz, 
2004). Astrocytes therefore provide the major source of GDNF in the substantia nigra of PD 
patients’ brains (Drinkut et al., 2012; Mogi et al., 2001) and secrete GDNF during ischemia as 
a compensatory responses (Kazuo Yamagata et al., 2007). Astrocytes also secrete other 
neurotrophic factors CDNF, BDNF, NGF, and in the midbrain, astrocytes and microglia 
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outnumber neurons 10 to 1 (Azevedo et al., 2009; Rocha et al., 2012). The major source of 
GDNF in the gut is also from glia cells, the enteric glia cells (Steinkamp et al., 2012; Von 
Boyen et al., 2011). Early studies isolated GDNF from type 1 astrocytes from the SN and found 
that astrocyte-derived GDNF enhanced dopaminergic neuron survival when nigral astrocytes 
were co-cultured with dopaminergic neurons as support cell monolayers (O’Malley et al., 
1992). Therefore, neuroprotective efforts targeting only neurons for long-term neuronal 
viability are unlikely to succeed if supportive astrocytes do not provide proper neurotrophic 
and metabolic enrichments (Takano, Oberheim, Cotrina, & Nedergaard, 2009). Several studies 
have found that intrastriatal viral-mediated GDNF gene delivery causes aberrant neurite 
growth towards the site of application (Biljana Georgievska et al., 2002; Tenenbaum & 
Humbert-Claude, 2017), suggesting that mimicking endogenous mode of expression is 
important to achieve functional effects. Several studies had focused on viral-delivery of GDNF 
into astrocytes, achieving localized, yet satisfactory neuroprotection (Drinkut et al., 2012). 
Building upon these studies, we found here that targeted GDNF upregulation in astrocytes 
could be achieved pharmacologically using non-invasive route of administration, which 
suggests that more research efforts should be placed back to astrocytes. 
The neuroprotective and neurorestorative effects afforded by IS20 could also be 
mediated through reduction of IBA1 expression in the SN. Astrocytes’ role in 
neuroinflammation associated with neurodegeneration has been increasingly recognized. SN 
has an extremely high density of microglia (Ouchi et al., 2005), and activated microglia are a 
common feature in this area, which is affected by PD pathology (Rickert et al., 2014). GDNF 
secreted from astrocytes has been shown to potently inhibit excessive production of reactive 
oxygen species from microglia in zymosan A-stimulated midbrain microglia cultures (Rocha 
166 
et al., 2012) and LPS-stimulated primary midbrain neuron-glia cultures (Wu et al., 2009). It is 
therefore also possible that astrocyte-derived GDNF could mediate protective effects by its 
anti-inflammatory effects on activated microglia (Rickert et al., 2014). In line with previous 
studies, we showed that IS20 treatment reduced IBA1 expression in the SN of 17-week 
MitoPark mice (Figure 9B). Furthermore, constitutive GDNF expression from viral transgene 
expression can cause downregulation of TH expression (Tereshchenko et al., 2014), possibly 
due to feedback loops between GDNF and dopamine reuptake (Gomes, Vaz, Ribeiro, & 
Sebastião, 2006; Kopra et al., 2017). Instead, a discontinuous GDNF delivery paradigm, in 
which GDNF levels were allowed to return to basal level, showed a reduction in such unwanted 
compensatory effects (Taylor et al., 2013; Tereshchenko et al., 2014). In the current study, 
pharmacodynamics studies in healthy control mice found that IS20-induced GDNF expression 
in striatum, SN, as well as whole brain returned to basal levels 6 h post-treatment (Fig. 5), 
avoiding constitutive GDNF expression. Consequently, we saw increases in TH in MitoPark 
mice treated with IS20 (Fig. 8). Yet another possible cause of unwanted compensatory effect 
results from high GDNF expression, at least one or two orders of the magnitude higher, driven 
by viral transgenes in other studies (Ibáñez & Andressoo, 2017). In our study, we have seen 2-
fold and 3-fold increase in GDNF expression induced by IS20 in the striatum and SN, 
respectively, and 0.5-fold increase over the control level in GDNF expression in whole brain 
(Fig. 5E). Further, we did not see overt signs of toxicity or significant reduction in bodyweight 
with administered doses and routes of administration while the mice were on study. This is in 
agreement with a previous published study, whereby subchronic intraperitoneal 
administrations of PK2 protein, which activates PKR1 and PKR2 in a relatively non-selective 
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fashion (Lattanzi et al., 2012), was administered systemically in C57Bl/6 mice and resulted in 
no serious toxicity seen (Beale et al., 2013).  
In summary, IS20 administration could pharmacologically upregulates GDNF levels in 
the nigrostriatal pathway, preserving dopaminergic neurons and functional innervations in 
neuroprotective and neurorestorative paradigms applied in PD animal models. The relative 
safety profile of IS20 makes it a promising pharmacological candidate for PD therapy.  
 
Materials and Methods 
Calcium Assays. Intracellular calcium mobilization was assessed using Fluo-4 NW 
Calcium Assay Kit (F36206) according to manufacturer’s instructions. Briefly, CHO cells 
were grown on 96 well plates the previous day. Molecular Devices FLIPR instrument was used 
to inject dissolved IS20 into the cell plate. 
Animal handling. All animal procedures were approved by Iowa State University’s 
Institutional Animal Care and Use Committee (IACUC). All mice were housed under a 12-h 
light cycle in a climate-controlled mouse facility (22±1 °C) with food and water available ad 
libitum. Male C57B/6 mice were pre-screened during behavioral assessments for normal 
baseline performance before being randomly assigned to experimental groups. Animals were 
not wounded or otherwise exhibited conditions that could affect behavior, and are taken off the 
study if any conditions have manifested which could affect behavioral measurements. 
Investigators involved with data collection and analysis were not blinded to group allocation.  
MPTP injections. Over a 5-day period, one i.p. injection of 18 mg kg MPTP was 
administered every day to each mouse in the MPTP group, and an equal volume of saline 
(vehicle) is received by the saline group.  
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Behavior monitoring. All groups were monitored for behavior using the automated 
VersaMax system software connected to motion-detection hardware (VersaMax monitor, 
model RXYZCM-16, and analyzer, model VMAUSB, AccuScan, Columbus, OH). Each 
animal was put in one chamber fitted with motion-detection hardware, and allowed to 
acclimate for 2 minutes, after which its spontaneous locomotor activities (horizontal activity, 
vertical activity, and speed) were recorded for 10 minutes.  
MitoPark transgenic mice. MitoPark transgenic mice were a kind gift from Dr Nils-
Göran Larsson of Karolinska Institute, Stockholm, from his laboratory at the Max Planck 
Institute for Biology of Ageing. MitoPark mouse model is created by inactivation of 
mitochondrial transcription factor A (Tfam) specifically in DA neurons by conditional 
knockout through control of the dopamine transporter promoter. The mice used were from the 
MitoPark breeding colony at Iowa State University. All mice were housed under a 12-h light 
cycle in a climate-controlled mouse facility (22±1 C) with food and water available ad libitum. 
After behavioral experiments were performed at the indicated ages, mice were sacrificed using 
procedures approved by Iowa State University’s Institutional Animal Care and Use Committee 
(IACUC). Mice were euthanized at the indicated time points via carbon dioxide asphyxiation 
as outlined in approved animal use protocols, and samples processed for either qRT-PCR or 
western blotting. 
Western blot. Dissected brain regions were collected in Eppendorf tubes and flash 
frozen. To isolate total protein, RIPA buffer with sodium orthovanadate, Protease and 
Phosphatase Inhibitor Cocktail (Thermo Fisher 78440) was added to each tube, and 
homogenized using a tissue homogenizer. Dissolved total lysate was centrifuged at 12,000g 
for 60 minutes, to remove cellular debris. Normalized protein samples were loaded into each 
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well and were separated by sodium dodecyl sulfate (SDS) gel electrophoresis (100V, 90 
minutes), using AnykD Mini-PROTEAN resolving gel (Bio-Rad, #4569035). Proteins on SDS 
gels were then transferred to a nitrocellulose membrane (26V, overnight) and blocked for 1h 
using fluorescent western blocking buffer (Rockland Immunochemicals). Primary antibodies 
were diluted in blocking buffer with 0.05% Tween 20, were then added to the membranes and 
incubated overnight at 4 °C. Next day, primary antibodies were taken off, and blots were 
washed (7 times, 5 minute each) in wash buffer comprising PBS containing 0.05% Tween 20 
(PBST). Secondary antibody (infrared dye-tagged) was added for 1 h. Blots were further 
washed in PBST for 3 more times, and once in PBS. β-Actin was used as a loading control. 
Membranes were scanned using the Odyssey IR imaging system (LI-COR) and digital images 
were captured via LI-COR Odyssey imager. Densitometric analysis was done using ImageJ 
software. 
Immunohistochemistry. Cells were fixed in 4% paraformaldehyde blocked with BSA 
and Triton-X to permeabilize the cell membranes. Primary antibodies were used as follows: 
rabbit anti-TH (1:1600 dilution), rabbit anti-PK2 (1:500 dilution), goat anti-GDNF (1:500 
dilution), goat anti-IBA1 (1:1000), rabbit anti-GFAP (1:1000 dilution). Alexa Fluor 
Fluorescent Secondary Antibodies from ThermoFisher were used against primary antibodies 
for fluorescent images. For DAB staining, HRP-conjugated secondary antibodies were used 
against primary antibodies, and VECTASTAIN Elite ABC HRP Kit (VectorLabs) was used 
for conjugation of HRP to secondary antibodies. DAB was used for color development.  
SYBR Green qRT-PCR. To obtain total RNA, tissue lysis buffer from Absolutely 
RNA Miniprep kit (Agilent Technologies) was added to dissected brain regions with addition 
of beta-mercaptoethanol as reducing agent to preserve RNA. A tissue homogenizer was used 
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to dissolve tissue into the lysis buffer, and lysates were processed according to kit 
manufacturer’s instructions. Isolated total RNA from each sample was quantified using 
Nanodrop instrument to determine RNA concentration and purity. First strand cDNA synthesis 
was performed using Affinity Script qPCR cDNA synthesis system (Agilent Technologies) 
with 1µg of total RNA in the reaction mixture. Real-time PCR was performed with the 
RT2 SYBR Green master mix (Qiagen) using diluted cDNA, and qPCR mouse primer sets 
were purchased from Qiagen (Quantitect primer mix). The 18S rRNA gene (mouse) was used 
as normalization of each sample as the housekeeping gene. The amount of each template was 
optimized empirically to maximize efficiency without inhibiting the PCR reaction. After the 
last cycle of the qPCR run, dissociation curves were run to ensure a single amplicon peak was 
obtained, indicating primer specificity. The results are reported as fold change in gene 
expression with the ΔΔCt method, using the threshold cycle (Ct) value for the housekeeping 
gene and for the respective gene of interest in each sample. Control animals serve as the 
baseline for fold change.  
Lentivirus production. PK2 lentivirus expression vector was obtained from Origene, 
and the MISSION Lentiviral Packaging Mix was obtained from Sigma (SHP001) and used 
according to manufacturer’s protocols. Briefly, the PK2 lentivirus expression vector was mixed 
with the Packaging Mix, and co-transfected into 293FT cells to package the virus. After 24h 
post-transfection, the supernatant, which contain the virus, was collected. The second 
harvesting of virus was done 48h post-transfection. The Lenti-X™ p24 Rapid Titer Kit from 
Clontech (632200) was used to titer the lentivirus.  
HPLC analysis of striatal dopamine levels. HPLC samples were prepared and 
processed as previously described (Gordon et al., 2016). Briefly, mice were euthanized, striata 
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were collected and neurotransmitters were extracted in 0.2 M perchloric acid solution 
containing 0.05% Na2EDTA, 0.1% Na2S2O5 and isoproterenol (internal standard). Dopamine 
and metabolites were separated isocratically by a reversed-phase column with a flow rate of 
0.6 ml min−1 using a Dionex Ultimate 3000 HPLC system (pump ISO-3100SD, Thermo 
Scientific, Bannockburn, IL) equipped with a refrigerated automatic sampler (model WPS-
3000TSL). The electrochemical detection system included a CoulArray model 5600A coupled 
with an analytical cell (microdialysis cell 5014B) and a guard cell (model 5020). Data 
acquisition and analysis were performed using Chromeleon 7 and ESA CoulArray 3.10 HPLC 
Software. 
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Figures 
 
Figure 1. Prokineticin receptor 1 is activated by recombinant PK2 protein and receptor 
agonist IS20. A. Model of PK2 binding to PKR1. B. PK2 then induces intracellular Ca2+ 
mobilization as measured by Fluor4NW assay kit on FlexStation. C. The lipophilic small 
molecule IS20 could bind inside the binding pocket of PKR1. D. The receptor agonist IS20 
could induce intracellular Ca2+ mobilization as measured by Fluor4NW assay kit.  
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Figure 2. PK2 and PK2 agonist IS20 increase GDNF in U373 human astrocyte cell line. 
A. Recombinant PK2 protein was dissolved in reduced serum (2% FBS) and incubated on 
U373 human astrocyte cells. Western blot assay found increased GDNF level in U373 treated 
183 
with 25nM PK2 recombinant protein, B. qPCR assay found increased GDNF gene expression 
in cells treated with 25nM PK2, but not when PC-7, a PKR1/PKR2 blocker, was co-incubated 
with IS20.  C. GDNF level in U373 cell lysates was also found to increase in GDNF ELISA 
assay. D, E. Lentiviral-mediated delivery of PK2 cDNA into U373 cells induced stable 
expression of PK2-eGFP as shown by fluorescent microscopy and western blot. F. GDNF level 
was found to increase in U373 transduced by lentiviral PK2-eGFP by western blot assay. G. 
qPCR assay found that treatment with PKR1 agonist IS20 could induce GDNF gene expression 
level in a time dependent manner. H. Quantitive PCR analysis of GDNF gene expression. 
overexpressed PKR1 expression vector is transiently transfected in increasing amounts of 
cDNA (0.5-15 µg) in U373 astrocytes, and the transfected cells were treated with 10µM IS20 
for 4h. Overexpression of PKR1 vector dose-dependently stimulated IS20-induced 
upregulation of GDNF mRNA, and the optimal stimulation (5-fold) was saturated between 5-
15 µg PKR1 expression plasmid. I. Stable PKR1 overexpression U373 cell line and found that 
PKR1 overexpression cells exhibited slightly increased expression of GDNF mRNA. J. PKR1 
overexpression cells seems to have higher GDNF immunoreactivity, and treatment with IS20 
(3-10 µM) further potentiated this upregulation. K. Quantitative PCR showed that CRISPR-
Cas9 guide RNA against PKR1 produced efficient knock down of PKR1 in U373 astrocytes. 
L. Quantitative PCR assay showed that IS20 was no longer able to modulate GDNF expression 
in PKR1 knock out cells. NTC: nontarget control. 
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Figure 3. IS20 protects against MPP+-induced cell death and preserves mitochondrial 
energetics in dopaminergic neuronal cells. A. MTS assay of N27 dopaminergic neurons after 
co-treatment with MPP+ and astrocytes conditioned media (ACM). To make Control ACM and 
IS20 ACM, U373 astrocytes were treated with or without IS20 for 2 h followed by a change 
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to fresh media and an additional incubation for 6 h. This astrocyte conditioned media (ACM) 
was collected and added to N27 dopaminergic neuronal cells, together with no MPP + or MPP+ 
(100-300 µM) for 24 h. B. Seahorse analysis of N27 cells treated with: Control ACM (blue 
line), IS20 ACM (red line), IS20 ACM added with MPP+, and MPP+ alone. B. IS20 ACM 
remarkably attenuated MPP+-induced reduction in oxygen consumption rate, C. basal 
respiration, D. reserve capacity, and E. ATP production F. MTS assay of primary striatal 
neurons isolated from the mouse. The same Control ACM, Control ACM added with MPP+, 
IS20 ACM + MPP+, IS21 ACM + MPP+, and the proper controls, were used to treat primary 
striatal neurons.  
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Figure 4. IS20 increases GDNF in primary mouse astrocytes in culture. A. GDNF 
ELISA found increased GDNF level in supernatant of primary mouse astrocytes treated with 
10uM IS20 at 2h over a time course of 1h to 8h. B. The optimum time point (2h) was chosen 
for dose response of IS20 on GDNF secretion. At 2h, ELISA found significantly increased 
GDNF secretion by primary mouse astrocytes treated with 10µM IS20. C. Similarly, qPCR 
found increased GDNF gene expression in primary mouse astrocytes treated with 3µM IS20 
at 3h and 4h over a time course of 1h to 7h. D. The optimum time of 3h was chosen for a dose 
response study. At 3h, qPCR assay found greatest increase in GDNF gene expression with 
10uM IS20 treatment. E. At 3h, qPCR analysis of GDNF receptor GFRα1 gene expression 
also showed increase at 10µM IS20. F. Western blot analysis of primary astrocytes treated 
with 1µM, 10µM IS20 or 25nM PK2 revealed increase in IS20 protein level in primary mouse 
astrocyte cultures at 4h and 8h post-treatment (top). Densitometric analysis of western blot 
shows approximately 2-fold increase in GDNF protein level (bottom). G. Immunostaining of 
GFAP confirms astrocytic marker in cultured primary mouse astrocytes. H. Quantitative PCR 
analysis of PK2 gene expression in cultured midbrain organotypic slices treated with 0, 3, 
30uM of IS20 for 4h. I. western blot analysis of PK2 protein levels in cultured organotypic 
slices treated with 0 or 30uM of IS20 for 4h.  
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Figure 5. Intraperitoneal or intranasal administration of IS20 induces GDNF family 
neurotrophic factors in naïve C57 black mice. A. Western blot analysis showed that 
intraperitoneal injection of 10mg/kg IS20 increased levels of GDNF 8 h post-administration 
B. GDNF in blood serum was also found by ELISA to increase at 8h. C. Liquid-
chromatography/mass spectrometry (LC/MS) analysis showed that intranasally administered 
IS20 become concentrated to approximately 4ng/mg in the brain at 30 minutes post-
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administration and rapidly reduced to less than 1 ng/mg at 6h in a time course from 30 minutes 
to 24h. D. ELISA assay showed highest GDNF level in brain (left) and blood serum (right) 30 
minutes post-administration which slowly reduced to basal levels at 24h. E. Quantitive PCR 
showed that At 3h post-intranasal administration, GDNF expression was increased in whole 
brain, SN, and striatum, while at 6h post-administration, only SN still had a modest but 
significant increase in GDNF gene expression level. F. Quantitive PCR also showed that gene 
expression of GDNF receptor GFRa1, and co-receptor RET both were increased 3h post-
administration of S20.  
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Figure 6. IS20 protects against MPTP-induced dopaminergic cell death in C57B/6 mice 
and restores GDNF expression. A. Treatment paradigm for MPTP and IS20 treatments. 
C57B/6 mice was peritoneally-injected with MPTP daily for 5 days. IS20 (10mg/kg) was 
injected peritoneally daily following MPTP injections, and continued for 7 more days after 
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cessation of MPTP injections, for a total of 12 injections total. B. After 12 days of treatments, 
GDNF gene expression was assessed by qPCR which found significant increases in striatum 
of the group co-treated with IS20 compared to MPTP group. HPLC analysis showed drastic 
decreases in dopamine (C), dopamine metabolites homovanillic acid (D) and DOPAC (E), in 
MPTP-treated group, while IS20 co-treatment group showed significantly increased levels of 
dopamine and metabolites compared to MPTP group. F. Software assisted dopaminergic 
neuron count of each group showed significantly more TH+ dopaminergic neurons in SNpc of 
IS20 co-treated mice compared to MPTP group. G. DAB immunohisto-staining of TH+ 
neurons in SNpc shown as 2x magnification (top) and 10x images (bottom).  
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Figure 7. IS20 protects against behavioral deficits in MitoPark model. A. Treatment 
paradigm of IS20 3mg/kg via intranasal administration. MitoPark mice were treated with 
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vehicle or IS20 every other day for 28 days. Weekly behavioral monitoring using B. VersaMax 
apparatus and software showed movement tracing over 10 minutes of monitoring C. Activity 
data from VersaMax showed restoration of horizontal locomotor activity after 28 days of 
treatments with IS20.  
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Figure 8. IS20 protects against dopaminergic neurodegeneration in MitoPark model. 
A. Mitopark mice (13-wk-old) were subjected to IS20 intranasal delivery, 3mg/kg every other 
day for 28 days. Quantitative PCR showed that IS20 treatment increased GDNF gene 
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expression in SN. N = 6. Western blot analysis of SN brain lysates probed using antibodies 
against GDNF, TH, IBA1, PKR1, showed increased levels of GDNF, TH, decreased IBA1, 
while PKR1 stayed constant. B. β-Actin was used as loading control. N = 6.  C. Densitometric 
analysis of western blot analysis shown in B. Student’s T test, P value < 0.05 (*),  < 0.01 (**), 
< 0.01 (***). D. SN brain sections co-immunostained with IBA1 and fluorojade showed 
decreased fluorojade immunoreactivity in MitoPark mice treated with IS20. E. Tyrosine 
hydroxylase (TH) immunostaining of SN sections. Images were taken at 2X magnification 
(top) and 10X magnification (bottom). F. Computer-assisted stereological counting of TH+ 
cells present in the SNpc. G. SN brain sections co-immunostained with TH and fluorojade in 
the SN showed increased TH immunoreactivity and decreased fluorojade staining in the group 
that received IS20. 
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Figure 9. IS20 activates p44/42, AKT pathways and induces pro-survival NRF2, BCL2 
gene expression. A. Western blot analysis of phosphorylated AKT, as well as p44 and p42. 
IS20 rapidly induced AKT phosphorylation and p44/42 phosphorylation. Primary astrocytes 
were treated and collected at 0.5h, 1h, 6h post-treatment with IS20. B. Quantitative PCR 
showed that IS20 induced a trend of early expression of Nrf2, although not statistically 
significant. C. Quantitative PCR showed that induction of Bcl2 gene expression was 
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significantly higher 1h post-treatment with IS20, and steadily decreased towards control levels 
at 2h and 3h. D. Western blot analysis of phospho-AKT and AKT in C57B/6 mice. 8h after IP 
injection, mice were sacrificed and probed for AKT phosphorylation in striatum and heart.  
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Supplementary Figure 1.  A. Double-labelling immunofluorescence for GDNF (red), 
PKR1 (green) in nigral sections from PD patients and age-matched controls probed using 
antibodies directed against the human GDNF and PKR1 proteins. Decreased levels of GDNF 
were evident in PD patient samples compared with control subjects while PKR1 levels seemed 
constant. Scale bar, 50 μm. For both Healthy Control panel and PD patient panel, the top 
portion is × 60 magnification to show PKR1 merging with several PKR1-positive cells and the 
bottom portion is with × 2.5 zoom to get a high magnification image of PKR1 and GDNF in 
one cell. B. Quantitative PCR showing GDNF downregulation in striatum of PD patients. Data 
represented as mean±s.e.m. and expressed as fold change over control with n=10. Asterisks 
denote a significant (**P<0.01) difference between control and PD samples using Student's t-
test. 
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CHAPTER 5.    CONCLUSIONS AND FUTURE DIRECTIONS 
This section serves as a general summary of the research chapters presented previously, 
and to discuss possible directions for future work on this topic. In this work, we showed that 
during MPP+--induced neurodegeneration, NRF1, EGR1 and HIF1α are potential regulators of 
PK2 gene expression. We then demonstrated the mechanism of PK2-mediated protection on 
Mn-treated dopaminergic neuronal cell culture model of PD via mitochondrial biogenesis and 
BCL-2 upregulation, and showed its in vivo relevance in Mn mouse model of PD. We lastly 
demonstrated the clinical relevance and potential of PK2 signaling via pharmacological 
activation of GDNF in MPTP and MitoPark model of PD.  
The decade-long neurodegenerative process is complex, involving toxicant exposure 
creating oxidative stress and mitochondrial dysfunction, exacerbated by self-propagating 
neuroinflammation. Little is yet known about epigenetic alternation, particularly DNA 
methylation, by environmental toxicants, such as Mn. Altered expression of PD-related genes 
such as alpha-synuclein, and PK2, by epigenetic mechanisms illustrate the process of 
environmental-gene interactions, and could account for differences in individual susceptibility 
and variability through the course of disease progression. This represents a new area of 
research that deserves more focus.  
 
PK2 Transcriptional Regulation during Neurodegeneration 
Despite recent advances in understanding of PK2’s functions in the brain, its role and 
its transcriptional regulation during neurotoxic stress remain incompletely understood. It has 
been shown that in the CNS, PK2 can be transcriptionally regulated via Enhancer-box (E-box) 
binding by basic helix-loop-helix (bHLH) transcription factors. CLOCK/BMAL1, the 
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circadian rhythm master regulators, and Ngn1/MASH1, proneural genes expressed during 
olfactory bulb neurogenesis, have been determined to regulate PK2 transcription. Further, 
HIF1α, another bHLH transcription factor, is speculated to regulate PK2 transcription via 
binding to several putative HIF1α binding sites on the PK2 proximal promoter. Our studies 
confirmed that overexpressed HIF1α could induce PK2 promoter activity and gene expression, 
while also confirming the involvement of EGR1 in regulating PK2 in a similar manner. 
Importantly, we found that except in the striatum, PK2 expression generally co-regulated with 
EGR1 and HIF1α in Mn overexposure model of neurotoxic stress. Further mechanistic studies 
conducted in dopaminergic cell cultures using CRISPR cas9-based knockdown and chemical 
inhibition of HIF1α, demonstrated that EGR1 and HIF1α are major regulators of PK2 gene 
expression during MPP+-induced PK2 upregulation. It has been reported that treatment with 
DHB, a HIF1α stabilizer, could rescue mitochondrial dysfunction, a major mechanism of 
DHB-mediated protective effects (D. W. Lee et al., 2009). Since PK2 could induce 
proliferator-activated receptor-γ coactivator 1α (PGC-1α) in the activation of mitochondrial 
biogenesis and respiration (Gordon et al., 2016), it therefore could be speculated that HIF1α 
activation of PK2 could help in mediating PGC-1α’s protective effects. Further studies need to 
be conducted to confirm the mechanism of a putative HIF1α-PK2-PGC-1α axis. 
EGR1 activation of PK2 transcription leading to neurotrophic factor upregulation 
represents another potential direction for future work. EGR1 is activated by MAPK/ERK 
signaling pathway to stimulate neurite outgrowth in a traumatic brain injury model 
(Chasseigneaux et al., 2011; Plummer, Van den Heuvel, Thornton, Corrigan, & Cappai, 2016). 
EGR1, EGR2, EGR3, and EGR4 are co-upregulated with brain-derived neurotrophic factor 
(BDNF) after treatment with pridopidine in Huntington disease mouse models (Kusko et al., 
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2018). EGR1, EGR2, EGR4 expression are induced by erythropoietin (EPO), a neuroprotective 
cytokine in models of ischemic injury (Mengozzi et al., 2012), while PK2 is also co-
upregulated during ischemic injury (M Y Cheng et al., 2012; Landucci et al., 2016). Further, 
EGR1 could induce angiogenesis via induction of PK1 in the peripheries (Sheng et al., 2018). 
In light of our current findings that suggest GDNF induction by PK2, further efforts could be 
put on confirming a putative EGR1-PK2-AKT-PI3K-GDNF signaling axis.  
An alternative pathway could also be proposed. EGR1 could also activate high levels 
of GDNF by directly binding to the Gdnf promoter (Shin et al., 2009). It has also been shown 
that PK2 could reciprocally activate EGR1 expression via ERK1/2 activation. Together with 
our findings currently presented here, this represent a reciprocal, positive-feedback loop that 
induce expression of both PK2 and EGR1. Therefore PK2-ERK-EGR1-GDNF signaling could 
represent an alternative signaling axis that deserves future effort for elucidation and validation. 
The contribution from each putative signaling pathway would also need to be evaluated.  
We have also found, in our present studies, that PK2 expression is induced early during 
neurodegenerative process induced by Mn overexposure, suggesting that PK2 could serve as a 
potential marker neurodegeneration. Elucidating the transcriptional mechanism underlying 
PK2 upregulation in dopaminergic neurons allow us to identify events upstream and players 
involved in PK2 upregulation, and begin to find other similarly co-regulated pathways. 
Understanding the perturbations in these complex pathways due to environmental factors or 
neurodegenerative events is crucial for targeting any pathway, such as the PK2 signaling 
pathway, to achieve neuroprotection.  
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Neuroprotective Effects of PK2 signaling  
We had previously reported that PK2 is induced during neurodegeneration in multiple 
cell culture, animal model, and clinical cases of PD. These data revealed a perhaps new 
function of PK2 in the brain, especially in relevance to PD. Following logical next steps, we 
had also reported the effects of AAV-mediated PK2 gene delivery in the striatum, a concept 
similar to delivery of AAV-neurturin in the mouse striatum (Jeffrey H. Kordower et al., 2006; 
Marks et al., 2010). We reported protection against MitoPark and MPTP-induced 
neurodegeneration and reduced inflammatory microglial activation in mice treated with AAV-
PK2 (Gordon et al., 2016). However, due to requirements of AAV-based gene delivery to be 
stereotaxically injected into the striatum, and the possibility of tumorigenesis as seen in the 
AAV-neurturin studies, which had found tumors in both mice injected with AAV vector as 
well as AAV-neurturin, long-term gene delivery via AAV is not currently optimal.  
Therefore, in the studies presented here, we showed the potential for a small-molecule 
PKR1 receptor agonist to activate PKR1 signaling and induce GDNF expression in cultured 
astrocytes and organotypic slices. Treatment with IS20 demonstrated neuroprotective and 
neurorestorative effects, suggesting its clinical relevance in PD therapy. In C57B/6 mice, 
intranasally administered IS20 successfully crosses the blood brain barrier to reach maximum 
concentration in around 30 minutes. Using C57B/6 mice injected with MPTP as mouse model 
of PD, we had found IS20 to protect dopaminergic neurons against MPTP-induced 
neurodegeneration and increases dopamine levels in the striatum of MPTP-treated mice. 
Furthermore, we showed that, in transgenic MitoPark mice, 4-week intranasal IS20 
administration induces GDNF and TH levels in the SN, reduces microglial activation and 
protects against dopaminergic neurodegeneration. These protective effects translate to 
functional improvements in locomotor activity in MitoPark mice. These findings also suggest 
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that pharmacological modulation of GDNF signaling could be achieved with minimum side 
effects using intranasal administration of a PKR1 receptor agonist, IS20. Furthermore, no 
exogenous proteins are injected, nor does IS20 persist in the brain. For the above reasons, 
pharmacological modulation of endogenous GDNF levels that could be tightly controlled 
might resolve issues associated with protein diffusion, leakage, and transgene tumorigenicity.  
Further considerations and experimentation are needed to improve and optimize the 
efficacy of intranasal administration of IS20. Optimization of formulations for carrier 
solutions, such as pH, choice of buffer solutions, and total volume could drastically improve 
delivery of IS20 into the nasal cavity and bioavailability in the CNS. Diffusion models that 
take into account the drug transport through the paracellular space across the nasal epithelium 
and perineural space, to reach the subarachnoid space of the brain, could immensely aid in 
design of delivery methods as well as determination of optimal dosing regimen (Cowie et al., 
2017).  
 
Induction of Neurotrophic Factors by PK2 
Current undergoing work is examining the effect of IS20 on other family members of 
the GDNF family, neurturin, artemin, and persephin, in cell culture models. Even though 
artemin co-receptor GFRα3 and persephin co-receptor GFRα4 have limited expression in the 
adult brain, neurturin and co-receptor GFRα2 are constitutively expressed in the adult brain, 
and neurturin has shown to approximate the neuroprotective effects demonstrated by GDNF. 
Since neurturin is being evaluated in phase II clinical trials, potential induction of neurturin by 
IS20 represents a new opportunity for study.  
Our preliminary studies suggest that PK2 could also induce GDNF in bone marrow-
derived stem cells, imply that IS20, as a PKR1 ligand, could also induce GDNF in these cells. 
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Given the therapeutic potential of stem cells in PD therapy for their capacity to secrete 
neurotrophic factors, PKR1-overexpressing stem cells that are implanted in PD patients could 
exhibit heightened production of neurotrophic factors upon IS20 treatment. Therefore, IS20-
induced GDNF upregulation in other cell types aside from astrocytes, if confirmed, could 
suggest larger, farther-reaching effects of IS20 in the brain.  
 
Further Considerations: Use of Appropriate Animal Models of PD 
It is worthwhile to emphasize that proper models of disease are needed to reduce 
pipeline attrition from a drug development perspective. Administration of Parkinsonian 
toxicant in rodents and primates has been widely employed for elicitation of dopaminergic 
neuronal cell death and PD-like motor symptoms. In preclinical studies for PD, they have been 
used in evaluating therapies that mitigate motor symptoms. However, in the narrow effort to 
obtain motor deficits and subsequently mitigate these motor symptoms using candidate 
therapies, less attention has been paid to assessing the animal models’ ability to recapitulate 
the chronic and progressive nature of the disease, or the specific processes associated with 
dopaminergic neurodegeneration. For example, subacute MPTP treatment (3-5 daily 
injections) in mice is widely used to generate loss of dopaminergic cells in SNpc, but it does 
not follow the progressive nature of the disease in humans, and due to rodents’ higher capacity 
for compensatory response against dopamine loss, do not reliably reproduce behavioral deficits 
(Rommelfanger et al., 2007; Schober, 2004; Tillerson, Caudle, Reverón, & Miller, 2002). 
Importantly, MPTP treatments do not induce complete loss of striatal dopaminergic neuron 
projections, while clinical data from observation of PD patient post-mortem brains showed 
complete degeneration of dopaminergic projections in the caudate-putamen at 5 years post-
diagnosis. Therefore, while putamenal gene delivery of GDNF can induce substantial GDNF 
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expression overall in the brain, the anticipated beneficial effects from anteriograde transport 
of GDNF into the SNpc might play a less prominent role. This might confound the results for 
studies delivering GDNF only in the striatum of advanced PD patients, as employed by clinical 
trials conducted by Amgen (Lang et al., 2006; Nutt et al., 2003; Tatarewicz et al., 2007) and 
others (Slevin et al., 2005, 2007). Instead, other neurotrophic signaling molecules that could 
diffuse and elicit GDNF expression beyond the caudate putamen might extend the beneficial 
effects of GDNF into the SNpc.  
Studies on the effects of PK2, specifically loss-of-function mutations, during 
neurodegeneration in wildtype adult mice are made difficult due to the developmental defects 
caused by a complete knockout of PK2. Therefore, a Cre-LoxP system which could 
conditionally and selectively ablate PK2 expression will be immensely useful in further 
studying the effects of PK2 compensatory responses, or a lack there of, during neurotoxic 
stress.  
 
Other Future Directions: Role of PK2 in Neurogenesis 
Preliminary data generated recently from our lab have demonstrated that PK2 
participates in CNS neurogenesis in the subventricular zone (SVZ) lining the lateral ventricles. 
In the adult brain, the SVZ-derived neuroprogenitor cells migrate through the rostral migratory 
stream (RMS) in a chain of cells, eventually arriving at the olfactory bulb, where they 
tangentially migrate from the inner layers of the olfactory bulb to the outer layers. PK2 is 
upregulated by Ngn/MASH1 for olfactory bulb neurogenesis during development. The 
secreted PK2 most likely acts as a chemoattractant, as PKR2 can be detected on almost all 
migrating neuroprogenitor cells in the RMS (Ng et al., 2005). However, less is known about 
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PK2’s role in adult neurogenesis, and even less is known regarding its role in 
neurodegenerative processes such as in PD. 
Environmental risk factors such as Mn exposure may lead to dysregulation of adult 
neurogenesis by reducing survival of neuroprogenitor cells as they migrate towards the 
olfactory bulb. The reduction of new olfactory bulb neurons affects not only the olfactory bulb 
functions, but also affect other brain regions such as the striatum, which is dependent on a 
continuous supply of neuroprogenitor cells to replenish lost neurons throughout adulthood and 
especially during neurodegeneration.  
The role that PK2 plays in neurogenesis and determination of neuronal fate is 
incompletely understood. Through our in silico analysis, we have found the presence of a 
putative binding site for neuron-restrictive silencer factor (NRSF), that could suggest PK2’s 
involvement in key processes of commitment of neuronal cell fate or axon sprouting. NRSF 
represses expression of neuronal genes in nonneuronal cells and in NPCs by negatively 
regulating the activity of neuropilin-1, a positive regulator of axon branching promoted by the 
actions of VEGF and EGF, thus representing a possible negative regulator of PK2 during 
neurogenesis (Huang, Myers, & Dingledine, 1999; Jones & Meech, 1999; Kurschat, 
Bielenberg, Rossignol-Tallandier, Stahl, & Klagsbrun, 2006). These lines of evidence suggest 
that this balancing control aims to prevent the expression of PK2 and other co-regulated 
neurogenesis-associated genes such as neuropilin-1 until the precise moment that they are 
needed. In the same vein, vertebrate homologues of enhancer of split complex (HES) is another 
bHLH TF that was predicted to bind to the PK2 promoter. HES1 is critically important for 
sustainable neurogenesis (Dearden, 2015); decreasing expression of HES1 promotes the 
expression of proneural genes, while reducing the pool of neural stem cells. Interestingly, loss 
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of HES1 function leads to increased MASH1-positive NPCs in the olfactory placode, and 
results in excess neurogenesis (Cau, Gradwohl, Casarosa, Kageyama, & Guillemot, 2000). 
Thus, by antagonizing the activity of MASH1, HES1 works to provide a delicate balance 
between neurogenesis of new neurons and maintenance of neural stem cell pool. Further, the 
expression of PK2 is differentially upregulated as NPC differentiate into functional neurons 
while they migrate within the SVZ, and the upstream events that result in the cell’s decision to 
precisely upregulate PK2 at the most opportune moment remains unclear. Factors such as 
NRSF and HES1 involved in suppressing neuronal genes could provide such fine control of 
PK2 expression. The positive regulation of neural genes such as PK2 during neurogenesis by 
MASH1, countered by possible negative regulation by HES1 to repressing proneural identity, 
represent an exciting area of research. The perturbation of this delicate balance caused by 
exposure to Parkinsonian toxicants such as Mn deserves more attention.  
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Figure 1. Integrated summary of the role of PK2 signaling between neuron and astrocytes as 
presented in this dissertation. MPP+ damages could induce PK2 upregulation in neurons, which 
is secreted outside of the cell. In astrocytes, PK2, and PK2 receptor agonist IS20, could induce 
GDNF upregulation and secretion which could in turn stimulate cell survival in neurons.  
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